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The Cannabinoid Use in Progressive Inflammatory brain
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placebo-controlled parallel-group multicentre trial and
economic evaluation of cannabinoids to slow progression
in multiple sclerosis
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*Corresponding author susan.ball@plymouth.ac.uk
Background: The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial aimed to
determine whether or not oral Δ9-tetrahydrocannabinol (Δ9-THC) slowed the course of progressive multiple
sclerosis (MS); evaluate safety of cannabinoid administration; and, improve methods for testing treatments
in progressive MS.
Objectives: There were three objectives in the CUPID study: (1) to evaluate whether or not Δ9-THC could
slow the course of progressive MS; (2) to assess the long-term safety of Δ9-THC; and (3) to explore newer
ways of conducting clinical trials in progressive MS.
Design: The CUPID trial was a randomised, double-blind, placebo-controlled, parallel-group, multicentre
trial. Patients were randomised in a 2 : 1 ratio to Δ9-THC or placebo. Randomisation was balanced
according to Expanded Disability Status Scale (EDSS) score, study site and disease type. Analyses were by
intention to treat, following a pre-specified statistical analysis plan. A cranial magnetic resonance imaging
(MRI) substudy, Rasch measurement theory (RMT) analyses and an economic evaluation were undertaken.
Setting: Twenty-seven UK sites.
Participants: Adults aged 18–65 years with primary or secondary progressive MS, 1-year evidence of
disease progression and baseline EDSS 4.0–6.5.
Interventions: Oral Δ9-THC (maximum 28mg/day) or matching placebo.
Assessment visits: Three and 6 months, and then 6-monthly up to 36 or 42 months.
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Main outcome measures: Primary outcomes were time to EDSS progression, and change in Multiple
Sclerosis Impact Scale-29 version 2 (MSIS-29v2) 20-point physical subscale (MSIS-29phys) score. Various
secondary patient- and clinician-reported outcomes and MRI outcomes were assessed. RMT analyses
examined performance of MS-specific rating scales as measurement instruments and tested for a
symptomatic or disease-modifying treatment effect. Economic evaluation estimated mean incremental
costs and quality-adjusted life-years (QALYs).
Results: Effectiveness – recruitment targets were achieved. Of the 498 randomised patients (332 to active
and 166 to placebo), 493 (329 active and 164 placebo) were analysed. Primary outcomes: no significant
treatment effect; hazard ratio EDSS score progression (active : placebo) 0.92 [95% confidence interval (CI)
0.68 to 1.23]; and estimated between-group difference in MSIS-29phys score (active–placebo) –0.9 points
(95% CI –2.0 to 0.2 points). Secondary clinical and MRI outcomes: no significant treatment effects.
Safety – at least one serious adverse event: 35% and 28% of active and placebo patients, respectively.
RMT analyses – scale evaluation: MSIS-29 version 2, MS Walking Scale-12 version 2 and MS Spasticity
Scale-88 were robust measurement instruments. There was no clear symptomatic or disease-modifying
treatment effect. Economic evaluation – estimated mean incremental cost to NHS over usual care, over
3 years £27,443.20 per patient. No between-group difference in QALYs.
Conclusions: The CUPID trial failed to demonstrate a significant treatment effect in primary or secondary
outcomes. There were no major safety concerns, but unwanted side effects seemed to affect compliance.
Participants were more disabled than in previous studies and deteriorated less than expected, possibly
reducing our ability to detect treatment effects. RMT analyses supported performance of MS-specific rating
scales as measures, enabled group- and individual person-level examination of treatment effects, but did
not influence study inferences. The intervention had significant additional costs with no improvement
in health outcomes; therefore, it was dominated by usual care and not cost-effective. Future work should
focus on determining further factors to predict clinical deterioration, to inform the development of new
studies, and modifying treatments in order to minimise side effects and improve study compliance.
The absence of disease-modifying treatments in progressive MS warrants further studies of the
cannabinoid pathway in potential neuroprotection.
Trial registration: Current Controlled Trials ISRCTN62942668.
Funding: The National Institute for Health Research Health Technology Assessment programme,
the Medical Research Council Efficacy and Mechanism Evaluation programme, Multiple Sclerosis Society
and Multiple Sclerosis Trust. The report will be published in full in Health Technology Assessment;
Vol. 19, No. 12. See the NIHR Journals Library website for further project information.
ABSTRACT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
viii
Contents
List of tables xiii
List of figures xix
List of abbreviations xxiii
Plain English summary xxv
Scientific summary xxvii
Chapter 1 Introduction 1
Structure of this report 1
Background and objectives 1
Multiple sclerosis and cannabinoids 1
Trials in progressive multiple sclerosis 2
Research aims 3
Chapter 2 Methods: main study and magnetic resonance imaging substudy 5
Study design 5
Setting 5
Study approvals 5
Training 5
Participant eligibility 6
Inclusion criteria 6
Exclusion criteria 6
Recruitment of participants 7
Study site personnel 7
Screening visit (consent and entry to trial) 7
Study diary 8
Randomisation and masking 8
Trial interventions 8
Outcome assessments 9
Participant-completed questionnaires 9
Baseline visit (provision of trial medication) 9
Subsequent participant follow-up 10
Safety monitoring 13
Magnetic resonance imaging substudy 13
Data management and monitoring 13
Trial oversight 13
Sample size and power 14
End Point Committee 14
Statistical methods 14
Pre-specified analyses of primary clinical outcomes 14
Pre-specified analyses of secondary clinical outcomes 15
Analysis of premature discontinuations of trial medication and losses to follow-up 16
Pre-specified analyses of magnetic resonance imaging substudy 16
Further analyses 16
DOI: 10.3310/hta19120 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 12
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ball et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
ix
Ethics and research governance approval 16
Trial registration 16
Role of the funding source 17
Summary of changes to the study protocol 17
Chapter 3 Results: main study and magnetic resonance imaging substudy 19
Unblinding of randomised treatments 19
Telephone-based assessment of Expanded Disability Status Scale score 19
Baseline comparability of randomised groups 21
Prescribed dose of trial medication 24
Random urine testing to determine any illicit cannabis use 28
Pre-specified analyses of primary clinical outcomes 32
Primary analysis of time to first confirmed Expanded Disability Status Scale
score progression 32
Sensitivity analyses of time to first confirmed Expanded Disability Status Scale
score progression 34
Pre-specified subgroup analyses of time to first confirmed Expanded Disability Status
Scale score progression 39
Primary analysis of change in Multiple Sclerosis Impact Scale-29 20-point physical subscale 39
Pre-specified analyses of secondary outcomes 39
Multiple Sclerosis Walking Scale-12 39
Multiple Sclerosis Functional Composite 42
Rivermead Mobility Index 44
Short Form questionnaire-36 items (physical health subscale) 44
Multiple Sclerosis Spasticity Scale-88 45
Investigation of adverse events and serious adverse events 50
Category rating scales 51
Analysis of premature discontinuations of trial medication and losses to follow-up 53
Pre-specified analyses of magnetic resonance imaging substudy 56
Chapter 4 Post-hoc exploratory analyses: main study and magnetic resonance
imaging substudy 61
Introduction 61
Methods 61
Subgroup analyses 61
On-treatment analyses 61
Expanded Disability Status Scale score transitions and recurrent progression events 62
Results 62
Subgroup analyses 62
On-treatment analyses 64
Expanded Disability Status Scale score transitions and recurrent progression events 66
Conclusions 73
Chapter 5 Rasch measurement theory analysis of multiple sclerosis rating scale data 75
Introduction 75
Section 1: rating scales, rating scale data analysis and the added value of Rasch
measurement theory 76
Section 2: within-study measurement performance of the Multiple Sclerosis Impact
Scale-29, Multiple Sclerosis Walking Scale-12 and Multiple Sclerosis Spasticity Scale-88
using Rasch measurement theory 79
Background 79
Methods 79
Results 82
CONTENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
x
Section 3: evaluation of treatment effect per protocol 88
Methods 88
Results 89
Summary 103
Section 4: exploratory evaluation of treatment effect by baseline disability level 103
Methods 104
Results 104
Summary 110
Section 5: reflections and lessons learned from Rasch measurement theory analysis of
Cannabinoid Use in Progressive Inflammatory brain Disease data 110
Chapter 6 Economic evaluation 113
Introduction 113
Methods 113
Resource use 113
Unit costs for resource use 114
Outcomes 116
Statistical methods 116
Results 118
Intervention costs (delivery of Δ9-tetrahydrocannabinol) 118
Health and social care resource use and costs, NHS/personal and social
services perspective 119
NHS-/personal and social services-funded other health-care costs 119
NHS-/personal and social services-funded social care costs 119
NHS-/personal and social services-funded multiple sclerosis-related hospital episodes 119
Total costs by treatment group and follow-up (complete cases and imputed data) 119
Comparison of NHS/personal and social services resource use costs by treatment group 124
Post-hoc subgroup analysis of total NHS costs by treatment group 124
Private-/patient-funded other health and social care resource use 125
Private-/patient-funded other health-care costs 127
Private-/patient-funded social care costs 128
Aggregated resource use costs by treatment group and follow-up (complete cases
and imputed data) 128
Comparison of private/patient resource use costs by treatment group 129
Post-hoc subgroup analysis of total private costs by treatment group 129
Health outcomes: quality-adjusted life-years 130
European Quality of Life-5 Dimensions scores by treatment group and follow-up 130
Comparison of quality-adjusted life-year outcomes between treatment groups 130
Post-hoc subgroup analysis of quality-adjusted life-year outcomes by treatment group 133
Conclusions 135
Chapter 7 Discussion 137
Primary outcome measures 137
Secondary outcome measures 137
Further analyses 138
Economic evaluation 138
Rasch analysis 138
Symptomatic evaluation 139
Safety 139
Further work 139
DOI: 10.3310/hta19120 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 12
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ball et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
xi
Chapter 8 Conclusions 141
Implications for health care 141
Recommendations for research 141
Acknowledgements 143
References 145
Appendix 1 Participating sites and principal investigators 147
Appendix 2 NHS research and development approval dates 149
Appendix 3 Study recruitment May 2006–July 2008 by site 151
Appendix 4 Participant information sheet 155
Appendix 5 Cannabinoid Use in Progressive Inflammatory brain Disease
trial organisation 163
Appendix 6 Patient and public involvement in the Cannabinoid Use in
Progressive Inflammatory brain Disease study 165
Appendix 7 End Point Committee terms of reference 167
Appendix 8 Economic evaluation 169
CONTENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xii
List of tables
TABLE 1 Number of capsules prescribed according to weight of participants
at baseline 10
TABLE 2 The CUPID study visit and questionnaire completion schedule 11
TABLE 3 Analysis set and study completion (all randomised patients) 20
TABLE 4 Baseline characteristics of patients by treatment group and overall 21
TABLE 5 Outcome variables at baseline for patients randomised to the two
treatment groups 22
TABLE 6 Prescribed daily dose of trial medication at each 6-monthly follow-up,
by treatment group, among non-withdrawals and overall 24
TABLE 7 Frequency and relative frequency (%) of patients in each treatment
group with a urine sample tested positive or negative for cannabinoid presence 29
TABLE 8 Summary of main results 30
TABLE 9 Occurrences of SAEs and the most common AEs 50
TABLE 10 Frequencies and relative frequencies (%) of responses to category
rating scale questions 9–16, by treatment group, at 3 months after baseline 51
TABLE 11 Frequencies and relative frequencies (%) of responses to category
rating scale questions 9–16, by treatment group, at 1 year after baseline 51
TABLE 12 Frequencies and relative frequencies (%) of responses to category
rating scale questions 9–16, by treatment group, at 2 years after baseline 52
TABLE 13 Frequencies and relative frequencies (%) of responses to category
rating scale questions 9–16, by treatment group, at 3 years after baseline 52
TABLE 14 Frequencies and relative frequencies (%) of reasons for discontinuation
of trial medication or loss to follow-up, by treatment group, disease type,
baseline EDSS, sex and overall 54
TABLE 15 Frequencies and relative frequencies (%) of reasons for loss to follow-up,
by treatment group, disease type, baseline EDSS, sex and overall 54
TABLE 16 Premature discontinuations of trial medication and losses to follow-up,
by study site 55
TABLE 17 Baseline characteristics of patients in the MRI substudy, by treatment
group and overall 57
DOI: 10.3310/hta19120 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 12
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ball et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
xiii
TABLE 18 Descriptive statistics and between-treatment-group comparisons for
MRI outcome measures at years 1, 2 and 3 58
TABLE 19 Summary of results from post-hoc exploratory subgroup and
on-treatment analyses 63
TABLE 20 Frequencies and relative frequencies (%) of patients seen to have
specified numbers of unconfirmed, recurrent progression events, by treatment
group, baseline EDSS score and overall 66
TABLE 21 Counts and proportions of transitions between EDSS score groups,
in each 6-monthly follow-up period 71
TABLE 22 Rasch measurement theory evaluation of MS-specific PRO measures 83
TABLE 23 Multiple Sclerosis Impact Scale-29, 20-point physical subscale:
symptomatic effect 90
TABLE 24 Multiple Sclerosis Impact Scale-29, psychological impact subscale:
symptomatic effect 90
TABLE 25 Multiple Sclerosis Walking Scale-12: symptomatic effect 91
TABLE 26 Multiple Sclerosis Spasticity Scale-88, muscle stiffness subscale, q01–12:
symptomatic effect 91
TABLE 27 Multiple Sclerosis Spasticity Scale-88, pain/discomfort subscale, q13–21:
symptomatic effect 92
TABLE 28 Multiple Sclerosis Spasticity Scale-88, muscle spasms subscale, q22–35:
symptomatic effect 92
TABLE 29 Multiple Sclerosis Spasticity Scale-88, ADL subscale, q36–46:
symptomatic effect 93
TABLE 30 Multiple Sclerosis Spasticity Scale-88, walking subscale, q47–56:
symptomatic effect 93
TABLE 31 Multiple Sclerosis Spasticity Scale-88, body movements subscale,
q57–67: symptomatic effect 94
TABLE 32 Multiple Sclerosis Spasticity Scale-88, feelings subscale, q68–80:
symptomatic effect 94
TABLE 33 Multiple Sclerosis Spasticity Scale-88, social function subscale, q81–88:
symptomatic effect 95
TABLE 34 Multiple Sclerosis Impact Scale-29, physical impact subscale:
disease-modifying effect 96
TABLE 35 Multiple Sclerosis Impact Scale-29, psychological impact subscale:
disease-modifying effect 96
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xiv
TABLE 36 Multiple Sclerosis Walking Scale-12: disease-modifying effect 97
TABLE 37 Multiple Sclerosis Spasticity Scale-88, muscle stiffness subscale, q01–12:
disease-modifying effect 97
TABLE 38 Multiple Sclerosis Spasticity Scale-88, pain/discomfort subscale, q13–21:
disease-modifying effect 98
TABLE 39 Multiple Sclerosis Spasticity Scale-88, muscle spasms subscale, q22–35:
disease-modifying effect 98
TABLE 40 Multiple Sclerosis Spasticity Scale-88, ADL subscale, q36–46:
disease-modifying effect 99
TABLE 41 Multiple Sclerosis Spasticity Scale-88, walking subscale, q47–56:
disease-modifying effect 99
TABLE 42 Multiple Sclerosis Spasticity Scale-88, body movements subscale,
q57–67: disease-modifying effect 100
TABLE 43 Multiple Sclerosis Spasticity Scale-88, feelings subscale, q68–80:
disease-modifying effect 100
TABLE 44 Multiple Sclerosis Spasticity Scale-88, social function subscale, q81–88:
disease-modifying effect 101
TABLE 45 Examination of symptomatic treatment effect in baseline EDSS
score-defined subgroups 105
TABLE 46 Examination of disease-modifying treatment effect in baseline
EDSS-defined subgroups 106
TABLE 47 Details of resource use data collected as part of the trial 113
TABLE 48 Unit costs and sources (£, 2010–11) 114
TABLE 49 Summary of missing cost data 117
TABLE 50 Summary of missing EQ-5D data 117
TABLE 51 Intervention resource use and costs (Δ9-THC) 118
TABLE 52 Summary of NHS/PSS costs by treatment group and resource use
category (complete case analysis, costs not discounted) 120
TABLE 53 Total other health and social care costs over trial period (excluding the
cost of the CUPID intervention): regression results (discounted, imputed data) 124
TABLE 54 Comparison of aggregated NHS/PSS mean costs (£) by treatment group
over trial period (discounted imputed data) 124
DOI: 10.3310/hta19120 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 12
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ball et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
xv
TABLE 55 Total costs (including the cost of the CUPID intervention) over trial
period, among the baseline EDSS score of 4.0–5.5 subgroup: regression results
(imputed data, discounted costs) 125
TABLE 56 Comparison of total mean NHS/PSS aggregated costs (£) by treatment
group over trial period for the baseline EDSS score of 4.0–5.5 subgroup
(discounted imputed data) 125
TABLE 57 Summary of private/patient costs (£) by treatment group and resource
use category (complete case analysis, costs not discounted) 126
TABLE 58 Total costs at month 33: regression results (imputed data,
discounted costs) 129
TABLE 59 Total costs over trial period, among baseline EDSS score of 4.0–5.5
subgroup: regression results (imputed data, discounted costs) 129
TABLE 60 Total QALYs at month 36: regression results (discounted,
imputed data) 132
TABLE 61 Quality-adjusted life-years by treatment group and year (imputed,
discounted QALYs) 133
TABLE 62 Total QALYs at month 36: regression results (discounted, imputed
subgroup analysis) 133
TABLE 63 Quality-adjusted life-years by treatment group and year (discounted,
imputed subgroup analysis) 133
TABLE 64 The CUPID study sites and PIs 147
TABLE 65 The CUPID study sites and dates of R&D approval 149
TABLE 66 CUPID study sites and monthly and total numbers of participants
recruited, between May 2006 and July 2008 152
TABLE 67 NHS/PSS resource use in natural units by treatment group and follow-up
(complete case analysis) 169
TABLE 68 NHS/PSS resource use costs by treatment group and follow-up
(complete case analysis, costs not discounted) 174
TABLE 69 Aggregated other NHS/PSS resource use costs by treatment group and
follow-up (discounted costs, complete cases) 179
TABLE 70 Aggregated other NHS/PSS resource use costs by treatment group and
follow-up (discounted costs, imputed data) 179
TABLE 71 Private resource use in natural units by treatment group and follow-up
(complete case analysis) 180
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xvi
TABLE 72 Private resource use costs by treatment group and follow-up
(complete case analysis, undiscounted) 182
TABLE 73 Aggregated private resource use costs by treatment group and
follow-up (discounted, complete cases) 185
TABLE 74 Concomitant medication costs by drug and drug class 186
DOI: 10.3310/hta19120 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 12
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ball et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
xvii

List of figures
FIGURE 1 The Consolidated Standards of Reporting Trials (CONSORT) flow diagram 20
FIGURE 2 Percentiles of prescribed daily dose of trial medication among
non-withdrawals at each visit, by treatment group and weight group 26
FIGURE 3 Kaplan–Meier estimates of the probability of progression on the EDSS
in the two treatment groups, confirmed after 6 months within the study period 32
FIGURE 4 Estimated HRs and 95% CIs for EDSS score progression from a Cox
regression model 33
FIGURE 5 Kaplan–Meier estimates of the probability of progression on the EDSS,
by baseline EDSS score, confirmed after 6 months within the study period 34
FIGURE 6 Estimated HRs (active : placebo) for EDSS score progression, with
95% CIs and p-values from Cox regression models, sequentially removing study
sites with high loss to follow-up for each of the two data sets and each of the
two ways of dealing with losses to follow-up 35
FIGURE 7 Estimated HRs (active : placebo) and 95% CIs for EDSS score
progression by subgroup 40
FIGURE 8 Estimated mean MSIS-29phys score, with 95% CIs, at each visit,
separated by treatment group 41
FIGURE 9 Estimated mean MSWS-12v2, with 95% CIs, at each visit, separated by
treatment group 41
FIGURE 10 Estimated mean MSFC composite (a), T25-FW (b), 9-HPT (c) and PASAT
(d) z-scores, with 95% CIs, at each visit, separated by treatment group 42
FIGURE 11 Estimated mean RMI, with 95% CIs, at each visit, separated by
treatment group 44
FIGURE 12 Estimated mean SF-36(PH), with 95% CIs, at each visit, separated by
treatment group 45
FIGURE 13 Estimated mean MSSS-88 subscales 1–8 scores, with 95% CIs, at each
visit, separated by treatment group 46
FIGURE 14 Estimated mean MSSS-88 (1) total score from subscales 1–3,
concerning muscle stiffness/spasms, pain and discomfort; MSSS-88 (2) total score
from subscales 4–6, concerning activity, walking and body movements; and
MSSS-88 (3) total score from subscales 7 and 8, concerning feelings and social
functioning, with 95% CIs, at each visit, separated by treatment group 49
FIGURE 15 Kaplan–Meier estimates of the probability of discontinuation of trial
medication in the two treatment groups 53
DOI: 10.3310/hta19120 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 12
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ball et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
xix
FIGURE 16 Flow of participants through the MRI substudy 57
FIGURE 17 Estimated mean cumulative PBVC (%), and 95% CI, by treatment
group, measured at yearly MRI visits 59
FIGURE 18 Kaplan–Meier estimates of the probability of progression on the EDSS
in the two treatment groups, confirmed after 6 months within the study period,
among the subgroup of patients with a baseline EDSS score of 4.0–5.5 64
FIGURE 19 Kaplan–Meier estimates of the probability of progression on the EDSS
in the two treatment groups, confirmed after 6 months within the study period,
based on an on-treatment data set, in which withdrawals from trial treatment
are considered as losses to follow-up at the time of withdrawal 65
FIGURE 20 Estimated mean cumulative PBVC (%), and 95% CI, by treatment
group, measured at yearly MRI visits, in the on-treatment data 65
FIGURE 21 Estimated probabilities of EDSS score progression (unconfirmed),
with 95% CI, by starting EDSS score, in each 6-monthly interval from baseline 67
FIGURE 22 Estimated probabilities of EDSS score progression (unconfirmed),
with 95% CI, by starting EDSS score, in all 6-monthly intervals from baseline 70
FIGURE 23 Estimated probabilities of unconfirmed EDSS score progression,
with 95% CI, in each 6-monthly interval from baseline and overall 72
FIGURE 24 Person-item threshold distribution for MSIS-29phys (grouping set to
interval length of 0.20 making 60 groups) 86
FIGURE 25 Person-item threshold distribution for MSWS-12v2 (grouping set to
interval length of 0.20 making 60 groups) 87
FIGURE 26 Standardised response means for the two MSIS-29v2 subscales,
by treatment group 102
FIGURE 27 Individual-person change for the MSIS-29phys, by treatment group 103
FIGURE 28 Standardised response means for the MSIS-29phys, by treatment
group and baseline EDSS score subgroup 107
FIGURE 29 Standardised response means for the MSWS-12v2, by treatment
group and baseline EDSS score subgroup 107
FIGURE 30 Individual-person change for the MSIS-29v2phys, in each treatment
group, by disability subgroup 108
FIGURE 31 Individual-person change for the MSWS-12v2, in each treatment
group, by disability subgroup 109
FIGURE 32 Roadmap to patient-focused outcome measurement in clinical trials 111
FIGURE 33 Qualification of COAs 112
LIST OF FIGURES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xx
FIGURE 34 Proportion (%) of costs attributable to each type of NHS-/PSS-funded
primary or acute care service provider in each treatment group 121
FIGURE 35 Proportion (%) of costs attributable to each type of NHS-/PSS-funded
social care provider in each treatment group 122
FIGURE 36 Proportion (%) of costs attributable to each type of MS-related
hospital episode in each treatment group 123
FIGURE 37 Proportion (%) of costs attributable to each type of private-/
patient-funded primary or acute care service provider in each treatment group 127
FIGURE 38 Proportion (%) of costs attributable to each type of private-/
patient-funded social care provider in each treatment group 128
FIGURE 39 Percentages of the different responses to each of the five dimensions
of the EQ-5D, at each follow-up, separated by treatment group (complete cases) 131
FIGURE 40 Mean EQ-5D scores, with 95% CIs, by treatment group and follow-up 132
FIGURE 41 European Quality of Life-5 Dimensions weighted index score by
follow-up and EDSS subgroup 134
DOI: 10.3310/hta19120 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 12
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ball et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
xxi

List of abbreviations
Δ9-THC Δ9-tetrahydrocannabinol
9-HPT 9-hole peg test
ADL activities of daily living
AE adverse event
ANOVA analysis of variance
BDI-II Beck Depression Inventory-II
CAMS Cannabinoids in Multiple Sclerosis
CI confidence interval
COA clinical outcome assessment
CRF case report form
CTT classical test theory
CUPID Cannabinoid Use in Progressive
Inflammatory brain Disease
DIF differential item functioning
EDSS Expanded Disability Status Scale
EPC End Point Committee
EQ-5D European Quality of Life-5
Dimensions
FDA Food and Drug Administration
GCP Good Clinical Practice
GLM generalised linear model
GP general practitioner
HR hazard ratio
HRQoL health-related quality of life
ICC item characteristic curve
ICE imputation using chained
equations
IDMC Independent Data Monitoring
Committee
ISRCTN International Standard Randomised
Controlled Trial Number
ITT intention to treat
MHRA Medicine and Healthcare products
Regulatory Agency
MRC Medical Research Council
MRI magnetic resonance imaging
MS multiple sclerosis
MSFC Multiple Sclerosis Functional
Composite
MSIS-29phys Multiple Sclerosis Impact Scale-29
version 2 20-point physical subscale
MSIS-29v2 Multiple Sclerosis Impact Scale-29
version 2
MSSS-88 Multiple Sclerosis Spasticity
Scale-88
MSWS-12v2 Multiple Sclerosis Walking Scale-12
version 2
NBV normalised brain volume
NICE National Institute For Health and
Care Excellence
OR odds ratio
PASAT Paced Auditory Serial Addition Test
PBVC percentage brain volume change
PH proportional hazard
PI principal investigator
PPMS primary progressive multiple
sclerosis
PRO patient-reported outcome
PSI person separation index
PSS Personal and Social Services
PSSRU Personal and Social Services
Research Unit
QALY quality-adjusted life-year
DOI: 10.3310/hta19120 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 12
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ball et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
xxiii
R&D research and development
RCT randomised controlled trial
REC research ethics committee
RMI Rivermead Mobility Index
RMT Rasch measurement theory
RRMS relapsing–remitting multiple
sclerosis
SAE serious adverse event
SAP statistical analysis plan
SD standard deviation
SE standard error
SF-36v2 Short Form questionnaire-36 items
version 2
SF-36(PH) Short Form questionnaire-36 items
version 2 (physical health subscale)
SPMS secondary progressive multiple
sclerosis
SRM standardised response mean
SUSAR suspected unexpected serious
adverse reaction
T25-FW timed 25-foot walk
THC tetrahydrocannabinol
TSC Trial Steering Committee
LIST OF ABBREVIATIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxiv
Plain English summary
The Cannabinoid Use in Progressive Inflammatory brain Disease study investigated the effectivenessand safety of the cannabinoid tetrahydrocannabinol (THC) in slowing progressive multiple sclerosis (MS)
over 3 years.
Four hundred and ninety-three people with primary or secondary progressive MS were recruited to the
study from 27 UK sites between May 2006 and July 2008. A requirement of study entry was that walking
was affected by MS but that participants could still walk, with aids if necessary. Participants were randomly
assigned to receive oral THC (329 people) or placebo (164 people) capsules in a ‘double-blind’ manner so
that neither participants nor research staff were aware of treatment allocations. Dose was titrated on an
individual basis according to body weight and side effects, before being gradually reduced to zero after
3 years.
The two primary measures of treatment effectiveness were scores on the Expanded Disability Status Scale
(EDSS) and MS Impact Scale-29 version 2 (MSIS-29v2). The EDSS was assessed 6-monthly, with progression
confirmed if sustained at two consecutive visits. Secondary measures included MS Functional Composite
and various self-completion questionnaires. Participants at 13 sites underwent yearly magnetic resonance
imaging brain scans.
The study found no evidence that THC has an effect on MS progression. EDSS and MSIS-29v2 scores
showed little change over the study period and no difference was found between the THC and placebo
groups. There was some evidence that THC might have a beneficial effect in participants at the lower end
of the disability scale, but numbers were small and further studies will be needed. The study raised no
major issues regarding safety of THC.
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Scientific summary
Background
Multiple sclerosis (MS) is the commonest cause of neurological disability in young adults. It is generally
regarded as an autoimmune disease, with early episodes of inflammation associated with axonal damage,
which becomes the major pathological process as the disease progresses. Initial clinical relapses are often
replaced by secondary gradual progression after several years. Although therapies for the inflammatory
phase are available, none has been shown to slow disease progression in the absence of relapses.
Cannabinoids are used to ameliorate MS-related symptoms, particularly muscle spasticity and pain. Our
previous large multicentre Cannabinoids in MS (CAMS) trial focused on testing symptomatic benefits of
cannabinoids for 15 weeks in 630 participants (95% with progressive disease). A treatment effect on
spasticity (assessed by the Ashworth scale) was not evident, although more participants reported benefits
from symptom alleviation in the active group than in the placebo group. Experimental evidence emerged to
suggest that cannabinoids have neuroprotective effects and might encourage remyelination. A follow-up
study, in which participants, masked to treatment, could continue study medication for up to 12 months,
reported significant effects of dronabinol [Δ9-tetrahydrocannabinol (Δ9-THC)] on spasticity, with some
evidence of an effect on disability, measured by the Expanded Disability Status Scale (EDSS) and Rivermead
Mobility Index (RMI). This provided clinical evidence to support experimental data suggesting that
cannabinoids might have a neuroprotective effect in progressive MS and confirmed that dronabinol
continued to ameliorate patients’ symptoms for up to 12 months. The Cannabinoid Use in Progressive
Inflammatory brain Disease (CUPID) trial aimed to test the hypothesis that oral dronabinol slows progression
of primary progressive MS (PPMS) and secondary progressive MS (SPMS) over 3 years.
Aims
In patients with PPMS and SPMS, three primary aims were investigated over 3 years. These were to:
l assess the value of Δ9-THC in slowing disease progression
l assess the safety of Δ9-THC
l use the information gained to improve methodology for conducting clinical trials in progressive MS.
Methods
Design
The CUPID trial was a randomised, double-blind, placebo-controlled, multicentre, parallel-group study in
adults with PPMS and SPMS, designed to assess the efficacy and safety of Δ9-THC in slowing disease
progression over 3 years.
Setting and participants
Participants were recruited from 27 UK neurology or rehabilitation departments. Eligible patients were
aged 18–65 years, with a diagnosis of PPMS or SPMS, evidence of disease progression in the preceding
year, EDSS score 4.0–6.5 and willingness to abstain from other cannabis use during the trial. Main
exclusion criteria were:
l immunosuppressive or immunomodulatory therapy in previous 12 months
l corticosteroids in previous 3 months
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l significant MS relapse in previous 6 months
l serious illness or medical condition likely to interfere with study assessment
l previous history of psychotic illness
l sesame seed allergy
l pregnancy
l cannabinoids (including nabilone) taken in previous 4 weeks.
Randomisation
Consenting patients were randomly assigned in a 2 : 1 ratio to oral Δ9-THC or placebo. Randomisation
was balanced according to EDSS score, study site and disease type, by stochastic minimisation,
using a computer-generated randomisation sequence. Participants and study staff were blinded to
treatment allocation.
Interventions
Oral Δ9-THC (maximum dose 28mg/day, titrated against body weight and adverse effects) or matching
placebo (vegetable oil capsules).
Outcome measures
Primary clinical outcomes were time to confirmed EDSS score progression (physician based) and change in
Multiple Sclerosis Impact Scale-29 version 2 20-point physical subscale (MSIS-29phys) score (patient based).
Secondary outcomes included: number and nature of adverse events (AEs); MS Walking Scale-12 version 2
(MSWS-12v2) score; MS Functional Composite (MSFC) score; RMI score; Short Form questionnaire-36
items version 2 (SF-36v2) score; European Quality of Life-5 Dimensions (EQ-5D) questionnaire score; MS
Spasticity Scale-88 (MSSS-88) score and category rating scale. Additionally, in the magnetic resonance
imaging (MRI) substudy, outcomes included brain atrophy [in terms of annual percentage brain volume
change (PBVC)] and occurrence of new T1 hypointense and new or newly enlarging T2 hyperintense
lesions from annual cranial MRI.
Expanded Disability Status Scale was assessed by the physician at follow-ups scheduled at 3 and 6 months,
then 6-monthly up to 36 months, unless EDSS score progression was seen at this time, in which case a
further visit was scheduled at 42 months. RMI was also assessed at these visits. MSFC (timed 25-foot walk;
9-hole peg test; paced auditory serial addition test) were assessed at 2 weeks (treated as baseline) and
at 12, 24 and 36 or 42 months. Data on MSIS-29phys, MSWS-12v2, SF-36v2 and EQ-5D were collected
from postal questionnaires at baseline, 3 and 6 months, and then 6-monthly up to 36 or 42 months.
Questionnaires also included MSSS-88 and category rating scales at 12, 24 and 36 or 42 months.
Sample size and power
Previous data suggested a progression rate of approximately 70% in the placebo group. Based on this and
an expected 5% annual loss to follow-up rate, recruiting 492 patients provided 90% power to detect a
one-third reduction in hazard of progression [i.e. hazard ratio (HR) 0.67], corresponding to a relative
reduction in risk of progression over 3 years of 21% (from 70% to 55% progression in the Δ9-THC group).
For the MRI substudy, allowing for a 5% annual loss to follow-up rate, it was estimated that 261 patients
allocated to active treatment and placebo in a 2 : 1 ratio gave 90% power to detect 40% slowing in
atrophy rate, with scans performed pre treatment and at years 1, 2 and 3.
Analysis
Analysis of time to EDSS score progression used Cox proportional hazards models. Analysis of repeated
measures of MSIS-29phys score, secondary clinical outcomes and PBVC used multilevel models, with
individual differences incorporated using random coefficients. Logistic regression models were used to
analyse data on new or newly enlarging T2 and T1 lesions. In all models, between-group differences were
estimated, adjusted for baseline patient and disease characteristics. Analysis, using statistical software R
version 2.14.2 (The R Foundation for Statistical Computing, Vienna, Austria), was by intention to treat.
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Investigation of adverse and serious adverse events
At each follow-up, participants were asked a question to elicit information about new or previously
reported AEs. Events which satisfied criteria for seriousness (according to standard reporting procedures for
clinical trials of investigational medicinal products) were reported by system organ class to an Independent
Data Monitoring Committee for scrutiny. Serious AEs (SAEs) categorised as suspected unexpected serious
adverse reactions were subject to expedited reporting to the sponsor, unblinded independently of the trials
team and reported to the Medicines and Healthcare products Regulatory Agency as required. Identification
and verification of AEs was substantiated by inspection of clinical case notes during site monitoring visits.
Rasch measurement theory
Data from MSIS-29v2, MSWS-12v2 and MSSS-88 were examined using Rasch measurement theory (RMT)
methods. RMT derives, from ordered rating scale scores, linear estimates of constructs they measure, which
are more scientifically sound values to analyse and are associated with individual person standard errors.
First, performance of the scales as measurement instruments was examined. Second, data were examined for
evidence of symptomatic changes (differences between measurements at baseline and end of dose titration
period) and disease-modifying changes (differences between measurements at baseline and last visit), at
group and individual person levels. Analyses included patients who remained on trial medication. At the
group level, statistical and clinical significance was assessed using paired t-tests and two effect sizes (Cohen’s
and standardised response means), respectively. At the individual person level, significance of each person
change score was computed, identifying them as significantly or non-significantly better, unchanged,
non-significantly or significantly worse.
Economic evaluation
In an economic evaluation, the primary analysis was based on a between-group comparison of costs and
quality-adjusted life-years (QALYs) (calculated using EQ-5D scores) over 3 years, from the UK NHS
and Personal Services perspective. Secondary analyses considered costs from the patient perspective.
Costs and QALYs were discounted after the first year at the 3.5% UK treasury rate. Missing data were
imputed using multiple imputation using chained equations. Regression methods were used to estimate
between-group differences in costs and QALYs adjusting for baseline values and pre-specified covariates.
Results
Of the 558 patients assessed for eligibility, 45 (8%) failed to meet the inclusion criteria. Of the 513 eligible
patients, 10 (2%) declined to participate and five (1%) were excluded due to uncontrolled hypertension
(n= 2) and not attending screening appointment (n= 3). Of the remaining 498 patients, 332 were
allocated to active treatment and 166 to placebo, of whom 329 and 164 patients, respectively, were
analysed. There were no important between-group differences in baseline patient and disease
characteristics. Primary analysis showed little evidence of treatment effect on time to confirmed EDSS score
progression. The HR (active : placebo) was 0.92 [95% confidence interval (CI) 0.68 to 1.23]. Conclusions
from this analysis were robust to sensitivity analyses. Pre-specified subgroup analyses of time to EDSS score
progression indicated a differential effect of treatment between participants with lower and higher
baseline EDSS scores. The estimated HR (active : placebo) for the subgroup with baseline EDSS score of
4.0–5.5 was below 1; those with an EDSS score of 6.0 and 6.5 were above 1.
A multilevel model fitted to repeated measures of MSIS-29phys score showed little evidence of a treatment
effect, i.e. the estimated between-group difference in MSIS-29phys score (dronabinol–placebo) was
–0.9 (95% CI –2.0 to 0.2; p= 0.11). Multilevel models showed little evidence of an effect of treatment
on MSFC z-score [estimated between-group difference (dronabinol–placebo) –0.03 (95% CI –0.19 to 0.09;
p= 0.72)]; MSWS-12v2 [estimated between-group difference (dronabinol–placebo) –0.19 (95% CI –0.97
to 0.60; p= 0.74)]; RMI [estimated between-group difference (dronabinol–placebo) 0.04 (95% CI –0.24 to
0.32; p= 076)]; or on any other clinical outcome.
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There was no significant treatment effect on brain atrophy; estimated between-group difference in PBVC
(dronabinol–placebo) –0.01% (95% CI –0.26% to 0.24%; p= 0.94). There was an effect of time on
atrophy (p< 0.0001); on average, cumulative PBVC was estimated to be –0.58%, –1.20% and –2.02% at
years 1, 2 and 3, respectively.
The suggestion of a treatment effect from subgroup analysis of time to EDSS score progression [HR
(active : placebo) 0.52, 95% CI 0.32 to 0.85; baseline EDSS score 4.0–5.5], led to post-hoc analysis of
progression among patients in this EDSS group, which suggested a potentially beneficial effect of active
treatment compared with placebo (p= 0.01, log-rank test). One hundred and fourteen (35%) patients in
the active group and 46 (28%) in the placebo group experienced at least one SAE, the most common
being hospital admission for MS-related events and infections. The number and nature of SAEs was similar
across treatment groups. There were numerous non-serious AEs in both groups, consistent with effects of
MS and the known safety profile of cannabinoids. The median number of events per participant was
11 (25th–75th percentiles 7–17) and 10 (25th–75th percentiles 6–14) in the active and placebo group,
respectively. Loss to follow-up rate was as predicted; however, unwanted side effects contributed to a
relatively high rate of discontinuation from trial medication in the active group. Among patients remaining
on trial medication (n= 178 active; n= 118 placebo), median prescribed daily dose during the final year of
follow-up was four capsules (25th–75th percentiles 2–6 capsules) and six capsules (25th–75th percentiles
4–8 capsules) in the active and placebo group, respectively.
Rasch measurement theory analysis showed that MS-specific scales performed well as measurement
instruments. Targeting was good enough to enable robust evaluation of scale performance and individual
person-level (and group-level) analysis of linear estimates. All subscales of MSIS-29v2, MSWS-12v2 and
MSSS-88 had response categories that worked as intended, items that mapped out continua on which
to measure people, items that were statistically cohesive, minimal or no item bias or instability. However,
targeting plots for some physical function scales (e.g. MSWS-12v2) were skewed, questioning whether or
not some scales underestimate changes and differences occurring in the study. Group-level analyses
of RMT-derived linear estimates implied dronabinol was not associated with symptomatic or
disease-modifying benefit. There was no evidence that dronabinol improved psychosocial functioning.
Post-hoc disability-defined subgroup analyses showed no clear symptomatic or disease-modifying
treatment effect. There were hints of a potential disease-modifying effect with reduced progression
measured by the MSIS-29phys and MSWS-12v2; between-group effect size differences for these two
scales/subscales were clinically moderate to large. These were not supported by benefit on related
MSSS-88 subscales.
Estimated mean incremental cost to the NHS for Δ9-THC over and above usual care over 3 years was
£27,443.20 per treated patient, with no between-group difference in QALYs. Post-hoc subgroup analyses
of patients with baseline EDSS 4.0–5.5 indicated incremental costs at £30,130 and estimated incremental
QALY gain of 0.066, with cost per QALY exceeding £400,000, well above the threshold at which the NHS
would consider an intervention cost-effective.
Conclusions
Primary analyses failed to demonstrate evidence of an effect of dronabinol in slowing progression of MS.
There were no major safety concerns, although compliance was almost certainly affected by minor side
effects leading to less treatment adherence in the active group. There was some evidence of a potentially
beneficial effect of dronabinol in participants with baseline EDSS 4.0–5.5, although this comprised only
20% of recruited participants. Conversely, there was evidence of potential active treatment-related
deterioration in more disabled participants.
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As dronabinol was not shown to be effective, a full cost-effectiveness analysis was not performed.
Analysis of costs and QALYs indicated that introduction of Δ9-THC, in addition to usual care, had
significant additional costs associated with treatment, with no improvement in health outcomes and
was therefore dominated by usual care (i.e. was more costly and no more effective) and not
considered cost-effective.
The CUPID trial was not designed to detect symptom benefit, which has been found in several previous
studies. However, there was some evidence for potential symptom amelioration when ancillary data on
additional medication and side effects were assessed. As a whole, the population recruited to the CUPID
trial was more disabled and progressed less over 3 years than other similar studies. This may have reduced
the potential for detecting a treatment effect if the opportunity to detect an effect is limited to earlier
disease states. Indeed, there was some evidence of a potentially beneficial effect at these lower disability
levels. Conversely, the antispastic symptomatic effect (demonstrated in previous studies) may have
contributed to any deterioration in those less able to walk, as removing spasticity from weak legs may
compromise strength and increase disability. Lack of compliance in the active group may have contributed
to the inability to detect a treatment effect. The continuing absence of disease-modifying treatment in
progressive MS demands that all opportunities to test potential treatments rigorously are taken. Before
cannabinoids are classed in the ‘symptom amelioration-only’ category of treatments, further studies using
better-tolerated treatments in less disabled patients are warranted. Further work is also required to identify
the population of MS patients who are most likely to deteriorate and in whom detection of a treatment
effect is most likely.
Trial registration
This trial is registered as ISRCTN62942668.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research, the Medical Research Council Efficacy and Mechanism Evaluation
programme, the Multiple Sclerosis Society and the Multiple Sclerosis Trust.
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Chapter 1 Introduction
This study was based on a randomised controlled trial (RCT) of oral Δ9-tetrahydrocannabinol (Δ9-THC)compared with matching placebo, in patients with progressive multiple sclerosis (MS), incorporating a
magnetic resonance imaging (MRI) substudy.1 We aimed to test the hypothesis that oral Δ9-THC will slow
progression of primary progressive MS (PPMS) and secondary progressive MS (SPMS) over 3 years.
Structure of this report
The report begins with a summary of the background to MS and treatments for the disease, findings
from our previous study testing symptomatic benefits from cannabinoid use in MS and a review of trials
focusing on alteration of disease course in progressive MS. This first chapter concludes with a description
of the research aims.
The report then describes the methods from the main study and MRI substudy, including study design,
recruitment and randomisation, outcome assessment, sample size and pre-specified statistical analyses.
This is followed by results from pre-specified statistical analyses of the primary and secondary outcomes in
the main study and MRI substudy. Subsequent chapters cover further results from post-hoc exploratory
analyses, Rasch measurement theory (RMT) analysis of rating scale data and economic evaluation.
The final chapters summarise the findings from the study, provide interpretation in the light of previous
studies and discuss the strengths and limitations of the research, implications for health care and
recommendations for future research.
Background and objectives
Multiple sclerosis and cannabinoids
Multiple sclerosis is the commonest cause of neurological disability in young adults, affecting around
100,000 people in the UK. The disease is thought to be due to a complex interaction between genes
(over 100 having been identified in recent association studies) and environment (with possible factors
including low levels of vitamin D and exposure to environmental agents such as the Epstein–Barr virus),
leading to an autoimmune attack on the myelin insulation around central nervous system neurons. Clinically
it typically initially manifests as episodes of relapse and remission in young adults [relapsing–remitting MS
(RRMS)]. Around 15% of people may present with an initial gradual deterioration in neurological function,
mostly at a slightly later age (PPMS). The majority of people who start with RRMS will eventually go on to a
more progressive clinical course (SPMS). MS is fundamentally unpredictable and it is not possible to be
certain about the clinical disease course in any single individual.
Treatments for MS fall into one of four main categories: symptom treatments; treatments for relapse
(corticosteroids); disease-modifying treatments; and other treatments (including physiotherapy). Although
there are an increasing number of disease-modifying treatments, these are all targeted at reducing MS
relapses and, therefore, are only effective in the earlier stages of MS. There are no treatments with proven
efficacy for MS progression in the absence of relapses.
Our initial Medical Research Council (MRC)-funded Cannabinoids in MS (CAMS) study2 focused on testing
symptomatic benefits from cannabinoids over a 15-week period. Participants were included on the basis
of having relatively stable MS in the 6 months prior to study recruitment and, of the 630 who received
treatment, 95% had progressive disease. Following the main 15-week trial period, patients were offered
the opportunity to continue medication in a blinded fashion for up to 12 months, during which period
both disability measures and symptomatic assessments were performed.3 The primary outcome measure
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assessed spasticity using the best available measurement at the time – the Ashworth scale. No treatment
effect on spasticity was found during the main study, although patients felt that active medication was
much more helpful than placebo in alleviating some of their distressing symptoms. This may partly
demonstrate the relative insensitivity of the Ashworth scale and certainly suggests that spasticity is a very
complex phenomenon. During the course of the study, experimental evidence was emerging to suggest
that cannabinoids might have a neuroprotective action, which led to particular interest in the results of the
12-month follow-up study.3 The results of the follow-up study showed significant effects on spasticity
scores in the Δ9-THC arm, but not in the cannabis extract arm. There was also some evidence for an effect
on disability, measured by the Expanded Disability Status Scale (EDSS) and the Rivermead Mobility Index
(RMI). It is worth stressing that although the effect size in the follow-up study may appear modest, we had
not expected to see any effect over a relatively short follow-up period in this group. A degree of possible
self-selection bias could be countered by the intention-to-treat (ITT) analysis (which may have diluted
the effect size), but it must be acknowledged that data acquisition for the long-term phase was not as
complete as it would have been if long-term follow-up had been the initial study aim. However, the CAMS
follow-up results did provide the first clinical evidence to support increasing experimental data raising the
possibility of a neuroprotective effect of cannabinoids, as well as confirming that these medicines
continued to ameliorate patient symptoms.
Most cannabinoid effects appear to be mediated through cannabinoid receptors, two types of which have
been isolated and cloned: CB1 and CB2. CB1 receptors are distributed widely in the nervous system and
seem to have a general role in the inhibition of neurotransmitter release, whereas CB2 receptors are
principally found on cells of the immune system. The discovery of a range of endogenous endocannabinoids,
the most important of which are thought to be 2-arachidonoylglycerol and arachidonoylethanolamide
(anandamide), has also provoked considerable interest. The experimental basis behind a neuroprotective
action for cannabinoids is becoming more convincing, with neuroprotective effects having been
demonstrated in animal models of head injury and MS. There is also in vitro evidence showing cannabinoids
reduce glutamate release and calcium flux as well as being antioxidants, thereby reducing free radical
damage. Excess excitatory neurotransmitter (especially glutamate), release increased calcium influx and free
radical damage have all been implicated in neuronal death and treatment strategies in neurodegenerative
conditions have focused on reducing the impact of some or all of these mechanisms. In addition, CB1
receptor activation has been shown to reduce oligodendrocyte apoptosis in vitro, which may be of
significance to some progressive forms of MS.
Trials in progressive multiple sclerosis
We conducted a systematic review by searching MEDLINE (1950 to May 2013), EMBASE (1980 to May
2013) and all Cochrane databases, using the search terms ‘cannabinoid’, ‘tetrahydrocannabinol’, ‘THC’,
‘multiple sclerosis’, ‘clinical trial’, ‘progression’, ‘primary progressive’, ‘secondary progressive’ and ‘disease
course’. We included all human clinical trials, focusing on alteration of disease course rather than
symptomatic benefit. These searches confirmed that there has never been a clinical trial using cannabinoids
to alter disease course in progressive MS. Although several other treatments have been tested in Phase II
and III clinical trials in progressive disease, including beta-interferons, rituximab, intravenous pooled
immunoglobulins, myelin basic protein peptide and glatiramer acetate, none has demonstrated convincing
clinical benefit.
Despite the considerable interest in developing neuroprotective treatments, several methodological
problems have been encountered in the successful delivery of RCTs in MS, which have affected recent
trials of progressive disease. In particular, difficulties in choice of outcome measure, coupled with high
drop-out rates make long-term studies difficult. Outcome measures used in MS research have been very
labour-intensive, deterring investigators from entering patients in long-term studies. Poor sensitivity means
effect sizes have needed to be large so that smaller effects, which may nevertheless be important from the
patient perspective, may have been missed. Ideally very large studies, with easily measured outcomes,
would provide more convincing evidence of effectiveness. At the moment, however, the field is limited by
methodology and the reluctance to accept alternative ways to measure disease impact. We have been
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focusing on developing patient-orientated outcome measures in the context of RCTs in MS, in order to
concentrate on the patient perspective, increase sensitivity (thereby intending to reduce length, size and
cost of RCTs), improve ease of administration and also aiming to reduce drop-out rates. One of the aims in
the Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial was, therefore, to build on
previous trial methods, incorporate a patient-reported outcome (PRO) as a coprimary outcome measure
and use the trial as a vehicle to develop improved methods for future trial design.
Research aims
l To assess the efficacy of treatment with Δ9-THC in slowing progressive MS over a follow-up period
of 3 years.
l To assess the safety of Δ9-THC.
l To assess the use of patient-orientated outcomes [in particular the MS Impact Scale-29 version 2
(MSIS-29v2) and 20-point physical subscale (MSIS-29phys)], in order to improve the methodology by
which clinical trials are conducted in progressive MS.
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Chapter 2 Methods: main study and magnetic
resonance imaging substudy
Study design
The CUPID study was a double-blind, randomised, placebo-controlled, multicentre, parallel-group trial
incorporating a MRI substudy. The study was designed to assess the safety and effectiveness of Δ9-THC in
slowing MS disease progression over a 3-year period.
Adults with progressive MS4 and an EDSS score of 4.0–6.5 (walking affected by disease but still able to
walk at least 20 metres without rest, with aids if necessary) were randomised individually to receive either
oral Δ9-THC or matching placebo, in a 2 : 1 ratio.
Setting
The study was conducted in 27 NHS study sites in England, Wales and Scotland, comprising 25 hospital
neurology departments and two rehabilitation departments (see Appendix 1). Principal investigators (PIs)
were consultant neurologists or consultants in rehabilitation medicine. The majority of study sites had
expressed an interest in the study and provided feasibility data before the trial started, but two sites were
recruited once the study was under way. Despite early identification of study sites, there was wide
variability in the time taken to obtain NHS research and development (R&D) approval at each site, putting
early pressure on the rate of participant recruitment.
Study approvals
Applications for approval to conduct the study were submitted to the South and West Devon Research
Ethics Committee (REC) and the Medicine and Healthcare products Regulatory Agency (MHRA) in
December 2005.
Research Ethics Committee approval was confirmed on 4 April 2006 following some minor clarifications to
the protocol. The REC reference was 06/Q2103/1. A clinical trial authorisation was granted by the MHRA
on 2 May 2006 following revision of the protocol to include an annual assessment of depression and to
strengthen the contraceptive advice for participants and partners. The trial was assigned European Union
Drug Regulating Authorities Clinical Trials (EudraCT) Number 2005–002728–33 and the International
Standard Randomised Controlled Trial Number (ISRCTN) ISRCTN62942668. NHS R&D approvals were
obtained from all participating sites (see Appendix 2).
Training
All research site staff including neurologists, MS specialist nurses, research nurses, physiotherapists,
pharmacists and MRI staff were invited to attend one of a series of study-specific training days held across
the UK before the start of the study. Training was provided on all aspects of the study protocol including
eligibility, recruitment, consent, prescription and titration of study treatment, study visit and assessment
schedule, study assessments, blinding, pharmacovigilance, data collection documentation, and laboratory
and MRI procedures. Individual training was provided for sites joining the study at a later stage.
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A short EDSS training film was produced specifically for the study and provided to sites in DVD format. All
neurologists undertaking EDSS assessments for the study were required to document that they had viewed
the EDSS training material prior to assessing study participants. A training DVD was also provided for those
site staff conducting the MS Functional Composite (MSFC) assessments and standardised equipment for
conducting the MSFC components [9-hole peg test (9-HPT), timed 25-foot walk (T25-FW) and Paced
Auditory Serial Addition Test (PASAT)] was provided to all sites.
All study team members involved in the recruitment and consent process, data collection, prescription of
trial treatment, adverse event (AE) reporting and participant assessment were required to undertake Good
Clinical Practice (GCP) training and to keep this up to date throughout their involvement in the trial.
Participant eligibility
The study eligibility criteria were as broad and pragmatic as possible to maximise both recruitment and
generalisability of results. As the aim of the study was to investigate the effectiveness of Δ9-THC in slowing
MS progression, patients whose disease had been stable for 12 months or more were excluded from
participation. In the absence of recent documented evidence of disease activity or status, the assessment
of disease stability relied on clinical judgement in discussion with the patient and/or family member.
Factors potentially influencing baseline EDSS assessment (e.g. recent relapse or steroid therapy) were
grounds for exclusion from the trial, but patients in this category could be rescreened for inclusion in the
trial at a later date. It was also deemed necessary to exclude patients with baseline EDSS scores of > 6.5
[an EDSS score of 6.5 was defined as constant bilateral support (canes, crutches or braces) required to
walk about 20 metres without resting] because of the relative difficulties of identifying further progression
in this group.
Inclusion criteria
Potential participants had to satisfy the following criteria to be enrolled in the study:
l 18–65 years old
l diagnosis of PPMS or SPMS
l evidence of disease progression in the preceding year
l EDSS score of 4.0–6.5
l willingness to abstain from other cannabis use during the trial.
Exclusion criteria
Potential participants who met any of the following criteria were excluded from study participation:
l immunosuppressive or immunomodulatory therapy in the previous 12 months
l corticosteroids in the previous 3 months
l significant MS relapse in the previous 6 months
l serious illness or medical condition likely to interfere with study assessment
l previous history of psychotic illness
l sesame seed allergy
l pregnancy
l cannabinoids (including nabilone) taken in the previous 4 weeks (positive urinary cannabinoid test prior
to study entry).
METHODS: MAIN STUDY AND MAGNETIC RESONANCE IMAGING SUBSTUDY
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Recruitment of participants
Patients were prospectively recruited to the study between May 2006 and July 2008. Potential participants
were identified by a health-care professional at each study site, usually from an existing caseload of
patients known to have a diagnosis of PPMS or SPMS. A small number of patients were referred to study
site neurologists by colleagues at non-participating hospitals close to recruiting sites. A few patients
self-referred as a result of publicity about the study in various local and national media or from information
obtained via the internet.
Arrangements for inviting patients to participate in the study varied according to circumstances, local practice
and available resources. As the study started before the inception of the Comprehensive Local Research
Networks, it was adopted onto the UK Clinical Research Network Dementias and Neurodegenerative
Diseases Research Network portfolio which allowed access to research support staff at a few study sites.
Study participants were recruited either individually or in cohorts, depending on practical arrangements
at each site. Some sites held dedicated research clinics and were thus able to follow-up several study
participants in one session. In terms of grouping EDSS assessments and batching laboratory samples, this was
generally an efficient model and was often well received by participants who had contact with one another
as a result. Other sites were only able to recruit and follow-up participants on an individual basis. Monthly
recruitment totals by site are shown in Appendix 3.
Initial identification of potential participants was predominantly by direct consultant referral to the
study team or by screening of hospital records. Potentially eligible patients were then contacted
individually – usually by a research nurse or MS specialist nurse on behalf of the PI – to discuss the study,
ascertain interest and check major eligibility criteria. Group information sessions were held at some sites
for interested patients and their families. Regardless of the mode of contact, all potentially eligible
patients were provided with a participant information sheet (see Appendix 4) for the study. Apparently
eligible patients who were interested in taking part in the study were subsequently invited to attend a
screening visit (visit 1).
Each study site kept a record of the number of patients invited for screening and the number of ineligible,
eligible, non-consenting, consenting, randomised and non-randomised patients was monitored by the
co-ordinating team. Throughout the study, the number of participants who discontinued trial medication
prematurely or were lost to follow-up was recorded, with reasons where known.
Study site personnel
Each study site was required to nominate a treating physician and a separate assessing physician for
the study, with appropriate arrangements for cover in case of staff absence. Treating physicians were
responsible for assessing patient eligibility, obtaining informed consent, prescription and titration of trial
treatment, reviewing participant progress and monitoring and recording AEs and concomitant medications.
Assessing physicians conducted the EDSS assessments. Other study assessments (i.e. the MSFC and RMI)
could be conducted by the assessing physician or a non-clinician with appropriate training. To reduce bias
from potential unblinding, clinicians were advised not to change their role during the study, particularly
from treating physician to assessor; this was monitored by the study co-ordinating team.
Screening visit (consent and entry to trial)
Patients attending the screening visit were given the opportunity to discuss the study and have any
questions answered. The main study inclusion and exclusion criteria were checked by the treating physician
(including EDSS score, assessed by the assessing clinician). Patients who were eligible and willing to
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participate gave written consent for the trial, including consent for their name and address to be held by
the study co-ordinating centre for central management of postal and web-based study questionnaires.
All patients were required to provide blood samples for pre-trial biochemical and haematological analysis
and a urine sample for baseline cannabinoid testing. Demographic data, medical history, concomitant
medications and vital signs were recorded at this visit. The RMI and a MSFC practice run were completed.
Inclusion in the study was confirmed within 2 weeks of the screening visit, following results of the
laboratory tests. Participants’ general practitioners (GPs) were notified of patients’ involvement in the trial
once enrolment had been confirmed.
Study diary
Each participant was given a study diary which provided space for the participant to record any side effects
or other relevant information to aid recall at subsequent study visits. The diary also contained advice on
when/how to take the trial medication, instructions on weekly dosage, research team contact details and
space for study appointment details. The diary contents were not used as part of the study data set.
Randomisation and masking
Once eligibility had been confirmed following receipt of laboratory results, participants were assigned via a
secure computer-generated randomisation system to receive oral Δ9-THC (dronabinol) or matched placebo
capsules for 36 months in a 2 : 1 active-to-placebo ratio. The allocation ratio was chosen in order to
increase the acceptability of the trial to patients, with the aim of maximising recruitment and retention
rates. The randomisation allocation sequence was generated by an independent statistician using a
stochastic minimisation algorithm and balanced according to EDSS score, study site and disease type
(PPMS or SPMS) with a random component. During the study, the independent statistician made periodic
checks of the allocation ratios according to the minimisation factors, to ensure that the randomisation
schedule was performing as intended.
To ensure allocation concealment, treatment assignment was undertaken by the co-ordinating pharmacy
based at the lead hospital site, independently of the research team. The randomisation list was stored
securely within the co-ordinating pharmacy and written procedures were in place in the event of a request
for emergency unblinding, either for clinical reasons or to facilitate monitoring of unexpected serious
adverse reactions.
Participants and all other personnel directly involved in the study were blinded to treatment allocation. The
discussion of symptoms and/or side effects between participants and assessing physicians was actively
discouraged, although assessing physicians occasionally had to review study patients outside the context of
the study, for routine clinical follow-up or during episodes of hospitalisation. On completion of the study,
each participant and the treating and assessing physicians were asked which treatment they thought the
participant had been allocated.
Trial interventions
Trial medication was supplied in bottles by Insys Therapeutics, Inc. (Chandler, AZ, USA), labelled in
accordance with relevant clinical trial guidelines. Active treatment (oral Δ9-THC, dronabinol) consisted of
hard gelatin capsules each containing 3.5 mg of Δ9-THC. Placebo treatment consisted of identically
matched sesame oil capsules such that dronabinol and placebo capsules were indistinguishable.
METHODS: MAIN STUDY AND MAGNETIC RESONANCE IMAGING SUBSTUDY
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Trial medication was originally supplied for storage at room temperature, with a 1-year expiry. Despite the
logistics of scheduling resupply at regular intervals, there were clear advantages to both participants and
study sites in providing trial medication with room temperature stability. However, economic pressures on
the suppliers during the course of the trial led to the introduction of refrigerated medication in order to
increase shelf life and reduce wastage.
Medication was distributed to sites on an individual participant basis by the co-ordinating pharmacy. Initial
supplies were provided on a weight-related basis following randomisation. Once participants were
established on a steady dose, subsequent resupplies were provided on a dose-related basis.
Outcome assessments
The primary clinician-based outcome was time to first EDSS score progression. This was defined as an
increase of at least 1 point from a baseline EDSS score of 4.0–5.0, or at least 0.5 points from a baseline
EDSS score of 5.5–6.5, confirmed at the next scheduled 6-monthly visit. The primary patient-based
outcome measure was change in MSIS-29phys score.
Secondary outcomes included the number and nature of AEs, MS Walking Scale-12 (MSWS-12v2) score,
MSFC score, RMI score, Short Form questionnaire-36 items version 2 (SF-36v2) score, European Quality of
Life-5 Dimensions (EQ-5D) questionnaire score, MS Spasticity Scale-88 (MSSS-88) score and a category
rating scale. In addition, for a subgroup of patients allocated to the MRI substudy, outcomes included
brain atrophy, in terms of annual percentage brain volume change (PBVC) and occurrence of new or newly
enlarging T2 and T1 lesions from annual cranial MRI.
The EDSS was assessed at each site by a neurologist, following study-specific training. The MSFC
assessment was performed by a non-physician, as long as training had been given. The RMI was similarly
assessed every 6 months.
Participant-completed questionnaires
Between the screening and baseline visits, participants were asked to complete a questionnaire booklet
comprising the MSIS-29v2, MSWS-12v2, SF-36v2, EQ-5D, MSSS-88 and category rating scale. The
questionnaire booklet was repeated in its entirety at 3, 12, 24 and 36 months and (excluding the MSSS-88
and category rating scale) at 6, 18 and 30 months.
The baseline questionnaire was sent to all participants by post from the co-ordinating centre with a
pre-paid reply envelope. Thereafter, participants could choose to complete subsequent questionnaires by
post or online via a secure web-based system. In the event of non-receipt of completed questionnaires,
repeat copies were sent, with e-mail reminders to those participants opting for online completion.
Participants were also asked to complete the Beck Depression Inventory-II (BDI-II) at baseline and annually
thereafter. As the BDI-II was included as a safety measure rather than an outcome assessment, total scores
were reported directly to PIs as they were provided.
Baseline visit (provision of trial medication)
The baseline visit (visit 2) was held approximately 2–4 weeks after the screening visit, following
confirmation of eligibility and randomisation. Vital signs and AEs were recorded at this visit and the
baseline MSFC assessment was completed. A prescription for trial medication was provided, with a starting
dose of one capsule (3.5 mg of Δ9-THC equivalent) twice daily for all participants.
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Owing to the large interindividual dose variation with oral cannabinoids, there was a 4-week titration
period in which participants in both study arms could increase their dose by one capsule twice daily
at weekly intervals, to a maximum weight-related dose (Table 1). Dose progression depended on adverse
effects. If unwanted side effects developed, participants were advised not to increase the dose. If these
side effects were considered intolerable, the dose was reduced.
Subsequent participant follow-up
Participants were scheduled to attend follow-up visits with the treating physician at 2 and 4 weeks after
the baseline visit, for AE monitoring and dose adjustment. Once participants had been settled on a suitable
treatment dose, clinician-based outcome data were collected at assessment visits at 3 and 6 months, then
6-monthly up to 36 months. Participants who demonstrated new EDSS score progression according to
the defined study end point at 36 months attended a further visit at 42 months to confirm EDSS score
progression. Monitoring of AEs, recording of vital signs and collection of safety blood samples were
undertaken at the clinic visits. Urine samples for cannabinoid analysis were requested from each participant
approximately four times during the study according to a random schedule, with the aim of detecting illicit
cannabis use in the placebo group. Study medication was gradually discontinued over a period of a few
weeks from the final visit (36 or 42 months depending on EDSS status). Table 2 shows the CUPID study
visit and questionnaire completion schedule.
Various strategies were implemented during the course of the study to improve follow-up and data
collection. It was identified that the completion rate for online questionnaires was lower than for postal
questionnaires, despite e-mail reminders. Recognising that study participants may access their e-mail
sporadically and, therefore, may miss electronic reminders, the co-ordinating centre added postal
reminders, leading to an improvement in online completion rates.
The number and length of PROs appeared burdensome for a number of participants, including some who
discontinued study medication prematurely but agreed to remain in follow-up. At the discretion of the
co-ordinating centre, the questionnaire battery was reduced for some individual participants in order to
secure at least some outcome data which otherwise were at risk of being lost completely. In these
circumstances, priority was given to capturing the patient-reported primary outcome data (MSIS-29v2)
at the expense of other measures, if necessary.
For participants in whom visual or motor/sensory impairment made questionnaire completion difficult,
telephone support was provided by the co-ordinating centre to supply responses. Some participants
with accumulating disability found it increasingly troublesome or tiring to attend clinic visits for EDSS
assessment. Participants in this category who had also stopped medication prematurely were particularly at
risk of being lost to follow-up since they had no need to attend in person for repeat supply of medication.
To improve data completeness, the option of validated telephone EDSS assessment for participants unable
or unwilling to attend clinic visits was introduced from June 2010. All telephone EDSS assessments were
conducted by a trained clinician from the Plymouth co-ordinating team, following formal consent
from participants.
TABLE 1 Number of capsules prescribed according to weight of participants at baseline
Weight (kg) Week 1 Week 2 Week 3 Week 4 to study end
< 60 One capsule twice a day Two capsules twice a day Two capsules twice a day Two capsules twice a day
60–80 One capsule twice a day Two capsules twice a day Three capsules twice a day Three capsules twice a day
> 80 One capsule twice a day Two capsules twice a day Three capsules twice a day Four capsules twice a day
METHODS: MAIN STUDY AND MAGNETIC RESONANCE IMAGING SUBSTUDY
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Safety monitoring
In addition to the annual assessment of depression (BDI-II), safety monitoring included standard clinical
laboratory assessments (chemistry, haematology, liver function) at 3 and 6 months and 6-monthly
thereafter. Blood samples were analysed by a central laboratory and results reported to the PI by the
co-ordinating centre.
Assessment of AEs was undertaken by the investigator at each study visit, with particular emphasis on the
titration phase. If participants could not attend either the 2- or 4-week visit, site teams were encouraged to
review AEs by telephone in order to optimise the individual dose of study treatment for each participant.
Signs and symptoms were graded as mild, moderate or severe. Seriousness and causality were assessed by
the reporting PI. AEs satisfying the criteria for serious AEs (SAEs) were subject to expedited reporting to
the co-ordinating centre where a second assessment of causality was made. If either causality assessment
indicated a definite, probable or possible relationship to study medication, an assessment of expectedness
was made with reference to the current Investigator’s Brochure.
Magnetic resonance imaging substudy
Thirteen study sites participated in a MRI substudy. MRI site selection was on the basis of capacity and
cost, with all MRI sites being required to perform a pre-enrolment qualifying scan prior to the start of
participant recruitment. Non-contrast brain MRI was performed at baseline and annually in 273 participants
(183 allocated to active treatment, 91 allocated to placebo). Images were analysed for PBVC and new
and enlarging lesions at the Queen Square Multiple Sclerosis Centre, NMR Research Unit Trials Office,
University College London’s Institute of Neurology, London, UK.
Data management and monitoring
Paper-based, two-part, no-carbon-required case report forms (CRFs) were used for both treating
physician- and assessor-acquired data. Original data were sent by post to the co-ordinating centre in
Plymouth and entered onto a central database held on a secure server. A system of double data entry
was used, enabling generation of a single data set following a process of data comparison. Bespoke
database reports were created to track participant status throughout the trial and ensure that data were
requested and received from sites in a timely manner. A robust process was in place for clarification of
queries in the case of missing or ambiguous data. The quality of the trial data were monitored using a
combination of centralised data checking and site visits at which participant CRFs were compared with
clinical case notes. Participants returned their self-completion questionnaires in Freepost™ envelopes
directly to the co-ordinating office for double data entry.
Trial oversight
A Trial Steering Committee (TSC) (see Appendix 5 for details), including an independent chairperson, a
neurologist, a statistician and a lay representative, was responsible for trial oversight and met on an annual
basis. An independent Data Monitoring Committee (IDMC) (see Appendix 5 for details) met annually to
review unblinded safety and efficacy data. Interim analyses of primary outcomes were produced by an
independent statistician on request from the IDMC, using the pre-defined Haybittle–Peto boundary
stopping rule. Four interim analyses were undertaken after 298 and 493 participants had been recruited
and, then, annually during the follow-up period. The IDMC recommended continuation of the trial
following all interim analyses. Appendix 6 gives details of patient and public involvement in the
CUPID study.
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Sample size and power
Previous data suggested a likely progression rate of approximately 70% in the placebo group.5 Based on
this and an expected 5% annual loss to follow-up rate, recruiting 492 patients provided 90% power, at a
two-sided 5% significance level, to detect a one-third reduction in hazard of progression [i.e. hazard ratio
(HR) 0.67], corresponding to a relative reduction in risk of progression over 3 years of 21% (from 70% to
55% progression in the Δ9-THC group).
Initial data from 210 patients with MS admitted in acute relapse for intravenous steroid treatment baseline
and post treatment showed the standard deviation (SD) of the scores from MSIS-29v2 at baseline and
follow-up were 21.8 and 24.3, respectively (Professor Jeremy Hobart, Institute of Neurology, London,
1999–2002, unpublished data). The SD of the difference in scores was estimated to be 20.6. With this SD,
a difference in means of seven points (one-third of a SD) could be detected in a sample of 492 on a
two-sided test carried out at the 5% level, with power in excess of 90%.
For the MRI substudy, allowing for losses to follow-up at a rate of 5% per year, it was estimated that a
total of 261 patients, allocated to active treatment and placebo in a 2 : 1 ratio, would give 90% power to
detect 40% slowing in rate of atrophy, with scans performed pre treatment and then at years 1, 2 and 3.
End Point Committee
An End Point Committee (EPC) was convened to adjudicate on EDSS score progression in participants
for whom missing EDSS scores prevented confirmation of this end point according to protocol. The
committee, comprising the chief investigator and two other consultant neurologists (one independent),
met once on 27 February 2012. The EPC review was blinded to treatment allocation and included
consideration of additional clinical details obtained from participants’ medical records. The outcomes
determined by this committee were used in sensitivity analyses of EDSS score progression. Terms of
reference are outlined in Appendix 7.
Statistical methods
The statistical analysis plan (SAP) was finalised and agreed by the TSC before unblinding. Data analysis,
using the statistical software R version 2.14.2 (The R Foundation for Statistical Computing, Vienna,
Austria), was undertaken on an ITT basis. All tests were carried out at the 5% significance level, with no
adjustments for multiple testing.
In models for each outcome, main effects of study site, baseline EDSS score, disease type, age at
registration, sex and weight were considered, as well as treatment allocation.
Pre-specified analyses of primary clinical outcomes
Primary analysis of time to first Expanded Disability Status Scale
score progression
Kaplan–Meier estimates were used to show probability of EDSS score progression in the two treatment
groups and in groups defined in terms of baseline EDSS score. Analysis of time to first EDSS score
progression used a Cox proportional hazards (PH) model. Primary analysis was based on EDSS data
obtained according to trial schedule; losses to follow-up before confirmed progression were considered
as missing data and treated as censored observations at the time of the last visit for which EDSS
measurements were taken.
METHODS: MAIN STUDY AND MAGNETIC RESONANCE IMAGING SUBSTUDY
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Sensitivity analyses of time to first Expanded Disability Status Scale
score progression
Sensitivity of conclusions from the main analysis of time to first EDSS score progression were assessed by
repeating the analysis, considering all losses to follow-up as progression events at the time of the
scheduled visit after the last visit for which EDSS measurements were taken.
Evidence for the sensitivity of conclusions to the effect of study sites with high losses to follow-up was
assessed by repeating the analysis, under each way of dealing with losses to follow-up (censored
observations or progression events), sequentially removing study sites with high rates of loss to follow-up.
Furthermore, sensitivity of conclusions to the decisions from the EPC review regarding EDSS score
progressions was assessed by repeating the analysis, under each way of dealing with losses to follow-up,
incorporating the findings from the EPC review.
Subgroup analyses of time to first Expanded Disability Status Scale
score progression
Hazard ratios (active : placebo) for EDSS score progression, in subgroups defined by sex, baseline EDSS
score, disease type, weight and age, were estimated.
Primary analysis of change in Multiple Sclerosis Impact Scale-29 20-point
physical subscale
Total MSIS-29phys scores were calculated using previously published methods.6 Repeated measures data
on MSIS-29phys were analysed using multilevel models, which included time (visit) as well as the other
pre-specified covariates. Individual differences in scores were incorporated using random coefficients.7
Backward elimination was used to identify a final, reduced model, including effects significant at the 5%
level, as well as effects of time and treatment allocation.
Pre-specified analyses of secondary clinical outcomes
Multiple Sclerosis Functional Composite, Multiple Sclerosis Walking Scale-12,
Rivermead Mobility Index, Short Form questionnaire-36 items (physical
health subscale), Multiple Sclerosis Spasticity Scale-88
Scores for each MSFC component were calculated using previously published methods.8 MSFC
component-wise z-scores9 were computed using results from all participants at visit 2 as the reference
population.8 MSFC composite scores were calculated from the mean of the component-wise z-scores.
Total scores for MSWS-12v2,10 RMI,6 SF-36v2 physical health subscale [SF-36(PH)]11 and MSSS-8812 were
calculated using an algorithm analogous to that used for MSIS-29phys for dealing with missing data.
Repeated measures of MSFC (composite and component-wise z-scores), MSWS-12v2 (total score),
RMI (total score), SF-36(PH) (total score) and MSSS-88 [total score for each of three sections from the eight
subscales, where MSSS-88 (1) combines subscales 1–3 and concerns muscle stiffness/spasms, pain and
discomfort; MSSS-88 (2) combines subscales 4–6 and concerns activity, walking and body movements;
and MSSS-88 (3) combines subscales 7 and 8 and concerns feelings and social functioning], were analysed
using multilevel models, using the same covariates and variable selection procedure as for MSIS-29phys.
Investigation of adverse events and serious adverse events
Serious adverse events and the most common AEs (i.e. those which affected at least 10% of all
participants) were summarised in terms of frequencies and relative frequencies.
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Category rating scales
Category rating scales, included in patient-completed questionnaires sent at 3 months, 1, 2 and 3 years
from baseline (visits 5, 7, 9 and 11), consisted of 16 questions: 1–8 related to how the patient felt over the
past week and 9–16 related to how the patient felt at the time of completing the questionnaire compared
with just before the start of the study. Analysis focused on questions 9–16, which were on a 1–11 scale,
where 1= very much better; 6= no difference; and 11= very much worse. Responses to these questions
were grouped as 1–5= better; 6= no change; 7–11=worse and summarised in terms of frequencies and
relative frequencies in the two treatment groups, at each follow-up. Chi-squared tests for trend were used
to test for an association between treatment allocation and response to question, allowing for the ordered
nature of the grouped responses. No adjustments were made for multiple comparisons.
Analysis of premature discontinuations of trial medication and losses
to follow-up
Kaplan–Meier estimates were used to show probability of discontinuation of trial medication in the two
treatment groups. Analyses of time to discontinuation of trial medication or loss to follow-up used Cox PH
models, in order to investigate the effect of treatment allocation and any potential pre-randomisation
variables, on the risk of discontinuation. A forward selection procedure was used to identify a suitable
model, including effects significant at the 5% level.
Pre-specified analyses of magnetic resonance imaging substudy
A multilevel model was used to analyse repeated measures data on PBVC13,14 from cranial MRI,
transformed to cumulative, relative PBVC on the log10 scale.
Logistic regression models were used to examine the effect of treatment allocation and other pre-specified
covariates on new T1 hypointense and new or enlarging T2 hyperintense lesions during follow-up.
Participants were classified as having either no, or at least one, new or enlarging lesion(s) during
follow-up. Final models were identified using a forward selection procedure and included main effects
and interactions significant at the 5% level, as well as the main effect of treatment.
Further analyses
Details of post-hoc exploratory analyses performed on outcomes from the main study and MRI substudy
are presented in Chapter 4.
One of the goals of the CUPID trial was to examine the contribution of advanced, but not widely used,
methods, particularly rating scale psychometric methods. With this in mind we undertook a RMT-based
analysis of data generation by the MSIS-29v2, MSWS-12v2 and MSSS-88. Specifically, when compared
with traditional psychometric methods, RMT enables a more sophisticated evaluation of rating scale
performance, the generation (contingent on appropriate findings) of interval-level measurements for
analysis (rather than ordinal scores) and legitimate analyses of changes and differences at the individual
person level. These methods are studied in detail in Chapter 5. An economic evaluation is detailed in
Chapter 6.
Ethics and research governance approval
The study was approved by the South and West Devon REC and conducted in accordance with
GCP guidelines. Eligible patients provided written informed consent before participation.
Trial registration
The trial was registered as Current Controlled Trials ISRCTN62942668.
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Role of the funding source
The funders had no role in study design, data collection, analysis, interpretation or writing of the report.
Summary of changes to the study protocol
The protocol as approved by MHRA and REC at the start of the study underwent four amendments of
significance to the conduct of the study. An additional exclusion criterion (recent use of any experimental
therapies with potential disease-modifying actions) was added during the first few months of the study
in order to reduce potential confounding of results. At the start of 2009, refrigerated storage conditions
for the trial medication were introduced. In April 2009, an additional follow-up phase was added to the
study – this used the fact that participants with new EDSS progression at 36 months were required to
be reviewed at 42 months on treatment as an opportunity to follow up the remaining participants off
treatment from months 36 and 42. The protocol was last amended in May 2010 to include the option of
EDSS assessment by telephone as opposed to face to face.
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Chapter 3 Results: main study and magnetic
resonance imaging substudy
Patients were randomised between May 2006 and July 2008 and the final follow-up data collectiontook place in January 2012.
Unblinding of randomised treatments
The treatment allocation was unblinded six times during the course of the trial at the request of the
sponsor organisation to assist in the management of suspected unexpected serious adverse reactions
(SUSARs). In addition, unblinding of four participants at four separate sites was carried out at the request
of the local investigator, on clinical grounds.
Telephone-based assessment of Expanded Disability Status
Scale score
Of 3812 assessments of EDSS score over the study period, 42 (1.1%) were by telephone, rather than face
to face. These telephone assessments were carried out on a total of 39 patients (25 assigned to active;
14 assigned to placebo).
Figure 1 shows the trial profile and Table 3 shows discontinuations of trial medication and losses to
follow-up. A total of 498 patients were randomly assigned to active treatment (n= 332) or matching
placebo (n= 166). The data from three patients (two randomised to active, one to placebo) were
removed from the trial because they withdrew their consent after randomisation. A further two patients
(one randomised to active, one to placebo) were found to be ineligible after randomisation. Four hundred
and ninety-three (329 active, 164 placebo) received their allocated intervention and were therefore
included in an ITT analysis. Of the 493 randomised and treated participants, 415 (84%) completed
follow-up, of whom 119 (29%) had prematurely discontinued trial medication (Figure 1).
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Assessed for eligibility (N = 558)
(549 unique patients)a
Excluded (n = 60)
Allocated to placebo (n = 166)Allocated to active intervention (n = 332)
• Did not meet inclusion criteria, n = 45
• Declined to participate, n = 10
• DNA screening appointment, n = 3
• Uncontrolled hypertension, n = 2
• Received allocated intervention, n = 164• Received allocated intervention, n = 329
• Did not receive allocated intervention, n = 2• Did not receive allocated intervention, n = 3
° Withdrew consent, n = 2
° Uncontrolled hypertension, n = 1
° Withdrew consent, n = 1
° Ineligible (medical history), n = 1
Randomised (n = 498)
Lost to follow-up (n = 62)
(six reached PEP)
Lost to follow-up (n = 16)
(one reached PEP)
Completed follow-up (n = 267, of whom 89
discontinued intervention prematurely)
Excluded from analysis (n = 0)
Completed follow-up (n = 148, of whom 30
discontinued intervention prematurely)
Excluded from analysis (n = 0)
FIGURE 1 The Consolidated Standards of Reporting Trials (CONSORT) flow diagram. a, Nine patients initially did
not fulfil entry criteria, but did so on subsequent rescreening. DNA, did not attend; PEP, primary end point of
EDSS score progression.
TABLE 3 Analysis set and study completion (all randomised patients)
Analysis population and scenarios
for follow-up
All randomised patients (N= 498)
Active (n= 329; 66.7%) Placebo (n= 164; 33.3%) All (n= 493)
Analysis population, n (%)
Full analysis set 329 (99.1) 164 (98.8) 493 (99.0)
Scenarios for follow-up, n (%) of full analysis set
Completed follow-up on trial treatment 178 (54.1) 118 (72.0) 296 (60.0)
Completed follow-up having prematurely
discontinued trial medication
89 (27.1) 30 (18.3) 119 (24.1)
Discontinued trial medication and
subsequently lost to follow-up
51 (15.5) 10 (6.1) 61 (12.4)
Lost to follow-up without previous
discontinuation of trial medication
11 (3.3) 6 (3.7) 17 (3.4)
Percentages may not sum to 100 due to rounding.
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Baseline comparability of randomised groups
Baseline patient and disease characteristics were similar in both treatment groups (Table 4). At baseline,
59% of participants were women, 61% had SPMS and 78% had an EDSS score of 6.0 or 6.5. There were
no important differences in outcome measures assessed at baseline (Table 5).
TABLE 4 Baseline characteristics of patients by treatment group and overall
Patient baseline characteristics
Randomised patients (N= 493;a 100%)
Active (n= 329; 66.7%) Placebo (n= 164; 33.3%) All (n= 493)
Age in years, mean (SD) 52.29 (7.6) 51.97 (8.2) 52.19 (7.8)
Weight in kg, mean (SD) 74.54 (16.5) 75.93 (16.5) 75.00 (16.5)
Men, n (%) 133 (40.4) 68 (41.5) 201 (40.8)
Women, n (%) 196 (59.6) 96 (58.5) 292 (59.2)
Disease type, n (%)b
PPMS 126 (38.3) 65 (39.6) 191 (38.7)
SPMS 203 (61.7) 99 (60.4) 302 (61.3)
EDSS score, n (%)b
4.0 20 (6.1) 9 (5.5) 29 (5.9)
4.5 18 (5.5) 7 (4.3) 25 (5.1)
5.0 22 (6.7) 10 (6.1) 32 (6.5)
5.5 16 (4.9) 8 (4.9) 24 (4.9)
6.0 169 (51.4) 85 (51.8) 254 (51.5)
6.5 84 (25.5) 45 (27.4) 129 (26.2)
Median (25th–75th percentiles) 6.0 (6.0–6.5) 6.0 (6.0–6.5) 6.0 (6.0–6.5)
Mean (SD) 5.83 (0.69) 5.88 (0.67) 5.85 (0.69)
a Excluding five post-randomisation exclusions.
b Stratification/minimisation variable.
Percentages may not sum to 100 due to rounding.
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TABLE 5 Outcome variables at baseline for patients randomised to the two treatment groups
Outcome measures at baseline
Randomised patients (N= 493;a 100%)
Active (n= 329; 66.7%) Placebo (n= 164; 33.3%) All (n= 493)
EDSS scoreb
Mean (SD) 5.83 (0.69) 5.88 (0.67) 5.85 (0.69)
Median (25th–75th percentiles) 6.0 (6.0–6.5) 6.0 (6.0–6.5) 6.0 (6.0–6.5)
MSIS-29phys scorec
Mean (SD) 55.03 (10.81) 55.19 (10.96) 55.08 (10.85)
Median (25th–75th percentiles) 55 (47.00–63.00) 56 (47.25–63.00) 55.78 (47.00–63.00)
Not reported, n (%) 3 (0.9) 2 (1.2) 5 (1.0)
MSFC componentsd
T25-FW
Time in seconds,e mean (SD) 20.34 30.16 15.25 13.41 18.64 25.9
Median (25th–75th percentiles) 10.95 (7.95–18.60) 10.85 (7.85–16.55) 10.90 (7.90–17.54)
Not reported, n (%) 4 (1.2) 1 (0.6) 5 (1.0)
9-HPT (dominant hand)
Time in seconds, mean (SD) 36.74 (41.68) 38.65 (43.42) 37.37 (42.23)
Median (25th–75th percentiles) 27.27 (22.39–34.1) 27.4 (22.89–35.34) 27.33 (22.55–34.79)
Not reported, n (%) 1 (0.3) 0 (0.0) 1 (0.2)
9-HPT (non-dominant hand)
Time in seconds, mean (SD) 41.79 (49.31) 34.82 (27.13) 39.46 (43.3)
Median (25th–75th percentiles) 28.08 (23.25–36.94) 28.62 (24.74–35.45) 28.12 (23.44–36.55)
Not reported, n (%) 1 (0.3) 0 (0.0) 1 (0.2)
9-HPT (standard score)f
Mean (SD) 0.04 (0.01) 0.03 (0.01) 0.04 (0.01)
Median (25th–75th percentiles) 0.04 (0.03–0.04) 0.04 (0.03–0.04) 0.04 (0.03–0.04)
Not reported, n (%) 1 (0.3) 0 (0.0) 1 (0.2)
PASAT scoreg
Mean (SD) 41.43 (13.75) 41.02 (13.42) 41.29 (13.63)
Median (25th–75th percentiles) 43 (30–53) 42 (31–53) 43 (31–53)
Not reported, n (%) 2 (0.6) 3 (1.8) 5 (1.0)
MSWS-12v2h
Mean (SD) 45.51 (6.96) 45.26 (7.14) 45.42 (7.01)
Median (25th–75th percentiles) 47 (42–51) 47 (41–51) 47 (41–51)
Not reported, n (%) 3 (0.9) 5 (3.0) 8 (1.6)
RMIi
Mean (SD) 11.40 2.51 11.64 2.20 11.48 2.41
Median (25th–75th percentiles) 12 (10–13) 12 (10–13) 12 (10–13)
Not reported, n (%) 1 (0.3) 0 (0.0) 1 (0.2)
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TABLE 5 Outcome variables at baseline for patients randomised to the two treatment groups (continued )
Outcome measures at baseline
Randomised patients (N= 493;a 100%)
Active (n= 329; 66.7%) Placebo (n= 164; 33.3%) All (n= 493)
SF-36(PH)j
Mean (SD) 44.31 6.08 44.18 5.76 44.26 5.97
Median (25th–75th percentiles) 44 (40.5–48.0) 44 (40.25–47.00) 44 (40–48)
Not reported, n (%) 2 (0.6) 2 (1.2) 4 (0.8)
MSSS-88
Section 1k
Mean (SD) 71.97 21.14 73.60 22.10 72.51 21.45
Median (25th–75th percentiles) 70 (55–84) 71 (56–88) 70 (55.26–85.00)
Not reported, n (%) 2 (0.61) 1 (0.61) 3 (0.61)
Section 2l
Mean (SD) 77.96 20.78 80.30 20.90 78.73 20.83
Median (25th–75th percentiles) 77 (63.5–93.0) 81 (66.00–94.97) 78.23 (64–94)
Not reported, n (%) 2 (0.61) 3 (1.83) 5 (1.00)
Section 3m
Mean (SD) 44.29 15.13 45.19 15.67 44.59 15.30
Median (25th–75th percentiles) 42 (32–55) 44 (32.25–56.75) 43 (32.0–55.5)
Not reported, n (%) 8 (2.43) 2 (1.22) 10 (2.00)
a Excluding five post-randomisation exclusions.
b Higher score indicates greater disability.
c Total score, calculated according to standard procedure for dealing with missing data, with a possible range from 20 to
80; a higher score indicates a greater physical impact of MS.
d Measured during visit 2 (visit 1 was a practice visit).
e A longer time indicates worse mobility and leg function.
f Standard score, calculated as the mean of the reciprocal of the mean of the dominant hand score and the reciprocal of
the mean of the non-dominant hand score; a higher score indicates greater finger dexterity.
g Standard score, corresponding to the number of correctly answered questions out of 60; a higher score indicates
greater capacity and rate of information processing.
h Total score, calculated according to standard procedure for dealing with missing data, with a possible range from 12 to
52; a higher score indicates a greater walking impairment.
i Total score, calculated according to standard procedure for dealing with missing data, with a possible range from 0 to
15; a lower score indicates worse mobility.
j Total score for the physical component, calculated according to standard procedure for dealing with missing data, with
a possible range from 12 to 112; a lower score indicates greater disability.
k Total score from subscales 1–3, calculated according to standard procedure for dealing with missing data, with a
possible range from 35 to 140; a higher score indicates greater distress.
l Total score from subscales 4–6, calculated according to standard procedure for dealing with missing data, with a
possible range from 32 to 128; a higher score indicates greater distress.
m Total score from subscales 7–8, calculated according to standard procedure for dealing with missing data, with a
possible range from 21 to 84; a higher score indicates greater distress.
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Prescribed dose of trial medication
Prescribed daily doses of trial medication at each 6-monthly follow-up are summarised in Table 6 for those
patients not discontinuing trial medication and for all patients. Among those patients not withdrawing
from trial medication (n= 178 active, n= 118 placebo), median prescribed daily dose during final year of
follow-up was four capsules (25th–75th percentiles 2–6 capsules) in the active group compared with six
(25th–75th percentiles 4–8 capsules) in the placebo group. Final year medians among all patients were four
capsules (25th–75th percentiles 2.0–5.5) for active and six capsules (25th–75th percentiles 4–8 capsules)
for placebo. Percentiles of prescribed daily dose among non-withdrawals, by treatment group and weight
group, are shown in Figure 2.
TABLE 6 Prescribed daily dose of trial medication at each 6-monthly follow-up, by treatment group, among
non-withdrawals and overall
Prescribed daily dose
(number of capsules)
of trial medication
Visit
Week 5 Week 13 Month 7 Month 13 Month 19 Month 25 Month 31
Non-withdrawals (n = 296)
Active (n= 178)
n 177 176 177 178 178 177 177
Missing 1 2 1 0 0 1 1
Mean 5 4.48 4.26 4.06 4.05 3.99 3.91
SD 1.91 1.97 2.02 2 2.02 1.98 1.93
Median 5 4 4 4 4 4 4
25th percentile 4 3 3 2 2 2 2
75th percentile 6 6 6 6 6 6 5
Minimum 1 1 1 1 1 1 1
Maximum 8 8 8 8 8 8 8
Placebo (n= 118)
n 117 118 118 118 118 118 118
Missing 1 0 0 0 0 0 0
Mean 6.32 6.14 5.97 5.92 5.85 5.85 5.85
SD 1.57 1.67 1.81 1.91 1.92 1.92 1.92
Median 6 6 6 6 6 6 6
25th percentile 6 5.25 4 4 4 4 4
75th percentile 8 8 8 8 8 8 8
Minimum 2 1 1 1 1 1 1
Maximum 8 8 8 8 8 8 8
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TABLE 6 Prescribed daily dose of trial medication at each 6-monthly follow-up, by treatment group, among
non-withdrawals and overall (continued )
Prescribed daily dose
(number of capsules)
of trial medication
Visit
Week 5 Week 13 Month 7 Month 13 Month 19 Month 25 Month 31
All patients (n = 493)
Active (n= 329)
n 315 290 260 235 215 198 189
Missing 14 39 69 94 114 131 140
Mean 4.98 4.31 4.08 3.94 3.91 3.94 3.91
SD 1.96 2 2.03 2.02 2.02 1.97 1.95
Median 5 4 4 4 4 4 4
25th percentile 4 3 2 2 2 2 2
75th percentile 6 6 6 6 6 6 5
Minimum 1 1 1 1 1 1 1
Maximum 8 8 8 8 8 8 8
Placebo (n= 164)
n 161 157 146 138 131 125 123
Missing 3 7 18 26 33 39 41
Mean 6.2 6.05 5.93 5.9 5.91 5.92 5.92
SD 1.57 1.68 1.76 1.89 1.89 1.91 1.92
Median 6 6 6 6 6 6 6
25th percentile 6 5 4 4 4 4 4
75th percentile 8 8 8 8 8 8 8
Minimum 2 1 1 1 1 1 1
Maximum 8 8 8 8 8 8 8
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FIGURE 2 Percentiles of prescribed daily dose of trial medication among non-withdrawals at each visit, by
treatment group and weight group. (a) Active, weight < 60 kg; (b) active, weight 60–80 kg; (c) active, weight
> 80 kg; (d) placebo, weight < 60 kg; (e) placebo, weight 60–80 kg; and (f) active, weight > 80 kg. Heavy solid line,
median; narrow solid lines, 25th and 75th percentiles; dashed lines, 5th and 90th percentiles. The maximum
weight-related daily dose is superimposed in green. (continued )
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FIGURE 2 Percentiles of prescribed daily dose of trial medication among non-withdrawals at each visit, by
treatment group and weight group. (a) Active, weight < 60 kg; (b) active, weight 60–80 kg; (c) active, weight
> 80 kg; (d) placebo, weight < 60 kg; (e) placebo, weight 60–80 kg; and (f) active, weight > 80 kg. Heavy solid line,
median; narrow solid lines, 25th and 75th percentiles; dashed lines, 5th and 90th percentiles. The maximum
weight-related daily dose is superimposed in green. (continued )
DOI: 10.3310/hta19120 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 12
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ball et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
27
Random urine testing to determine any illicit cannabis use
Results from urinalyses throughout the study are given in Table 7. These results showed little illicit cannabis
use in the placebo group and an increasing proportion of negative test results within the active group
over time.
The main results are summarised in Table 8 and detailed below.
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FIGURE 2 Percentiles of prescribed daily dose of trial medication among non-withdrawals at each visit, by
treatment group and weight group. (a) Active, weight < 60 kg; (b) active, weight 60–80 kg; (c) active, weight
> 80 kg; (d) placebo, weight < 60 kg; (e) placebo, weight 60–80 kg; and (f) active, weight > 80 kg. Heavy solid line,
median; narrow solid lines, 25th and 75th percentiles; dashed lines, 5th and 90th percentiles. The maximum
weight-related daily dose is superimposed in green.
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TABLE 8 Summary of main results
Outcome
measure
Summary
statistics Treatment group Analysis
Estimated treatment
effect (95% CI) p-value
Main study
Active
(n = 329)
Placebo
(n = 164)
EDSS (all
participants)
No. of first
progression
events
145 73 Primary: HR (active : placebo)
from Cox regression analysis
(losses to follow-up considered
as censored observations)
0.92 (0.68 to 1.23) 0.57
No. of first
progression
events per
patient-yeara
0.24 0.23
No. of first
progression
events
201 88 Sensitivity: HR (active : placebo)
from Cox regression analysis
(losses to follow-up considered
as progression events)
1.11 (0.86 to 1.44) 0.41
No. of first
progression
events per
patient-yeara
0.34 0.27
No. of first
progression
events
157 83 Sensitivity: HR (active : placebo)
from Cox regression analysis
(EPC derived data, losses to
follow-up considered as
censored observations)
0.88 (0.67 to 1.17) 0.39
No. of first
progression
events per
patient-yeara
0.26 0.26
No. of first
progression
events
204 90 Sensitivity: HR (active : placebo)
from Cox regression analysis
(EPC-derived data, losses to
follow-up considered as
progression events)
1.11 (0.86 to 1.43) 0.42
No. of first
progression
events per
patient-yeara
0.34 0.28
Subgroup analyses: HR
(active : placebo) from Cox
regression analysis
Baseline EDSS score
of 4.0–5.5: 0.52
(0.32 to 0.85)
0.01
Baseline EDSS score
of 6.0: 1.15
(0.76 to 1.73)
0.51
Baseline EDSS score
of 6.5: 1.63
(0.85 to 3.10)
0.14
MSIS-29phys Mean (SD)
annual
change
0.62
(3.29)
1.03
(3.74)
Multilevel model: estimated
between-group difference
(active–placebo)
–0.91 (–2.01 to 0.19) 0.11
MSFC
composite
(z-score)
Mean (SD)
annual
change
–0.17
(0.28)
–0.16
(0.30)
Multilevel model: estimated
between-group difference
(active–placebo)
–0.03 (–0.19 to 0.09) 0.72
T25-FW
(z-score)
Mean (SD)
annual
change
–0.37
(0.73)
–0.41
(0.74)
Multilevel model: estimated
between-group difference
(active–placebo)
–0.08 (–0.25 to 0.09) 0.37
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TABLE 8 Summary of main results (continued )
Outcome
measure
Summary
statistics Treatment group Analysis
Estimated treatment
effect (95% CI) p-value
Main study
Active
(n = 329)
Placebo
(n = 164)
9-HPT
(z-score)
Mean (SD)
annual
change
–0.13
(0.23)
–0.14
(0.27)
Multilevel model: estimated
between-group difference
(active–placebo)
0.05 (–0.04 to 0.13) 0.28
PASAT
(z-score)
Mean (SD)
annual
change
–0.025
(0.21)
–0.0074
(0.20)
Multilevel model: estimated
between-group difference
(active–placebo)
–0.01 (–0.10 to 0.09) 0.92
MSWS-12v2 Mean (SD)
annual
change
0.37
(2.33)
0.52
(2.68)
Multilevel model: estimated
between-group difference
(active–placebo)
–0.19 (–0.97 to 0.60) 0.74
RMI Mean (SD)
annual
change
–0.58
(0.96)
–0.72
(1.08)
Multilevel model: estimated
between-group difference
(active–placebo)
0.04 (–0.24 to 0.32) 0.76
SF-36(PH) Mean (SD)
annual
change
–0.58
(2.07)
–0.49
(2.06)
Multilevel model: estimated
between-group difference
(active–placebo)
–0.15 (–0.83 to 0.53) 0.67
MSSS-88 (1) Mean (SD)
annual
change
0.20
(6.25)
0.54
(7.42)
Multilevel model: estimated
between-group difference
(active–placebo)
0.26 (–1.99 to 2.52) 0.82
MSSS-88 (2) Mean (SD)
annual
change
1.27
(6.71)
1.30
(6.50)
Multilevel model: estimated
between-group difference
(active–placebo)
–0.02 (–2.35 to 2.32) 0.99
MSSS-88 (3) Mean (SD)
annual
change
–0.34
(4.88)
–0.97
(5.03)
Multilevel model: estimated
between-group difference
(active–placebo)
1.00 (–0.70 to 2.70) 0.25
MRI
substudy
Active
(n = 182)
Placebo
(n = 91)
PBVC Mean (SD)
annual
change
–0.68
(0.95)
–0.66
(0.98)
Multilevel model: estimated
between-group difference
(active–placebo)
–0.01 (–0.26 to 0.24) 0.94
Occurrence
of new or
enlarging
T2 lesions
n (%) 60 (37) 34 (40) Logistic regression model:
estimated OR (active : placebo)
0.89 (0.50 to 1.58) 0.70
Occurrence
of new or
enlarging
T1 lesions
n (%) 54 (34) 28 (33) Logistic regression model:
estimated OR (active : placebo)
1.05 (0.59 to 1.88) 0.87
CI, confidence interval; OR, odds ratio.
a Assuming progression events occur at the mid-point of the 6 month period between follow-ups.
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Pre-specified analyses of primary clinical outcomes
Primary analysis of time to first confirmed Expanded Disability Status Scale
score progression
Primary analysis using a Cox regression model showed no evidence of an effect of age (p= 0.36), disease
type (p= 0.12), sex (p= 0.56), weight (p= 0.11) or treatment (p= 0.57; see Table 8) on time to confirmed
EDSS score progression. The HR for first EDSS score progression event in patients randomly assigned to
dronabinol compared with those assigned to placebo was 0.92 [95% confidence interval (CI) 0.68 to 1.23;
see Table 8]. At trial completion, Kaplan–Meier estimates of the probability of EDSS score progression were
0.55 (95% CI 0.46 to 0.63) in the dronabinol group compared with 0.60 (95% CI 0.44 to 0.71) in the
placebo group (Figure 3).
We noted evidence of some study site effects and of an effect of baseline EDSS score on time to
confirmed progression (Figure 4). Most notably, relative to a baseline EDSS score of 4.0, there was an
increased hazard of disease progression among those with a baseline EDSS score of 5.5 (HR 3.17, 95% CI
1.45 to 6.93; p= 0.004) and a reduced hazard among those with a baseline EDSS score of 6.5 (HR 0.49,
95% CI 0.24 to 0.98; p= 0.04). However, the numbers of participants in the individual EDSS groups are
small (Figure 5), as are the numbers in some study sites (see Table 16 and Appendix 3).
The global PH test gave no evidence that the PH assumption was violated (χ2= 36, 36 degrees of
freedom; p= 0.47).
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FIGURE 3 Kaplan–Meier estimates of the probability of progression on the EDSS in the two treatment groups,
confirmed after 6 months within the study period. The numbers at risk (cumulative number of censored
observations) are given. Those patients who were lost to follow-up during the trial are marked by +. Those who
reached the end of the trial without progressing are marked by x.
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Sensitivity analyses of time to first confirmed Expanded Disability Status
Scale score progression
Results of sensitivity analysis showed that when losses to follow-up were treated as progression events
rather than censored observations, the estimated HR (active : placebo) for EDSS score progression changed
to 1.11 (95% CI 0.86 to 1.44; see Table 8), but the estimated effect of treatment remained non-significant
(p= 0.41). This change in HR might be because the dronabinol group had a higher proportion of losses to
follow-up for EDSS assessment [56 of 71 (79%)] than the placebo group [15 of 71 (21%)] and represents
a worst-case scenario in terms of patient deterioration and hence the potential benefit of dronabinol.
The EPC reviewed data on 95 patients [71 active (74.7%); 24 placebo (25.3%)], for which there were
ambiguities regarding EDSS scores. The EPC considered 22 (12 active; 10 placebo) of these patients to have
progressed. These patients had no confirmed progression according to the data collected from the trial
schedule. A further four patients (three active; one placebo) were considered to have progressed prior to
the time of progression determined from the trial schedule. Clinical information on the remaining
69 patients reviewed by the EPC either confirmed non-progression or was insufficient to draw any further
conclusions over those made on the primary data. As a result, data derived following EPC review consisted
of a total of 240 first progression events compared with 218 in the primary data (with losses to follow-up
considered as censored observations in both).
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FIGURE 5 Kaplan–Meier estimates of the probability of progression on the EDSS, by baseline EDSS score, confirmed
after 6 months within the study period. The numbers at risk (cumulative number of censored observations) are
given. Those patients who were lost to follow-up during the trial are marked by +. Those who reached the end of
the trial without progressing are marked by x. BL, baseline.
RESULTS: MAIN STUDY AND MAGNETIC RESONANCE IMAGING SUBSTUDY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
34
Conclusions from the main analyses of time to first EDSS score progression were robust to sensitivity
analyses in terms of whether or not conclusions from the EPC were considered in defining EDSS
progressions under both approaches to dealing with losses to follow-up, that is treated as censored
observations or as progression events (see Table 8).
Furthermore, estimated HRs (active : placebo) for EDSS score progression remained similar after sequential
removal of study sites with high loss to follow-up rates, under each of the two ways of treating losses to
follow-up and each of the two data sets, that is according to trial schedule or following EPC review (Figure 6).
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FIGURE 6 Estimated HRs (active : placebo) for EDSS score progression, with 95% CIs and p-values from Cox
regression models, sequentially removing study sites with high loss to follow-up for each of the two data sets
and each of the two ways of dealing with losses to follow-up. (a) Data= according to trial schedule, losses to
follow-up= censored observations; (b) data= according to trial schedule, losses to follow-up=progression events;
(c) data= following EPC review, losses to follow-up= censored observations; and (d) data= following EPC review,
losses to follow-up=progression events. The two rows of n (%) on horizontal axes show top row=number of sites
removed (% losses to follow-up in remaining data); bottom row= site number removed (within-site % losses to
follow-up). n, number of participants included in each fitted model. (continued )
DOI: 10.3310/hta19120 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 12
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ball et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
35
H
az
ar
d
 r
at
io
 (
ac
ti
ve
 : p
la
ce
b
o
)
(b)
1.6
1.5
1.4
1.3
1.2
1.1
1.0
0.9
0.8
0.7
0.6
0.5
p = 0.412
p = 0.867 p = 0.831
p = 0.562 p = 0.571 p = 0.657 p = 0.637
p = 0.939
n = 493
n = 471 n = 461
n = 431 n = 412
n = 391 n = 380
n = 359
7 (7.2%)0 (14.4%) 1 (12.7%)
15 (50%)
2 (12.1%) 3 (10.4%) 4 (9.5%) 5 (8.4%)
24 (29%)26 (37%) 18 (32%)31 (40%)
6 (7.9%)
02 (27%) 25 (19%)
Study sites removed (losses to follow-up)
FIGURE 6 Estimated HRs (active : placebo) for EDSS score progression, with 95% CIs and p-values from Cox
regression models, sequentially removing study sites with high loss to follow-up for each of the two data sets
and each of the two ways of dealing with losses to follow-up. (a) Data= according to trial schedule, losses to
follow-up= censored observations; (b) data= according to trial schedule, losses to follow-up=progression events;
(c) data= following EPC review, losses to follow-up= censored observations; and (d) data= following EPC review,
losses to follow-up=progression events. The two rows of n (%) on horizontal axes show top row=number of sites
removed (% losses to follow-up in remaining data); bottom row= site number removed (within-site % losses to
follow-up). n, number of participants included in each fitted model. (continued )
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FIGURE 6 Estimated HRs (active : placebo) for EDSS score progression, with 95% CIs and p-values from Cox
regression models, sequentially removing study sites with high loss to follow-up for each of the two data sets
and each of the two ways of dealing with losses to follow-up. (a) Data= according to trial schedule, losses to
follow-up= censored observations; (b) data= according to trial schedule, losses to follow-up=progression events;
(c) data= following EPC review, losses to follow-up= censored observations; and (d) data= following EPC review,
losses to follow-up=progression events. The two rows of n (%) on horizontal axes show top row=number of sites
removed (% losses to follow-up in remaining data); bottom row= site number removed (within-site % losses to
follow-up). n, number of participants included in each fitted model. (continued )
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FIGURE 6 Estimated HRs (active : placebo) for EDSS score progression, with 95% CIs and p-values from Cox
regression models, sequentially removing study sites with high loss to follow-up for each of the two data sets
and each of the two ways of dealing with losses to follow-up. (a) Data= according to trial schedule, losses to
follow-up= censored observations; (b) data= according to trial schedule, losses to follow-up=progression events;
(c) data= following EPC review, losses to follow-up= censored observations; and (d) data= following EPC review,
losses to follow-up=progression events. The two rows of n (%) on horizontal axes show top row=number of sites
removed (% losses to follow-up in remaining data); bottom row= site number removed (within-site % losses to
follow-up). n, number of participants included in each fitted model.
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Pre-specified subgroup analyses of time to first confirmed Expanded
Disability Status Scale score progression
Pre-specified subgroup analyses of time to first EDSS score progression suggested a differential effect of
treatment between participants with lower (4.0–5.5) and higher (6.0–6.5) baseline EDSS scores (Figure 7).
There was little evidence of differential effects of treatment among subgroups defined in terms of sex,
disease type, or age or weight at registration.
Primary analysis of change in Multiple Sclerosis Impact Scale-29 20-point
physical subscale
A multilevel model fitted to repeated measures of MSIS-29phys score showed no evidence of an effect of
treatment [estimated between-group difference (active–placebo) −0.91 points, 95% CI −2.01 to 0.19
points; p= 0.11; see Table 8], or of disease type, sex, weight or study site (data not shown; p> 0.05
for all).
It was estimated that MSIS-29phys score reduced by a mean of 1.4 points (95% CI 0.3 to 2.5 points;
p= 0.02) for every 10-year increase in age. In both treatment groups, mean MSIS-29phys score decreased
from baseline to month 3, after which it tended to increase (Figure 8).
With the exception of a small reduction in MSIS-29phys score in patients with a baseline EDSS score of 5.0
compared with those with a score of 4.0, MSIS-29phys score tended to increase with increasing baseline
EDSS score (data not shown).
Results from the primary analysis of repeated measures of MSIS-29phys remained unchanged after removal
of non-significant terms from the fitted model and under an alternative analysis based on comparison of
treatment groups in terms of change from baseline to last valid observation [estimated between-group
difference (active–placebo) –1.4 points, 95% CI –3.3 to 0.4 points; p= 0.13].
Pre-specified analyses of secondary outcomes
Results of multilevel models fitted to data on the secondary outcomes MSWS-12v2, MSFC, RMI, SF-36(PH)
and MSSS-88 are summarised in Table 8 and detailed below.
Multiple Sclerosis Walking Scale-12
A multilevel model fitted to repeated measures of MSWS-12v2 score showed no evidence of an effect of
treatment [estimated effect –0.19 (95% CI –0.97 to 0.60); p= 0.74; see Table 8], or of disease type, sex or
weight (data not shown; p> 0.05 for all). There was some evidence of study site effects (data not shown)
and of effects of baseline EDSS score. Compared with those with a baseline EDSS score of 4.0, MSWS-12v2
was estimated to be, on average, 5.7 (95% CI 2.3 to 9.0), 6.1 (95% CI 3.7 to 8.5) and 9.3 (95% CI 6.8
to 11.8) points higher in those with a baseline EDSS score 5.5, 6.0 and 6.5, respectively. In both
treatment groups, mean MSWS-12v2 score decreased from baseline to month 3, after which it tended
to increase (Figure 9).
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FIGURE 8 Estimated mean MSIS-29phys score, with 95% CIs, at each visit, separated by treatment group. The numbers
of patients with total scores calculated at each visit, in each treatment group, are given directly above the CI for
placebo and directly below the CI for active. Green points, active treatment; black points, placebo.
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FIGURE 9 Estimated mean MSWS-12v2, with 95% CIs, at each visit, separated by treatment group. The numbers of
patients with total scores calculated at each visit, in each treatment group, are given directly above the CI for
placebo and directly below the CI for active. Green points, active treatment; black points, placebo.
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Multiple Sclerosis Functional Composite
A multilevel model fitted to repeated measures of MSFC composite z-score showed no evidence of an
effect of treatment; estimated between-group difference (active–placebo) –0.03 (95% CI –0.19 to 0.09;
p= 0.72; see Table 8). Multilevel models fitted to the MSFC component-wise z-scores each showed no
evidence of an effect of treatment. Estimated between-group differences (active–placebo) were: T25-FW
–0.08 (95% CI –0.25 to 0.09; p= 0.37); 9-HPT 0.05 (95% CI –0.04 to 0.13; p= 0.28); and PASAT –0.01
(95% CI –0.10 to 0.09; p= 0.92). Across both treatment groups, mean T25-FW, 9-HPT and composite
z-scores increased from baseline to week 1, after which they tended to decrease. After an initial increase
at week 1, PASAT z-scores remained relatively constant over the 3-year study period (Figure 10).
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FIGURE 10 Estimated mean MSFC composite (a), T25-FW (b), 9-HPT (c) and PASAT (d) z-scores, with 95% CIs,
at each visit, separated by treatment group. The numbers of patients with scores calculated at each visit,
in each treatment group, are given directly above the CI for placebo and directly below the CI for active.
Green points, active treatment; black points, placebo. (continued )
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FIGURE 10 Estimated mean MSFC composite (a), T25-FW (b), 9-HPT (c) and PASAT (d) z-scores, with 95% CIs,
at each visit, separated by treatment group. The numbers of patients with scores calculated at each visit,
in each treatment group, are given directly above the CI for placebo and directly below the CI for active.
Green points, active treatment; black points, placebo.
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Rivermead Mobility Index
A multilevel model fitted to repeated measures of RMI showed no evidence of an effect of treatment
[the estimated between-group difference (active–placebo) was 0.04 (95% CI –0.24 to 0.32; p= 0.76;
see Table 8)] or of disease type, sex or weight (data not shown; p> 0.05 for all). There was some evidence
of study site effects (data not shown) and of effects of baseline EDSS score. Compared with those with a
baseline EDSS score of 4.0, RMI was estimated to be, on average, 1.57 points (95% CI 0.38 to 2.76
points), 2.44 points (95% CI 1.59 to 3.30 points) and 4.99 points (95% CI 4.10 to 5.88 points) lower in
those with a baseline EDSS score of 5.5, 6.0 and 6.5, respectively. In both treatment groups, RMI
decreased from baseline to 30 months, after which it remained fairly constant (Figure 11).
Short Form questionnaire-36 items (physical health subscale)
A multilevel model fitted to repeated measures of SF-36(PH) showed no evidence of an effect of treatment
[the estimated between-group difference (active–placebo) was –0.15 (95% CI –0.83 to 0.53; p= 0.67;
see Table 8)], or of disease type, sex or weight (data not shown; p> 0.05 for all). In both treatment groups,
mean SF-36(PH) score increased from baseline to month 3, after which it tended to decrease (Figure 12).
With the exception of a small increase in SF-36(PH) score in patients with a baseline EDSS score of 5.0
compared with those with a score of 4.0, SF-36(PH) score tended to decrease with increasing baseline
EDSS score (data not shown).
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FIGURE 11 Estimated mean RMI, with 95% CIs, at each visit, separated by treatment group. The numbers of
patients with total scores calculated at each visit, in each treatment group, are given directly above the CI for
placebo and directly below the CI for active. Green points, active treatment; black points, placebo.
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Multiple Sclerosis Spasticity Scale-88
Figure 13 shows estimated mean MSSS-88 scores, with 95% CIs, by visit and treatment group, for each of
the eight subscales.
For each of the physical components of the MSSS-88, subscales 1 to 6 inclusive, after an initial decrease
from baseline to month 3, mean scores tended to increase. Estimated means were consistent across
treatment groups, as seen by the overlapping CIs. For the two psychological components, subscales 7 and 8,
after an initial decrease from baseline to month 3, mean scores remained relatively constant over the
study period. Estimated mean scores for these components tended to be higher in the active group than
in placebo, but any differences failed to reach statistical significance.
Multilevel models fitted to three groups of the MSSS-88, where MSSS-88 (1) combines subscales 1–3;
MSSS-88 (2) combines subscales 4–6 and MSSS-88 (3) combines subscales 7 and 8 (as described in
Chapter 2), each showed no evidence of an effect of treatment. Estimated between-group difference
(active–placebo) for MSSS-88 (1) was 0.26 (95% CI –1.99 to 2.52; p= 0.82; see Table 8); for MSSS-88
(2) was –0.02 (95% CI –2.35 to 2.32; p= 0.99; see Table 8); and for MSSS-88 (3) was 1.00 (95% CI –0.70 to
2.70; p= 0.25; see Table 8). In both treatment groups, mean MSSS-88 (1) and mean MSSS-88 (2) decreased
from baseline to month 3, after which they tended to increase (Figure 14). After an initial decrease from
baseline to month 3, mean MSSS-88 (3) remained relatively constant over the study period (see Figure 14).
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FIGURE 12 Estimated mean SF-36(PH), with 95% CIs, at each visit, separated by treatment group. The numbers of
patients with total scores calculated at each visit, in each treatment group, are given directly above the CI for
placebo and directly below the CI for active. Green points, active treatment; black points, placebo.
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FIGURE 13 Estimated mean MSSS-88 subscales 1–8 scores, with 95% CIs, at each visit, separated by treatment
group. The numbers of patients with total scores calculated at each visit, in each treatment group, are given
directly above the CI for placebo and directly below the CI for active. Subscales relate to how bothered the patient
has been by their spasticity in the past 2 weeks, where 1=muscle stiffness; 2=pain and discomfort; 3=muscle
spasms; 4= effect of spasticity on daily activities; 5= effect of spasticity on ability to walk; 6= effect of spasticity on
body movements; 7= effect of spasticity on feelings; and 8= effect of spasticity on social functioning. Green points,
active treatment; black points, placebo. (continued )
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FIGURE 13 Estimated mean MSSS-88 subscales 1–8 scores, with 95% CIs, at each visit, separated by treatment
group. The numbers of patients with total scores calculated at each visit, in each treatment group, are given
directly above the CI for placebo and directly below the CI for active. Subscales relate to how bothered the patient
has been by their spasticity in the past 2 weeks, where 1=muscle stiffness; 2=pain and discomfort; 3=muscle
spasms; 4= effect of spasticity on daily activities; 5= effect of spasticity on ability to walk; 6= effect of spasticity on
body movements; 7= effect of spasticity on feelings; and 8= effect of spasticity on social functioning. Green points,
active treatment; black points, placebo. (continued )
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FIGURE 13 Estimated mean MSSS-88 subscales 1–8 scores, with 95% CIs, at each visit, separated by treatment
group. The numbers of patients with total scores calculated at each visit, in each treatment group, are given
directly above the CI for placebo and directly below the CI for active. Subscales relate to how bothered the patient
has been by their spasticity in the past 2 weeks, where 1=muscle stiffness; 2=pain and discomfort; 3=muscle
spasms; 4= effect of spasticity on daily activities; 5= effect of spasticity on ability to walk; 6= effect of spasticity on
body movements; 7= effect of spasticity on feelings; and 8= effect of spasticity on social functioning. Green points,
active treatment; black points, placebo.
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FIGURE 14 Estimated mean MSSS-88 (1) total score from subscales 1–3, concerning muscle stiffness/spasms, pain
and discomfort; MSSS-88 (2) total score from subscales 4–6, concerning activity, walking and body movements; and
MSSS-88 (3) total score from subscales 7 and 8, concerning feelings and social functioning, with 95% CIs, at each
visit, separated by treatment group. The numbers of patients with total scores calculated at each visit, in each
treatment group, are given directly above the CI for placebo and directly below the CI for active. Green points,
active treatment; black points, placebo.
DOI: 10.3310/hta19120 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 12
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ball et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
49
Investigation of adverse events and serious adverse events
The number of participants experiencing at least one SAE was 114 (35%) in the Δ9-THC group and
46 (28%) in the placebo group, the most common SAE being admission to hospital for MS-related events
and infections. The number and nature of SAEs experienced was similar across treatment groups (Table 9).
There were numerous non-serious AEs in both groups, consistent with the effects of MS and the known
safety profile of cannabinoids. The median number of events per participant in the active group was
11 (25th–75th percentiles 7–17) compared with 10 (25th–75th percentiles 6–14) in the placebo group.
Of those events judged to be either moderate or severe, the most frequent are documented in Table 9.
Among these AEs, there was some suggestion that those participants on active treatment were more likely
to experience dizziness or light-headedness and dissociative and thinking or perception disorders. On the
other hand, a higher proportion of patients in the placebo group experienced musculoskeletal pain and
aches than in the active group.
Six SAEs were classified as potential SUSARs in accordance with European clinical trials legislation.
Three events occurred in each of the active and placebo groups. Trial treatment was discontinued in
three participants as a result of the SAE. Three SAEs were classified as nervous system disorders: two were
psychiatric events and one related to the gastrointestinal tract.
TABLE 9 Occurrences of SAEs and the most common AEs
Classification or description of event
Number of patients (% of group)
Active (n= 329) Placebo (n= 164) All (n= 493)
SAEs
Death 6 (1.8) 1 (0.6) 7 (1.4)
Admission to hospital 106 (32) 44 (27) 150 (30)
Life-threatening or important medical event 10 (3.0) 4 (2.4) 14 (2.8)
At least one of the above 114 (35) 46 (28) 160 (32)
Most common AEs
Falls and injuries 101 (31) 51 (31) 152 (31)
Mobility, balance and co-ordination problems 108 (33) 43 (26) 151 (31)
Infections (excluding urinary tract) 95 (29) 47 (29) 142 (29)
Fatigue and tiredness 81 (25) 38 (23) 119 (24)
Dizziness and light-headedness 105 (32) 12 (7) 117 (24)
Muscle disorders (spasticity, stiffness, spasms or tremor) 78 (24) 38 (23) 116 (24)
Muscle disorders (weakness) 74 (22) 32 (20) 106 (22)
Dissociative and thinking or perception disorders 98 (30) 6 (4) 104 (21)
Mood disorders (depression) 66 (20) 26 (16) 92 (19)
Musculoskeletal pain and aches 49 (15) 41 (25) 90 (18)
Constipation, diarrhoea, faecal incontinence 56 (17) 22 (13) 78 (16)
Joint disorders 47 (14) 28 (17) 75 (15)
Urinary tract infections 44 (13) 28 (17) 72 (15)
RESULTS: MAIN STUDY AND MAGNETIC RESONANCE IMAGING SUBSTUDY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
50
Category rating scales
Responses to questions 9–16 of the category rating scales, relating to how the patient felt at the time of
completing the questionnaire, compared with just before the start of the study, have been grouped
(as described in Chapter 2) and summarised, in terms of frequencies and relative frequencies in the
two treatment groups, at each follow-up (Tables 10–13). Unadjusted p-values from chi-squared tests for
trend are given.
TABLE 10 Frequencies and relative frequencies (%) of responses to category rating scale questions 9–16, by
treatment group, at 3 months after baseline. Percentages are taken with respect to total number of patients
in the corresponding treatment group
Visit 5 (3 months after baseline)
Better
(scores 1–5)
No change
(score 6)
Worse
(scores 7–11)
p-valueaActive Placebo Active Placebo Active Placebo
Fatigue (n= 422; na= 276; np= 146) 58 (21) 27 (18) 118 (43) 67 (46) 100 (36) 52 (36) 0.80
Forgetfulness (n= 386; na= 254; np= 132) 32 (13) 18 (14) 141 (56) 94 (71) 81 (32) 20 (15) 0.0067
Sensory loss or numbness (n= 394; na= 254;
np= 140)
40 (16) 21 (15) 152 (60) 74 (53) 62 (24) 45 (32) 0.21
Co-ordination (n= 445; na= 290; np= 155) 188 (65) 107 (69) 35 (12) 19 (12) 67 (23) 29 (19) 0.29
Irritability (n= 370; na= 238; np= 132) 43 (18) 22 (17) 130 (55) 80 (61) 65 (27) 30 (23) 0.65
Depression (n= 356; na= 238; np= 118) 43 (18) 27 (23) 130 (55) 67 (57) 65 (27) 24 (20) 0.12
Tremor (n= 438; na= 284; np= 154) 34 (12) 20 (13) 103 (36) 64 (42) 147 (52) 70 (45) 0.29
Bladder problems (n= 412; na= 270; np= 142) 56 (21) 30 (21) 129 (48) 72 (51) 85 (31) 40 (28) 0.61
n, total number of patients; na, total number of patients in active treatment group; np, total number of patients in the
placebo group.
a From chi-squared test for trend (with 1 degree of freedom), with no adjustments for multiple comparisons.
TABLE 11 Frequencies and relative frequencies (%) of responses to category rating scale questions 9–16, by
treatment group, at 1 year after baseline. Percentages are taken with respect to total number of patients in the
corresponding treatment group
Visit 7 (1 year after baseline)
Better
(scores 1–5)
No change
(score 6)
Worse
(scores 7–11)
p-valueaActive Placebo Active Placebo Active Placebo
Fatigue (n= 385; na= 250; np= 135) 32 (13) 25 (19) 80 (32) 39 (29) 138 (55) 71 (53) 0.29
Forgetfulness (n= 340; na= 222; np= 118) 18 (8) 12 (10) 96 (43) 56 (47) 108 (49) 50 (42) 0.25
Sensory loss or numbness (n= 348; na= 222;
np= 126)
25 (11) 15 (12) 95 (43) 58 (46) 102 (46) 53 (42) 0.55
Co-ordination (n= 368; na= 239; np= 129) 23 (10) 9 (7) 98 (41) 61 (47) 118 (49) 59 (46) 0.89
Irritability (n= 349; na= 225; np= 124) 29 (13) 16 (13) 116 (52) 58 (47) 80 (36) 50 (40) 0.52
Depression (n= 335; na=225; np=110) 29 (13) 19 (17) 116 (52) 45 (41) 80 (36) 46 (42) 0.81
Tremor (n= 274; na= 117; np= 97) 22 (12) 23 (24) 78 (44) 43 (44) 77 (44) 31 (32) 0.011
Bladder problems (n= 380; na= 246; np= 134) 41 (17) 30 (22) 80 (33) 53 (40) 125 (51) 51 (38) 0.023
n, total number of patients; na, total number of patients in active treatment group; np, total number of patients in the
placebo group.
a From chi-squared test for trend (with 1 degree of freedom), with no adjustments for multiple comparisons.
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Generally, a higher proportion of patients on active treatment than on placebo reported being more
forgetful at the time of follow-up compared with before the study. At 3 months from baseline, there was
an approximately twofold increase in proportion of responses classified as ‘worse’ in the active group
compared with placebo (32% active, 15% placebo; p= 0.0067; see Table 10). These proportions were
similar across treatment groups at 1-year follow-up (49% active, 42% placebo; p= 0.25; see Table 11),
at 2 years there was an approximately 30% increase in ‘worse’ responses in the active group compared
with placebo (57% active, 44% placebo; p= 0.037; see Table 12) and similarly at 3 years, with a 33%
increase (60% active, 45% placebo; p= 0.11; see Table 13). Responses to the remaining questions were
similar across treatment groups.
TABLE 12 Frequencies and relative frequencies (%) of responses to category rating scale questions 9–16, by
treatment group, at 2 years after baseline. Percentages are taken with respect to total number of patients in the
corresponding treatment group
Visit 9 (2 years after baseline)
Better
(scores 1–5)
No change
(score 6)
Worse
(scores 7–11)
p-valueaActive Placebo Active Placebo Active Placebo
Fatigue (n= 358; na= 232; np= 126) 30 (13) 15 (12) 51 (22) 31 (25) 151 (65) 80 (63) 0.94
Forgetfulness (n= 327; na= 218; np= 109) 18 (8) 12 (11) 75 (34) 49 (45) 125 (57) 48 (44) 0.037
Sensory loss or numbness (n= 339; na= 220;
np= 119)
25 (11) 9 (8) 91 (41) 48 (40) 104 (47) 62 (52) 0.25
Co-ordination (n= 344; na= 222; np= 122) 18 (8) 7 (6) 70 (32) 36 (30) 134 (60) 79 (65) 0.34
Irritability (n= 320; na= 207; np= 113) 37 (18) 15 (13) 83 (40) 45 (40) 87 (42) 53 (47) 0.26
Depression (n= 316; na= 207; np= 109) 37 (18) 19 (17) 83 (40) 43 (39) 87 (42) 47 (43) 0.86
Tremor (n= 276; na= 117; np= 99) 27 (15) 9 (9) 76 (43) 45 (45) 74 (42) 45 (45) 0.25
Bladder problems (n= 357; na= 233; np= 124) 39 (17) 18 (15) 63 (27) 32 (26) 131 (56) 74 (60) 0.50
n, total number of patients; na total number of patients in active treatment group; np, total number of patients in the
placebo group.
a From chi-squared test for trend (with 1 degree of freedom), with no adjustments for multiple comparisons.
TABLE 13 Frequencies and relative frequencies (%) of responses to category rating scale questions 9–16, by
treatment group, at 3 years after baseline. Percentages are taken with respect to total number of patients in the
corresponding treatment group
Visit 11 (3 years after baseline)
Better
(scores 1–5)
No change
(score 6)
Worse
(scores 7–11)
p-valueaActive Placebo Active Placebo Active Placebo
Fatigue (n= 332; na= 209; np= 123) 33 (16) 10 (8) 44 (21) 30 (24) 132 (63) 83 (67) 0.14
Forgetfulness (n= 301; na= 191; np= 110) 22 (12) 11 (10) 54 (28) 49 (45) 115 (60) 50 (45) 0.11
Sensory loss or numbness (n= 315; na= 201;
np= 114)
25 (12) 8 (7) 80 (40) 46 (40) 96 (48) 60 (53) 0.19
Co-ordination (n= 321; na= 203; np= 118) 21 (10) 5 (4) 65 (32) 44 (37) 117 (58) 69 (58) 0.35
Irritability (n= 296; na= 185; np= 111) 29 (16) 10 (9) 87 (47) 58 (52) 69 (37) 43 (39) 0.31
Depression (n= 283; na= 185; np= 98) 29 (16) 18 (18) 87 (47) 42 (43) 69 (37) 38 (39) 0.89
Tremor (n= 252; na= 161; np= 91) 24 (15) 9 (10) 54 (34) 38 (42) 83 (52) 44 (48) 0.84
Bladder problems (n= 330; na= 209; np= 121) 38 (18) 21 (17) 46 (22) 32 (26) 125 (60) 68 (56) 0.75
n, total number of patients; na, total number of patients in active treatment group; np, total number of patients in the
placebo group.
a From chi-squared test for trend (with 1 degree of freedom), with no adjustments for multiple comparisons.
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Analysis of premature discontinuations of trial medication and
losses to follow-up
Of the 493 patients included in the ITT analysis, 119 (24.1%; 89 active, 30 placebo) prematurely
discontinued trial medication but remained in follow-up. Seventy-eight patients (15.8%; 62 active,
16 placebo) were lost to follow-up, meaning that 296 (60%) patients completed the study on
trial treatment.
There was evidence of an increased risk of discontinuation of trial medication in the active group
compared with placebo (p< 0.001, log-rank test) (Figure 15).
Reasons for discontinuation of trial medication or loss to follow-up were dominated by AEs, accounting for
65% of all early discontinuations (Table 14). Reasons for loss to follow-up are summarised in Table 15.
The most common reasons were reported as ‘MS or other health issues’ and ‘other’, accounting for 50%
(39 out of 78) of all losses to follow-up. ‘Travel or burden of the trial’ accounted for 22% (17 out of 78)
of reasons for loss to follow-up and accounted for a larger proportion of losses in placebo patients
[5 out of 16 (31%) compared with 12 out of 62 (19%) of the losses in the active group].
Rates of discontinuations from trial medication or loss to follow-up varied across study sites (Table 16).
Following a forward selection procedure, a Cox regression model fitted to data on time to discontinuation
of trial medication or loss to follow-up showed evidence of effects of treatment allocation, sex and study
site on the risk of withdrawal or loss to follow-up. The risk of withdrawal or loss to follow-up was
estimated to be higher in men than in women [HR (men : women) 1.37, 95% CI 1.02 to 1.84] and higher
in the active group than in the placebo group [HR (active : placebo) 1.97, 95% CI 1.41 to 2.76].
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FIGURE 15 Kaplan–Meier estimates of the probability of discontinuation of trial medication in the two treatment
groups. Those patients who were lost to follow-up during the trial, without previous discontinuation of trial
medication, are marked by +. Those patients who reached the end of the trial without discontinuing trial
medication are marked by x.
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TABLE 14 Frequencies and relative frequencies (%) of reasons for discontinuation of trial medication or loss to
follow-up, by treatment group, disease type, baseline EDSS, sex and overall
Patient characteristics Total
Reason for discontinuation of trial medication or loss to follow-up
AE Death Lack of efficacy Other
Treatment group
Active 151 113 (74.8) 3 (2.0) 20 (13.2) 15 (9.9)
Placebo 46 14 (30.4) 1 (2.2) 22 (47.8) 9 (19.6)
Disease type
PPMS 80 48 (60.0) 4 (5.0) 20 (25.0) 8 (10.0)
SPMS 117 79 (67.5) 0 (0.0) 22 (18.8) 16 (13.7)
Baseline EDSS score
4.0–5.5 44 29 (65.9) 1 (2.3) 7 (15.9) 7 (15.9)
6.0 102 71 (69.6) 1 (1.0) 20 (19.6) 10 (9.8)
6.5 51 27 (52.9) 2 (3.9) 15 (29.4) 7 (13.7)
Sex
Women 107 68 (63.6) 2 (1.9) 24 (22.4) 13 (12.1)
Men 90 59 (65.6) 2 (2.2) 18 (20.0) 11 (12.2)
Overall 197 127 (64.5) 4 (2.0) 42 (21.3) 24 (12.2)
Percentages may not sum to 100 due to rounding.
TABLE 15 Frequencies and relative frequencies (%) of reasons for loss to follow-up, by treatment group, disease
type, baseline EDSS, sex and overall
Patient
characteristics Total
Reason for loss to follow-up
Death
Moved out
of area AE
MS or other
health issue
Travel or burden
of the trial Ineligible Other
Treatment group
Active 62 7 (11.3) 5 (8.1) 6 (9.7) 17 (27.4) 12 (19.4) 1 (1.6) 14 (22.6)
Placebo 16 1 (6.3) 1 (6.3) 0 (0.0) 3 (18.8) 5 (31.3) 1 (6.3) 5 (31.3)
Disease type
PPMS 32 4 (12.5) 2 (6.3) 3 (9.4) 8 (25.0) 4 (12.5) 1 (3.1) 10 (31.2)
SPMS 46 4 (8.7) 4 (8.7) 3 (6.5) 12 (26.1) 13 (28.3) 1 (2.2) 9 (19.6)
Baseline EDSS score
4.0–5.5 15 2 (13.3) 1 (6.7) 2 (13.3) 3 (20.0) 1 (6.7) 0 (0.0) 6 (40.0)
6.0 41 3 (7.3) 3 (7.3) 3 (7.3) 10 (24.4) 11 (26.8) 1 (2.4) 10 (24.4)
6.5 22 3 (13.6) 2 (9.1) 1 (4.5) 7 (31.8) 5 (22.7) 1 (4.5) 3 (13.6)
Sex
Women 42 4 (9.5) 2 (4.8) 3 (7.1) 7 (16.7) 11 (26.2) 1 (2.4) 14 (33.3)
Men 36 4 (11.1) 4 (11.1) 3 (8.3) 13 (36.1) 6 (16.7) 1 (2.8) 5 (13.9)
Overall 78 8 (10.3) 6 (7.7) 6 (7.7) 20 (25.6) 17 (21.8) 2 (2.6) 19 (24.4)
Percentages may not sum to 100 due to rounding.
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Pre-specified analyses of magnetic resonance imaging substudy
Two hundred and seventy-four patients from 13 study sites were allocated to the MRI substudy. Of these,
one patient was excluded at baseline visit (as baseline scan was deemed problematic, due to patient tremor).
Baseline data on demographic and disease characteristics were similar across treatment groups (Table 17).
Fifty-nine per cent of patients were women, 64% had SPMS and 76% had an EDSS score of 6.0 or 6.5.
Forty-seven of the 182 patients (25.8%) on active treatment and 17 of the 91 patients (18.7%) on placebo
were lost to follow-up during the study period. Figure 16 shows the flow of patients over the 3-year
follow-up period.
Between-treatment-group comparisons of PBVC and numbers of new or enlarging T2 and new T1 lesions
at each annual follow-up showed little evidence of an association between treatment allocation and these
outcomes (Table 18).
A multilevel model fitted to cumulative PBVC showed no evidence of an effect of active treatment on brain
atrophy compared with placebo over the course of the study [estimated between-group difference in PBVC
(active–placebo) was −0.01%, 95% CI −0.26% to 0.24%; p= 0.94; see Table 8]. However, brain atrophy
did change significantly over time (p< 0.0001); using a fitted model, cumulative PBVC was estimated to be
a mean of −0.58% at year 1, −1.20% at year 2 and −2.02% at year 3 (Figure 17).
There was evidence of an effect of baseline normalised brain volume (NBV) on brain atrophy. Using a fitted
model, it was estimated that, for a 100-unit reduction in baseline NBV, brain atrophy increased by a mean
of 0.21% (95% CI 0.08% to 0.34%; p= 0.003).
Treatment did not significantly affect the occurrence of new or newly enlarging T2 lesions [estimated odds
ratio (OR) (active : placebo) 0.89, 95% CI 0.50 to 1.58; p= 0.70; see Table 8] or new T1 lesions [estimated
OR (active : placebo) 1.05, 95% CI 0.59 to 1.88; p= 0.87; see Table 8].
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TABLE 17 Baseline characteristics of patients in the MRI substudy, by treatment group and overall
Patient baseline characteristics
Treatment group
All (N= 273)Active (N= 182; 66.7%) Placebo (N= 91; 33.3%)
Age in years at registration, mean (SD) 52.4 (7.3) 52.2 (8.1) 52.3 (7.6)
Weight in kg at registration, mean (SD) 74.3 (16.1) 75.7 (17.5) 74.8 (16.6)
Men, n (%) 80 (44.0) 31 (34.1) 111 (40.7)
Women, n (%) 102 (56.0) 60 (65.9) 162 (59.3)
PPMS, n (%) 60 (33.0) 38 (41.8) 98 (35.9)
SPMS, n (%) 122 (67.0) 53 (58.2) 175 (64.1)
EDSS score at baseline, n (%)
4.0 14 (7.7) 6 (6.6) 20 (7.3)
4.5 12 (6.6) 5 (5.5) 17 (6.2)
5.0 12 (6.6) 6 (6.6) 18 (6.6)
5.5 8 (4.4) 3 (3.3) 11 (4.0)
6.0 95 (52.2) 47 (51.6) 142 (52.0)
6.5 41 (22.5) 24 (26.4) 65 (23.8)
Normalised brain volume, mean (SD) 1422 (91.0) 1417 (85.1) 1420 (88.9)
Not reported, n (%) 24 (13.2) 8 (8.8) 32 (11.7)
Percentages may not sum to 100 due to rounding.
Year 3 scan (n = 135) Year 3 scan (n = 74)
Lost to follow-up (n = 7)Lost to follow-up (n = 12)
Lost to follow-up (n = 14)
Lost to follow-up (n = 21)
Lost to follow-up (n = 4)
Lost to follow-up (n = 6)
Placebo (n = 91)Active (n = 183)
Excluded (n = 1)
Allocated to MRI substudy (N = 274)
Baseline scan (n = 91)
Missed appointment, n = 0
Baseline scan (n = 182)
Missed appointment, n = 0
Year 1 scan (n = 159)
Missed appointment, n = 2
Year 1 scan (n = 84)
Missed appointment, n = 1
Year 2 scan (n = 79)
Missed appointment, n = 2
Year 2 scan (n = 146)
Missed appointment, n = 1
FIGURE 16 Flow of participants through the MRI substudy.
DOI: 10.3310/hta19120 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 12
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ball et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
57
TABLE 18 Descriptive statistics and between-treatment-group comparisons for MRI outcome measures at
years 1, 2 and 3
Outcome measures
Year 1 Year 2 Year 3
Active
(n= 159)
Placebo
(n= 84)
Active
(n= 146)
Placebo
(n= 79)
Active
(n= 135)
Placebo
(n= 74)
PBVC
Mean (SD) –0.60 (0.99) –0.59 (0.95) –0.58 (0.96) –0.65 (0.95) –0.88 (0.87) –0.76 (1.04)
Median (25th–75th
percentiles)
–0.60
(–1.32, –0.05)
–0.47
(–1.03, –0.08)
–0.52
(–1.21, –0.06)
–0.78
(–1.17, –0.10)
–0.78
(–1.43, –0.44)
–0.81
(–1.42, 0.20)
Not reported, n (%) 3 (1.9) 1 (1.2) 5 (3.4) 2 (2.5) 7 (5.2) 2 (2.7)
p-valuea 0.9 0.6 0.4
New or newly enlarging T2 lesions, n (%)
0 118 (74.2) 56 (66.7) 111 (76.0) 71 (89.9) 113 (83.7) 61 (82.4)
1 20 (12.6) 15 (17.9) 23 (15.8) 5 (6.3) 16 (11.9) 9 (12.2)
≥ 2 21 (13.2) 13 (15.5) 12 (8.2) 3 (3.8) 6 (4.4) 4 (5.4)
Not reported 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
p-valueb 0.40 0.05 0.96
New T1 lesions, n (%)
0 123 (77.4) 64 (76.2) 122 (83.6) 74 (93.7) 118 (87.4) 62 (83.8)
1 20 (12.6) 12 (14.3) 16 (11.0) 3 (3.8) 13 (9.6) 10 (13.5)
≥ 2 16 (10.1) 8 (9.5) 8 (5.5) 2 (2.5) 4 (3.0) 2 (2.7)
Not reported 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
p-valueb 0.9 0.1 0.7
a From two-sample t-test, with no adjustments for multiple comparisons.
b From Fisher’s exact test, with no adjustments for multiple comparisons.
Percentages may not sum to 100 due to rounding.
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FIGURE 17 Estimated mean cumulative PBVC (%), and 95% CI, by treatment group, measured at yearly MRI visits.
Green points, active treatment; black points, placebo. n, number of patients with cumulative PBVC calculated at
each visit, given directly above the CI for placebo and directly below the CI for active.
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Chapter 4 Post-hoc exploratory analyses: main
study and magnetic resonance imaging substudy
Introduction
Post-hoc exploratory analyses covered three main areas, as described below.
Firstly, the suggestion of a treatment effect from pre-specified subgroup analysis of time to first confirmed
EDSS score progression led to a post-hoc analysis of time to EDSS score progression among patients in
this EDSS group. Further analysis examined the effect of treatment allocation in the two participant groups
with a baseline EDSS score of 4.0–5.5 and 6.0–6.5, on change in MSIS-29phys and PBVC.
Secondly, an on-treatment data set included follow-up data on all patients up to the time of withdrawal from
trial treatment, loss to follow-up or end of study – whichever came first. Further analyses of time to first
confirmed EDSS score progression, change in MSIS-29phys and PBVC were carried out using these data sets.
Thirdly, in contrast to pre-specified analyses, presented in the previous chapter, which were based on time
to first progression event (or last follow-up) with any subsequent changes in EDSS score not considered,
post-hoc exploratory analyses considered EDSS progression as an unconfirmed, recurrent event, using the
following criteria:
The first progression event is when EDSS score increases by at least 1 point from a baseline score of 4.0,
4.5 or 5.0, or by at least 0.5 points from a baseline score of 5.5 or higher. Subsequent progression events
are when the EDSS score increases by these amounts, from the score at the previous progression.
Progressions do not need to be confirmed at the next scheduled 6-monthly visit.
Methods
Subgroup analyses
Subgroup analysis of time to EDSS score progression, based on a total of 110 patients with a baseline
EDSS score of 4.0–5.5, included inspection of Kaplan–Meier estimates of the probability of EDSS score
progression, by treatment group and comparison using a log-rank test.
The effect of treatment allocation in the two participant groups with a baseline EDSS score of 4.0–5.5 and
6.0–6.5, on change in MSIS-29phys and on PBVC, was examined. This was done by including separate
effects of treatment in the groups of patients with a baseline EDSS score of 4.0–5.5 and 6.0–6.5 in the
multilevel models fitted to the data sets used in the primary analyses of change in MSIS-29phys and
of PBVC.
On-treatment analyses
Kaplan–Meier estimates were used to show probability of EDSS score progression in the on-treatment data
set, by treatment group.
In the on-treatment analysis, in which there were fewer observed first progression events than in the
primary analysis, there were one or more study sites for which no progression events were observed.
Therefore, two Cox PH models were fitted; the first included individual study site effects and the second
included individual effects for the larger sites (with 20 or more patients) and a single, combined effect for
the study sites with low throughput (n< 20).
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Multilevel models, analogous to those fitted in the primary analyses of change in MSIS-29phys and
PBVC (including single main effects of treatment and other pre-specified covariates), were fitted to the
on-treatment data sets, which included all available data on MSIS-29phys scores and MRI scans performed,
respectively, up to time of withdrawal from trial treatment, loss to follow-up or end of study – whichever
came first.
Expanded Disability Status Scale score transitions and recurrent
progression events
Transitions in EDSS scores from one 6-monthly visit to the next were investigated. Probabilities of each
possible transition from given starting EDSS scores and, hence, the probability of EDSS score progression
(unconfirmed) were estimated. EDSS scores were also grouped into low (5.5 or lower), medium (6.0) and
high (6.5 or higher) and transitions between these states and probabilities of progression from these states
were estimated. In these analyses, patients were allowed to have more than one unconfirmed progression
event during the study period.
Results
Results from post-hoc exploratory subgroup and on-treatment analyses are summarised in Table 19 and
detailed below.
Subgroup analyses
Figure 18 shows Kaplan–Meier estimates of the probability of EDSS score progression in the subgroup of
patients with a baseline EDSS score of 4.0–5.5, separated by treatment group. There was some evidence
of a potentially beneficial effect of active treatment, compared with placebo in this low-score EDSS
subgroup (p= 0.01, log-rank test).
There was some evidence of an effect of treatment on change in MSIS-29phys score in the group of
patients with a baseline EDSS score of 4.0–5.5. On average, MSIS-29phys scores in the active treatment
group were estimated to be 3.26 points lower (95% CI for reduction 1.63 to 4.89 points; p= 0.0001;
see Table 19) than in the placebo group. There was no significant effect of treatment on change in
MSIS-29phys score in the group of participants with a baseline EDSS score of 6.0–6.5 [estimated
between-group difference (active–placebo) –0.21, 95% CI –1.37 to 0.96; p= 0.73; see Table 19].
There was no significant effect of treatment on brain atrophy in the two participant groups defined by
baseline EDSS score; estimated between-group differences in PBVC (active–placebo) were –0.06% (95% CI
–0.42% to 0.29%; p= 0.73; see Table 19) and 0.01% (95% CI –0.26% to 0.28%; p= 0.95; see Table 19)
for baseline EDSS scores of 4.0–5.5 and 6.0–6.5, respectively.
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TABLE 19 Summary of results from post-hoc exploratory subgroup and on-treatment analyses
Outcome measure
Summary
statistics
Treatment
group
Analysis
Estimated
treatment
effect (95% CI) p-valueActive Placebo
EDSS (subgroup of
participants with a
baseline EDSS score
of 4.0–5.5)
No. of first
progression
events
44 26 Post-hoc subgroup analyses:
log-rank test
– 0.01
No. of first
progression
events per
patient-yeara
0.35 0.64
MSIS-29phys Mean (SD)
annual change;
subgroup, a
baseline EDSS
score of 4.0–5.5
0.50
(3.16)
1.72
(3.46)
Post-hoc multilevel model
with separate treatment
effects for EDSS groups
4.0–5.5 and 6.0–6.5:
estimated between-group
differences (active–placebo)
Baseline EDSS
score of 4.0–5.5:
–3.26 (–4.89 to
–1.63)
0.0001
Mean (SD)
annual change;
subgroup,
baseline EDSS
score of 6.0–6.5
0.64
(3.35)
0.90
(3.79)
Baseline EDSS
score of 6.0–6.5:
–0.21 (–1.37 to
0.96)
0.73
MRI: PBVC Mean (SD)
annual change;
subgroup,
baseline EDSS
score of 4.0–5.5
–0.57
(0.49)
–0.36
(0.37)
Post-hoc multilevel model
with separate treatment
effects for EDSS groups
4.0–5.5 and 6.0–6.5:
estimated between-group
differences (active–placebo)
Baseline EDSS
score of 4.0–5.5:
–0.06% (–0.42%
to 0.29%)
0.73
Mean (SD)
annual change;
subgroup,
baseline EDSS
score of 6.0–6.5
–0.70
(0.52)
–0.70
(0.50)
Baseline EDSS
score of 6.0–6.5:
0.01% (–0.26 to
0.28%)
0.95
EDSS (on-treatment
data set; participants
on trial treatment at
end of study or last
follow-up)
No. of first
progression
events
114 63 HR (active : placebo) from
post-hoc Cox regression
analysis (losses to follow-up
considered as censored
observations), individual study
site effects
0.96 (0.69 to 1.34) 0.83
No. of first
progression
events per
patient-yeara
0.23 0.22
EDSS (on-treatment
data set; participants
on trial treatment at
end of study or last
follow-up)
No. of first
progression
events
114 63 HR (active : placebo) from
post-hoc Cox regression
analysis (losses to follow-up
considered as censored
observations), grouped study
site effects
0.95 (0.69 to 1.31) 0.76
No. of first
progression
events per
patient-yeara
0.23 0.22
MSIS-29phys
(on-treatment data
set; participants on
trial treatment at
end of study or last
follow-up)
Mean (SD)
annual change
0.59
(3.37)
0.87
(3.85)
Post-hoc multilevel model:
estimated between-group
difference (active–placebo)
–0.77 (–1.92 to
0.38)
0.19
MRI: PBVC
(on-treatment data
set; participants on
trial treatment at
end of study or last
follow-up)
Mean (SD)
annual change
–0.64
(0.53)
–0.62
(0.40)
Post-hoc multilevel model:
estimated between-group
difference (active–placebo)
0.03% (–0.24% to
0.31%)
0.80
a Assuming progression events occur at the mid-point of the 6-month period between follow-ups.
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On-treatment analyses
Analysis of time to first confirmed EDSS score progression was carried out using the on-treatment data set
described above. Considering all withdrawals from trial treatment as losses to follow-up at the time of
withdrawal, the on-treatment data set included 177 first progression events (114 in the active group,
63 in the placebo group), compared with 218 (145 active, 73 placebo) in the ITT data set used in the
primary analysis. A Cox regression model provided no evidence of an effect of treatment on probability of
progression [HR (active : placebo) 0.96, 95% CI 0.69 to 1.34; p= 0.83; see Table 19]. This estimated
treatment effect was similar when study sites with low throughput (< 20 patients) were combined in a
single effect in the fitted model [HR (active : placebo) 0.95, 95% CI 0.69 to 1.31; p= 0.76; see Table 19].
The global PH test gave no evidence that the PH assumption was violated under either fitted model
(χ2= 30.2, 36 degrees of freedom, p= 0.74 for a Cox model including individual study site effects; and
χ2= 13.3, 19 degrees of freedom, p= 0.82 for a Cox model including a single effect for sites with
low throughput).
At trial completion, Kaplan–Meier estimates of the probability of EDSS score progression were 0.54
(95% CI 0.43 to 0.62) in the dronabinol group, compared with 0.58 (95% CI 0.41 to 0.71) in the placebo
group (Figure 19).
A multilevel model fitted to repeated measures of MSIS-29phys score in the on-treatment data set showed
no evidence of an effect of treatment. The estimated between-group difference in MSIS-29phys
(active–placebo) score was –0.77 (95% CI –1.92 to 0.38; p= 0.19; see Table 19).
Analysis of brain atrophy in the on-treatment data set on the MRI substudy was based on a total of
418 observations among 202 patients and included 200 measures of PBVC at year 1, 175 measures
of cumulative PBVC at year 2 and 43 at year 3. There was no evidence of an effect of treatment on brain
atrophy; the estimated between-group difference in PBVC (active–placebo) was 0.03% (95% CI –0.24%
to 0.31%; p= 0.80; see Table 19). Using a fitted model, cumulative PBVC was estimated to be a mean
of −0.60% at year 1, −1.17% at year 2 and −2.01% at year 3 (Figure 20).
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FIGURE 18 Kaplan–Meier estimates of the probability of progression on the EDSS in the two treatment groups,
confirmed after 6 months within the study period, among the subgroup of patients with a baseline EDSS score of
4.0–5.5. The numbers at risk (cumulative number of censored observations) are given. Those patients who were lost
to follow-up during the trial are marked by +. Those who reached the end of the trial without progressing are
marked by x.
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FIGURE 19 Kaplan–Meier estimates of the probability of progression on the EDSS in the two treatment groups,
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number of censored observations) are given. Those patients who were lost to follow-up during the trial are
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FIGURE 20 Estimated mean cumulative PBVC (%), and 95% CI, by treatment group, measured at yearly MRI visits,
in the on-treatment data. Green points, active treatment; black points, placebo. n, number of patients with
cumulative PBVC calculated at each visit, given directly above the CI for placebo and directly below the CI for active.
DOI: 10.3310/hta19120 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 12
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ball et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
65
There was evidence of an effect of baseline NBV on brain atrophy. Using a fitted model, it was estimated
that, for a 100-unit reduction in baseline NBV, atrophy increased by a mean of 0.20% (95% CI 0.06% to
0.35%; p= 0.008).
Expanded Disability Status Scale score transitions and recurrent
progression events
Based on the definition of unconfirmed, recurrent progression events introduced earlier in this chapter,
there were a total of 380 (245 among 182 patients on active treatment, 135 among 97 patients on
placebo) progression events observed over the course of the trial. Frequencies and relative frequencies of
patients having different numbers of events during follow-up are given in Table 20.
The probability of unconfirmed EDSS score progression appeared to depend on the starting EDSS score
(Figures 21 and 22). For example, the probability of progression from a score of 5.5 tended to be higher
than probabilities of progression from other starting scores. It is notable that this is the starting score for
which the definition of progression changes from a 1-point increase to a 0.5-point increase. As starting
EDSS score increased from 5.5, the probability of progression tended to decrease.
TABLE 20 Frequencies and relative frequencies (%) of patients seen to have specified numbers of unconfirmed,
recurrent progression events, by treatment group, baseline EDSS score and overall
Patient characteristics
Number of progression events
0 1 2 3 or 4
Treatment group
Active (n= 329) 147 (44.7) 128 (38.9) 45 (13.7) 9 (2.7)
Placebo (n= 164) 67 (40.9) 68 (41.5) 21 (12.8) 8 (4.9)
Baseline EDSS score
4.0–5.5 (n= 110) 33 (30.0) 58 (52.7) 17 (15.5) 2 (1.8)
6.0 (n= 254) 111 (43.7) 107 (42.1) 25 (9.8) 11 (4.3)
6.5 (n= 129) 70 (54.3) 31 (24.0) 24 (18.6) 4 (3.1)
Total (N= 493) 214 (43.4) 196 (39.8) 66 (13.4) 17 (3.4)
Percentages may not sum to 100 due to rounding.
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FIGURE 21 Estimated probabilities of EDSS score progression (unconfirmed), with 95% CI, by starting EDSS score,
in each 6-monthly interval from baseline. (a) 0–6 months (0–182 days from baseline); (b) 6–12 months (183–365 days
from baseline); (c) 12–18 months (366–548 days from baseline); (d) 18–24 months (549–731 days from baseline);
(e) 24–30 months (732–914 days from baseline); and (f) 30–36/42 months (915 or more days from baseline).
n, number of patients with given starting EDSS score who have an EDSS score recorded at the end of the
6-monthly interval. (continued )
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FIGURE 21 Estimated probabilities of EDSS score progression (unconfirmed), with 95% CI, by starting EDSS score,
in each 6-monthly interval from baseline. (a) 0–6 months (0–182 days from baseline); (b) 6–12 months (183–365 days
from baseline); (c) 12–18 months (366–548 days from baseline); (d) 18–24 months (549–731 days from baseline);
(e) 24–30 months (732–914 days from baseline); and (f) 30–36/42 months (915 or more days from baseline).
n, number of patients with given starting EDSS score who have an EDSS score recorded at the end of the
6-monthly interval. (continued )
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FIGURE 21 Estimated probabilities of EDSS score progression (unconfirmed), with 95% CI, by starting EDSS score,
in each 6-monthly interval from baseline. (a) 0–6 months (0–182 days from baseline); (b) 6–12 months (183–365 days
from baseline); (c) 12–18 months (366–548 days from baseline); (d) 18–24 months (549–731 days from baseline);
(e) 24–30 months (732–914 days from baseline); and (f) 30–36/42 months (915 or more days from baseline).
n, number of patients with given starting EDSS score who have an EDSS score recorded at the end of the
6-monthly interval.
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Overall, at a starting EDSS score of < 5.5, the probability of progression was slightly lower than for a
starting EDSS score of 5.5 and slightly higher than for a starting EDSS score > 5.5 (see Figure 22).
However, the number of observations at this lower end of the EDSS is relatively small, as reflected in the
wide CIs.
Starting EDSS scores at baseline and at each 6-monthly follow-up were grouped into L, M and H, as
described earlier in this chapter. Transition matrices were found for moving between states (Table 21).
When considering progression from these three states, with the exception of the time period from
baseline to 6 months, the probability of progression decreased with increasing starting EDSS score,
for each 6-monthly period and overall (Figure 23).
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FIGURE 22 Estimated probabilities of EDSS score progression (unconfirmed), with 95% CI, by starting EDSS score,
in all 6-monthly intervals from baseline. n, number of patients with given starting EDSS score who have an
EDSS score recorded at the end of the 6-monthly interval.
POST-HOC EXPLORATORY ANALYSES: MAIN STUDY AND MAGNETIC RESONANCE IMAGING SUBSTUDY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
TABLE 21 Counts and proportions of transitions between EDSS score groups, in each 6-monthly follow-up period
Time interval (number of observations, % of total) Counts Row proportions
From To From To
L M H L M H
0–6 months (0–182 days from baseline)
(n= 457, 92.7%)
L 79 20 4 L 0.7670 0.1942 0.0388
M 16 149 69 M 0.0684 0.6368 0.2949
H 2 19 99 H 0.0167 0.1583 0.8250
6–12 months (183–365 days from baseline)
(n= 355, 72.0%)
L 60 23 3 L 0.6977 0.2674 0.0349
M 6 129 29 M 0.0366 0.7866 0.1768
H 0 25 80 H 0.0000 0.2381 0.7619
12–18 months (366–548 days from baseline)
(n= 300, 60.9%)
L 47 9 0 L 0.8393 0.1607 0.0000
M 7 126 26 M 0.0440 0.7925 0.1635
H 0 13 72 H 0.0000 0.1529 0.8471
18–24 months (549–731 days from baseline)
(n= 265, 53.8%)
L 38 11 1 L 0.7600 0.2200 0.0200
M 5 112 21 M 0.0362 0.8116 0.1522
H 0 12 65 H 0.0000 0.1558 0.8442
24–30 months (732–914 days from baseline)
(n= 230, 46.7%)
L 34 6 0 L 0.8500 0.1500 0.0000
M 9 92 23 M 0.0726 0.7419 0.1855
H 0 11 55 H 0.0000 0.1667 0.8333
30–36/42 months (915 or more days from baseline)
(n= 207, 42.0%)
L 35 9 0 L 0.7955 0.2045 0.0000
M 0 85 19 M 0.0000 0.8173 0.1827
H 0 8 51 H 0.0000 0.1356 0.8644
H, EDSS score of 6.5 or higher; L, EDSS score of 5.5 or lower; M, EDSS score of 6.0.
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FIGURE 23 Estimated probabilities of unconfirmed EDSS score progression, with 95% CI, in each 6-monthly interval
from baseline and overall. 0–6 months (0–182 days from baseline); 6–12 months (183–365 days from baseline);
12–18 months (366–548 days from baseline); 18–24 months (549–731 days from baseline); 24–30 months
(732–914 days from baseline); 30–36/42 months (915 or more days from baseline). In each case, the three estimates
and intervals correspond to different starting EDSS score groups: left= L (starting EDSS score of 5.5 or less);
centre=M (starting EDSS score of 6.0); right=H (starting EDSS score of 6.5 or higher).
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Conclusions
Post-hoc exploratory analyses showed some evidence of a potentially beneficial effect of active treatment
in terms of time to first confirmed EDSS score progression and change in MSIS-29phys score among those
patients with a baseline EDSS score of 4.0–5.5. However, this subgroup of participants consists of just
110 individuals and so findings should be interpreted with caution. This beneficial effect was not seen in
the MRI outcome, PBVC.
Results from analysis of time to first EDSS score progression, change in MSIS-29phys score and PBVC based
on an on-treatment data set showed no evidence of a treatment effect on these outcomes and supported
the conclusions from the primary analyses.
Detailed inspection of transition between EDSS scores highlighted the relatively low probability of progression
on the EDSS when starting from the more disabled end of this scale. It also suggested an increased probability
of progression from an EDSS score of 5.5; the lowest score at which a 0.5-point increase is deemed a
progression. There was also an indication of an increased probability of progression from a baseline EDSS
score of 5.5 in the primary analysis of time to first confirmed EDSS score progression (see Figures 4 and 5) but,
once again, these findings must be interpreted with caution because of the small numbers of patients in the
individual groups defined by baseline EDSS score.
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Chapter 5 Rasch measurement theory analysis of
multiple sclerosis rating scale data
Introduction
This chapter concerns the application in the CUPID study of RMT analyses. RMT is a modern psychometric
method for constructing and evaluating rating scales. It has a number of advantages for clinical trials
over traditional methods of analysing rating scale data. These advantages include the ability to derive
interval-level measurement estimates from necessarily ordinal rating scale scores and the ability to
examine change legitimately at the individual person level. In addition, RMT enables a very sophisticated
evaluation of rating scale performance. This chapter, which has five sections, capitalises on those
advantages of RMT.
Section 1 gives a brief introduction to RMT.
Section 2 reports the RMT-based evaluation of the performance as measurement instruments of
MS-specific PROs used in the CUPID study: MSIS-29v2, MSWS-12v2 and MSSS-88 scores. Specifically,
for each subscale within each instrument (e.g. MSIS-29v2 has two subscales; MSSS-88 has eight subscales;
MSWS-12v2 has one scale), three performance-related issues were examined: scale-to-sample targeting
(relative range of person and item locations, shape of person distribution); aspects of scale’s item
performance [response category working, mapped continuum mapped by items, item fit statistics, item
bias, differential item functioning (DIF)]; and aspects of derived person measurements [person separation
index (PSI), person fit residuals, extreme scores]. It was concluded that all 11 scales/subscales performed
well. This enabled interval-level measurement estimates for individual patients, with individual person
standard error (SE) estimates, to be derived and taken forward to sections 3 and 4. Naturally, there were
some issues of scale performance that could have been better.
Section 3 reports and compares the changes associated with active and placebo for those people in each
treatment group, who remained on trial medication and had paired measurements at the two appropriate
time points. These analyses used the interval-level measurement estimates and individual person SE
estimates derived from section 2. Specifically, two potential benefits of dronabinol were examined: a
symptomatic benefit between baseline and visit 5, and a disease-modifying benefit between baseline and
the end of the study. For each benefit analysis, relative changes in the active and placebo groups at
the group and individual person level were examined. At the group level, for each scale/subscale, the
statistical significance of change scores [analysis of variance (ANOVA) paired sample t-tests] and the clinical
significance of change scores [Cohen’s effect size; standardised response means (SRMs)] was examined in
paired samples. At the individual person level, the proportions of people in each treatment group who
achieved five levels of change (significantly better, non-significantly better, no change, non-significantly
worse, significantly worse) were examined. In essence, analyses showed no significant differences between
people treated with dronabinol or placebo. A notable finding was limited progression in the placebo
group implying less progression over the study period than might have been expected in a cohort of
people with progressive MS.
Section 4 reports post-hoc exploratory analyses. These analyses capitalise on the finding of a suggestion of
a treatment effect in people with less EDSS-measured disability at baseline. Here the analyses of section 3
were repeated in two subgroups of people: those with a baseline EDSS score of 4.0–5.5; and those with
a baseline EDSS score of 6.0–6.5. These post-hoc exploratory analyses alluded to the possibility of a
clinically significant treatment effect in people with lower disability at baseline. It was also notable that
placebo-treated people with higher levels of disability at baseline had surprisingly little progression during
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the CUPID study. This implies a limited pathophysiological substrate for examining the hypothesis that any
treatment may have a disease-modifying effect.
Section 5 reflects on the findings and the lessons learned from the RMT analyses of the CUPID data.
Section 1: rating scales, rating scale data analysis and the added
value of Rasch measurement theory
This section aims to give a very brief account of how rating scales work as measurement instruments,
the scientific methods that underpin them and the case for choosing RMT as the most appropriate
method for analysing rating scales data in the CUPID study. Fuller and heavily referenced accounts are
given elsewhere.6,15–17
Rating scales attempt to measure variables that cannot be easily quantified using other methods. For
example, the MSWS-12v2 attempts to measure the walking ability of people with MS. Rating scales
achieve measurement through a set of questions, each of which has two or more response options. The
response options are allotted sequential integer scores. People answer the questions, choosing the most
relevant response option. Measurements are derived from these data. This method of measurement stems
from a body of research beginning in the early 1900s in education and psychology and with it developed
the methods of testing the quality of the measurement process known as reliability and validity testing.
The methods for developing rating scales and examining their reliability and validity have become known
as psychometric methods.
Any rating scale can be considered a hypothesis of how a variable might be measured. A number of
reasons underpin this statement. First, the aspects of people who rating scales are seeking to measure are
complex socially constructed variables; here, aspects of the impact of MS. As such, their measurement
cannot be easy. Second, there is uncertainty concerning the definitions of these variables. This hampers
the construction of rating scales and opens the door for a range of potential measurement methods.
Third, socially constructed variables are measured through their manifestations. For example, the walking
ability of an individual is estimated from their performance on a finite set of tasks. It follows then, that the
extent to which performance on a set of tasks can be combined is an empirical question. Finally, there is
uncertainty of the extent to which the numbers generated by any rating scales satisfy criteria as reliable
and valid measurements. For these reasons, any scale is a hypothesis of how a complex clinical variable
might be measured and as such this hypothesis requires careful testing. For example, the MSWS-12v2
should be viewed as a hypothesis of how walking ability might be measured that requires careful testing.
RMT provides a criterion for part of that hypothesis test.
Most rating scales assign successive integer scores to two or more ordered-item response categories that
imply increasing problems. For example, in the MSIS-29v2 the four response options are: not at all= 1;
slightly= 2; moderately= 3; and extremely= 4. Then, scores for groups of items that form subscales
(e.g. the 20 physical impact items of the MSIS-29v2) are generally summed to produce a subscale score,
which is used as a numerical index for a person on the physical scale and likewise for the other scales.
The general goal of psychometric evaluations of rating scales is to test whether or not this process of item
scoring and summation satisfies the criteria for deriving measurements. More specifically, the goal is to
establish whether or not it is legitimate to sum the integer-scored responses of a group of items and
to determine the extent to which these summed scores are free from random error (whether or not they
are reliable) in accounting for differences among people and measuring the attributes they purport to
measure (whether or not they are valid). There are three main paradigms for developing, analysing and
modifying rating scales: classical test theory (CTT), item response theory and RMT.
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An evaluation of rating scales is well suited to the RMT paradigm because the Rasch model, a
mathematical equation (model), provides a hypothesis test. This is because it articulates, a priori, the
requirements of rating scale data for rating scales to satisfy criteria as measurement instruments.
The model was derived from theory and is independent of any data set. Therefore, discrepancies
detected by the analysis, that is between the hypothesis (scale data) and the hypothesis test (Rasch model
requirements), indicate anomalies in the hypothesis (scale) as a measurement instrument. In this way,
a RMT analysis provides diagnostic information-informing measurement instrument development by
exposing anomalies to be understood and improved empirically.
Rasch measurement theory analyses use a mathematical model to test scale performance and generate
measurements of people. The Rasch model, a probabilistic measurement model, was developed to express
the requirement of invariant comparisons. By this we mean that the performance of the measurement
method (here, a rating scale’s items) should, within reason, be independent of the people it is tested on
and the measurements of people should be independent of the measurement method (here, a set of scale
items) used to measure them. The Rasch model does not arise from the need to model (explain or
summarise) any particular data set, and is compatible with the requirements of measurement methods
used in physics, called fundamental or additive conjoint measurement.
One important property of the Rasch model is that for items with ordered response categories, as they are
in the MS-specific rating scales using in the CUPID study, the successive categories should be scored with
successive integers. This is a consequence of the requirement of invariance and not an assumption of the
Rasch model. The use of both successive integer scores for scoring successive categories within items,
and then the total sum score across items to characterise a person, is also a feature of the theory that
underpins traditional psychometric methods (called traditional true score theory). However, in traditional
psychometric methods (CTT), these are essentially starting points of the theory and do not arise from a
priori requirements as they do in RMT.
A Rasch analysis of data, therefore, examines the extent to which the observed data accord with the
requirements of the model. Therefore, at a general level it assesses the degree to which the responses of
the persons to the items can be summed to provide a single score for each person which summarises each
person’s location (measurement) on a scale. In other words, it tests whether or not the scale is able to
place people in order on a scale, such that those who are ‘worse’ (in this case, suffer more from the
effects of fatigue) produce higher scores than those who are ‘better’ (suffer less fatigue). This test of
accord between the observed data and the expectations of the model is generally referred to as a
‘test of fit’. Tests of fit can be constructed to assess various specific hypotheses, such as that of
multidimensionality and of unexpected dependence between pairs of items within subscales.
The procedure for testing the fit of the responses to the Rasch model involves first estimating the parameters
of the model, which include a location parameter for each person and location parameters of the thresholds
of the items which define the categories of a rating scale. A threshold is the transition point between
adjacent item response categories. Specifically, it is the point on the scale at which the probability of scoring
in adjacent categories is 50%. For example, each MSIS-29v2 item has four response categories: 1, 2, 3 and 4.
Therefore, each item has three thresholds, 1–2, 2–3 and 3–4, which mark the three points on the scale at
which the probability is 50% of scoring 1 and 2, 2 and 3, and 3 and 4, respectively. These parameter
estimates are effectively the relevant summaries of the data. Given these estimates and the model, evidence
is found of the extent to which the actual responses of people to the scale’s items can be recovered. This
evidence is examined to assess the fit of the responses of each item to the Rasch model.
There is no necessary and sufficient test of fit between the data and the model. Therefore, multiple pieces
of evidence of fit are required. Each focuses on different but related aspects as to where the responses
might diverge from the model’s expectations. Typically, when using RUMM2030 (Rasch Unidimensional
Measurement Models, Perth, WA, Australia), three statistical tests are used: chi-squared, fit residual
and the residual correlation.
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The chi-squared test of fit operates at the level of class intervals formed on the basis of the total scores of
persons and then provides an estimate of the magnitude of departure of the mean score for an item in
each class interval from the mean value expected according to the model. This is the most general test of
fit and provides a graphical counterpart [item characteristic curves (ICCs)], which is also examined.
The fit residual test of fit operates at the level of the response of each person to each item and provides
evidence that an item discriminates either more or less than is expected. Although there are multiple
reasons why an item might discriminate more or less than expected, a smaller discrimination than expected
might imply that the item is assessing a somewhat different construct from that assessed by the majority of
items, whereas one greater than expected might imply that it is part of a subset of items that are overly
dependent and in some sense are redundant.
The residual correlations test of fit provides evidence regarding which subsets of items might either be
assessing some aspect that is common but different from the majority of the items, or which items might
be redundant in their assessment relative to the rest. Which of these hypotheses is believed to be the case
depends on a qualitative understanding of the construct, the items and the response formats.
Evidence not directly involving statistical tests of fit is also relevant. First, an important aspect of validity is
examining the evidence that the scoring of successive categories by successive integers is justified. If it
is not justified, it implies that the endorsement of a higher score does not imply more of the construct
being assessed (impact of MS) than a lower score. In principle, it reflects some operational or conceptual
problem with the ordering of the categories, such that respondents might consistently interpret the
response categories in a different way than intended. Second, for the same reasons that we examine
the empirical ordering of the item categories, we also consider whether or not the item locations represent
a conceptually meaningful order, such that they constitute a measurement continuum. In other words,
responses to items in a scale should follow a consistent order that represents the level of ‘severity’ of
the construct. Finally, reliability was quantified using the PSI, which is analogous to Cronbach’s alpha.
This index can be interpreted in terms of the spread of the persons generated by the items, and is used in
two ways. First, a low PSI means that the power of the test of fit to detect misfit between the responses
and the model is weak. Second, if an item shows marginal fit and removing the item reduces the PSI, it
suggests that the item is adding random error and may not be consistent with the majority of the items.
The information provided by a RMT analysis is both sophisticated and extensive. Information from
multiple tests is integrated. These are considered simultaneously and interactively, rather than individually
and sequentially. Test result interpretation requires professional judgement, rather than adherence to rigid
criteria, because the information needs to be contextualised and most statistical tests are sample size
dependent. Additionally, as the analyses compare observed rating scale data against a stringent
mathematical model, anomalies are expected. To facilitate interpretation, analyses are grouped under
three broad, clinically relevant, simple (but not simplistic) questions: (1) is the scale to sample targeting
adequate for making judgements about the performance of the scale and the measurement of people?;
(2) has a measurement ruler been constructed successfully (scale/item analysis)?; and (3) how have the
people been measured by the ruler (person measurement)? Data analyses reported here used RUMM2030.
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Section 2: within-study measurement performance of the
Multiple Sclerosis Impact Scale-29, Multiple Sclerosis Walking
Scale-12 and Multiple Sclerosis Spasticity Scale-88 using
Rasch measurement theory
Background
Very few studies report a performance evaluation of the rating scales they use as clinical outcome
assessments (COAs). This appears to be because there is a belief that once scales are ‘validated’ further
evaluations are not necessary. This is somewhat misguided as there is no such thing as a ‘validated’ scale
because rating scale performance is based on an evaluation of the observed data generated by their use.
Theoretically, every time a scale is used its performance should be examined and the implications
considered. Here, a RMT analysis of the data generated by three MS-specific PROs used in the CUPID
study is reported: MSIS-29v2, MSWS-12v2 and MSSS-88.
Methods
The information provided by a RMT analysis is both sophisticated and extensive. Information from multiple
tests is integrated. These are considered simultaneously and interactively, rather than individually and
sequentially. Test result interpretation requires professional judgement, rather than adherence to rigid
criteria, because the information needs to be contextualised and most statistical tests are sample
size dependent. In addition, as the analyses compare observed rating scale data against a stringent
mathematical model, anomalies are expected. To facilitate interpretation, analyses are grouped under
three broad, clinically relevant, simple (but not simplistic) headings: scale-to-sample targeting, scale
performance (item analysis) and person measurement (person analysis). Data analysis used RUMM2030
and SPSS (SPSS Inc., Chicago, IL, USA). Analyses included all data for the three scales generated during the
CUPID study.
Scale-to-sample targeting
Scale-to-sample targeting analyses seek to determine if the match between the range of the construct
measured by the scale and the range of the construct measured in the sample, is adequate enough
to enable judgements about the performance of the scale and the measurement of people. There are no
binary criteria to assess scale-to-sample targeting.
Scale-to-sample targeting concerns the match between the range of the target variable (e.g. walking
ability) measured by the scale (e.g. MSWS-12v2) and the range of the target variable measured in the
CUPID sample by the scale. A simple examination of histograms of two relative distributions – person
locations from the sample and item location from the scale – provides a frame of reference for interpreting
the other results, informs about the suitability of the sample for evaluating the scale and the suitability of
the scale for measuring the sample. Not surprisingly, the better the targeting, the better the information.
Scale-to-sample targeting was examined for MSIS-29v2, MSWS-12v2 and MSSS-88 across all time points.
Scale performance (item analysis)
A set of analyses were undertaken to determine if a measurement ruler had been constructed successfully.
The MSWS-12v2 is used for illustrative purposes when needed, but the concepts apply to all of the scales
examined (MSWS-29v2, MSWS-12v2 and MSSS-88).
Item response categories: to what extent do the item response categories work
as intended?
Each scale item has multiple response categories labelled to imply an ordered continuum from less to
more. This continuum is implied further by assigning sequential integer scores to the response categories.
For example, consider item 6 of the MSWS-12v2 ‘limited your balance when standing and walking’: 1= not
at all, 2= a little, 3=moderately, 4= quite a bit and 5= extremely.
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While this rank ordering is intuitively sound and clinically sensible at the individual item level, it must
also work when an item is part of a set. By this we mean that the item’s response categories must have
the same logical sequence when a person moves up and down the variable measured by the whole
MSWS-12v2 set (here, walking ability). For example, as a person’s walking ability worsens, their scores
on all the 12 items components should progress sequentially, that is 1, 2, 3, 4, 5 for items 4–12 and
1, 2, 3 for items 1–3.
Rasch measurement theory analyses test this requirement empirically by estimating the location, on the
walking ability scale, of the points of transition (thresholds) between adjacent categories. A threshold
is the location, on the cognitive performance variable, at which the probability of responding in adjacent
categories is 50%. Thus, the MSWS-12v2 item 6, which has five response categories, has four transition points:
1–2, 2–3, 3–4 and 4–5. When the categories are working as intended the thresholds are ordered sequentially
along the continuum: threshold 0–1< threshold 1–2< threshold 2–3< threshold 3–4< threshold 4–5.
When the thresholds are not correctly ordered (i.e. they are disordered), the implication is that the
response categories for that component are not working as intended. Clinically, for the MSWS-12v2, this
means that a higher score does not necessarily mean more walking disability. This has huge implications
for clinical trials. Visually, thresholds are displayed as category probability curves which provide potential
diagnostic information.
The extent to which the item response categories worked as intended was examined for each of the three
scales. Data from all time points were pooled to maximise the power of the analysis to detect anomalies.
Mapped continuum: to what extent do the items map out a continuum on
which people might be measured?
Before anything can be measured, the variable (or continuum) along which measurements are to be
made needs to be marked out. Rating scales, such as the MSWS-12v2, use a set of items to define the
variable they intend to measure. Therefore, for the MSWS-12v2 to define a walking ability variable along
which measures can be interpreted, the items must be located at different points so that the direction
and meaning of the variable can be identified. This question is addressed by examining the MSWS-12v2
threshold locations, their range, how they are spread, their proximity to each other and the precision of the
estimates (SE). An item threshold location estimate is the point on the continuum at which the probability of
scoring adjacent responses is 50%. For example, item 6 of the MSWS-12v2 has four thresholds, which mark
the points on the walking ability continuum mapped out by the set of 12 MSWS-12v2 items at which there
is a 50% probability of scoring: 1 and 2, 2 and 3, 3 and 4, and 4 and 5. The item location estimate is the
mean of all the threshold location estimates for an item.
The extent to which the items of each instrument (scale and/or subscale) mapped out a continuum for
measurement was examined. Data from all time points were pooled to maximise the power of the analysis
to detect anomalies.
Item fit: to what extent do the items of a scale work together?
The components of a scale should work together as a conformable set both clinically and statistically.
Otherwise it does not make sense conceptually, logically, clinically or empirically to sum component
responses to get a total score and consider using that total score as a measurement of a person. If the
components spread out and work together to define a single continuum then the responses to items should
be predictable. Thus, examining the responses to each item for their consistency is important to determine
if the components define a cohesive continuum. Specifically, the responses to components should be in
general agreement with the ordering of persons implied by the majority of components. When this is not
the case, the validity of the components and the higher-order construct they seek to measure is questioned.
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These ideas are examined formally using indicators of goodness of fit of the observed rating scale data to
the requirements of the Rasch mathematical model. No one indicator is sufficient to describe fit. We
examined two statistical (fit residuals and chi-squared statistics) and one graphical (ICCs) indicator of fit.
Two item fit statistics (fit residuals and chi-squared values) and ICCs were examined for each instrument
(scale and/or subscale). Data from all time points were pooled to maximise the power of the analysis to
detect anomalies.
Item bias: do responses to one component bias responses to others?
The response to one scale item is expected, in general, to be related to another. For example, people who
are less walking disabled are likely to perform better on all MSWS-12v2 items than people who are more
walking disabled. However, the response to one scale item should not directly influence (or be dependent
on) the response to another scale item. When this happens measurement estimates are artificially inflated
or deflated (biased) and reliability is artificially elevated. Therefore, it is important to look actively for
dependence among scale items. This is done by examining three indicators: correlations among the
residuals, fit residuals and, when necessary, subtest analyses.
A residual is the difference between a person’s observed score on an item and their expected value for
that item derived from the RMT analysis. Correlations among residuals, derived from the whole sample,
reflect the degree of the inter-relationships between the residuals of the scale’s items. When measurement
error is random, residuals are randomly distributed and correlations among residuals of components are
low (rule of thumb range –0.30 to +0.30). However, when people’s responses to one component
are biased by (dependent on) their responses to another component, the resulting residuals are not
randomly distributed and higher correlations among residuals result (–0.30< r>+0.30).
Residuals also provide a statistical indication of the observed data’s ’fit’ to the requirements of the Rasch
measurement model. For each item, residuals are combined across individuals and standardised to produce
the fit residual summary statistic. When there is dependency among components, a high score on one
component results in an unexpectedly high score on another component. Likewise, a low score on
one component results in an unexpectedly low score on another component. When viewed across the
range of the measurement continuum and shown on the ICC, this pattern of dependency leads to
the curve of observed scores being steeper than the curve of expected scores. This is reflected in the fit
residual statistic as a high negative value. As a rule of thumb fit residual values are recommended to lie in
the range –2.50 to +2.50 and values < –2.50 points to potential dependency. Naturally, as fit residuals are
sample size dependent they need to be interpreted with this in mind.
In a subtest analysis, potentially dependent items are combined together to form a single ‘super item’
or subtest. This neutralises the dependency between the components. Dependency is determined by
examining the impact of subtesting on the PSI, a reliability indicator. The magnitude of the drop in PSI,
when the subtest analysis is compared with the ‘non-subtest’ analysis, indicates the extent to which the
reliability of the latter is falsely elevated and the degree of dependency between components.
For each instrument (scale and/or subscale) the correlations among the residuals were examined to
determine if there was evidence to suggest item score dependency. Fit residual values were also examined
and where appropriate subtest analyses were undertaken. Data from all time points were pooled to
maximise the power of the analysis to detect anomalies.
Item stability: is item performance stable across important groups?
When the ruler mapped out by a rating scale’s items is stable, the measurements generated by them can
be used to make meaningful comparisons. Thus, we need the scale items to perform similarly across
important groups that we might wish to study and compare (e.g. men and women, different age groups,
different time points, different treatments). When item performance is not stable across important
groups and display DIF, the measurement ruler is not stable across circumstances and measurement is
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affected to an unknown degree. The three MS PROs (MSIS-29v2, MSWS-12v2 and MSSS-88) were
examined for DIF across randomisation groups (active and placebo) and time points.
Person measurement (person analysis)
When targeting is reasonable and scale performance is adequate it is possible to go on and examine the
measurements derived for individuals. A range of analyses are possible and two specific questions
were examined.
Person separation: to what extent are people in the sample separated by the
items of the scale?
The aim of measurement is to locate people on a line (continuum) and detect differences between people
and changes over time. It is, therefore, valuable to examine the extent to which a scale can detect
differences between people in any study sample. In RMT analyses this is quantified as the PSI, computed as
the ratio of error-corrected person variance to the total person variance. In addition, the distribution of
person measurements and the percentage of extremes also provide information on the success of the scale
to separate the sample. It is important to note that the PSI is sample specific.
The PSI of RMT is analogous to a Cronbach’s alpha coefficient in CTT, i.e. it is a reliability statistic that can
range from 0 to 1, with greater values indicating greater separation of the people in this specific sample
by this specific scale. Values do not generalise directly from sample to sample. Although CTT posits
recommended values for alphas, this is somewhat misleading as it is a finding about the data. However,
the PSI has implications for the power of the tests of fit. The greater the separation index the greater the
power of the tests of fit to detect fit when it is present.
The PSI was examined for each instrument (scale and/or subscale) in the pooled data from all samples.
Person fit statistics: how valid are person measurements?
When a person is measured using a scale it is important to know that the scale has been used in the
expected way. That is, consistent with the idea that the items map out a variable along which the items
have a unique order. This can be determined by examining the extent to which the responses for an
individual person are in general agreement with the ordering of items implied by the majority of persons.
If not, the validity of that person’s measurement is questionable. This is determined by examining the
person fit residual, which is analogous to the item fit residual.
Person fit residuals were examined for each instrument (scale and/or subscale) in the pooled data from
all samples.
Results
Table 22 summarises the results from the RMT analysis of the MSIS-29v2, MSWS-12v2 and MSSS-88.
These three COAs contain 11 different measurement scales/subscales that differ in their content and
number of items (from 8 to 20).
All available scale completions were included in the analysis. The total number of measurements entered
into the RMT analyses varied across the scales (2223–3686). These represent the person’s x time points
and are influenced by the number of people dropping out over time, the frequency with which the scale is
administered and whether or not scale completion was appropriate. For example, people who were unable
to walk did not complete the walking scales.
The number of extremes varied across scales from a low of 16 (4.3%, MSIS-29phys) to a high of 429
(12.9%, MSWS-12v2). However, the highest percentage of extremes was 16.7% (391/2341, MSSS-88
spasms subscale). Extreme scores are similar to floor and ceiling effects. An extreme is person scale
completion in which either all items have the minimum possible score or all items have the maximum
possible score. As such, extremes are dependent on the number of items answered. However, extremes
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differ from floor and ceiling effects which are the percentage of person scale completions in which the
maximum possible and minimum possible scale scores are achieved. Extremes are important because
people at the extremes may have true changes in the target variables underestimated or not detected by
the scale.
Scale-to-sample targeting
Scale-to-sample targeting was generally adequate. For all scales the spread of person measures exceeded
the spread of item thresholds. This is a common finding because thresholds are the points on the continuum
at which a person is likely to have a 50% chance of responding in adjacent response categories. There
are two implications. Firstly, the CUPID sample was adequate for examining the performance of all
11 scales/subscales of the three MS-specific COAs. Secondly, this raises the possibility that all 11 scales
may have the potential to underestimate the true change in target variables.
The shapes of the person measurement distributions of the individual scales/subscale were examined.
Although all person measure distributions were generally Gaussian in nature, most distributions (9 out of
11) were skewed to some extent. The two non-skewed distributions were for the MSIS-29phys (Figure 24)
and MSSS-88 muscle stiffness subscales. Six distributions were left skewed (towards less problems), three
mildly (MSIS-29v2 psychological; MSSS-88 spasms and body movement), three moderately [MSSS-88
pain/discomfort, activities of daily living (ADL) and social function]. These scales have the potential to
underestimate some improvements if they occur.
Three person measure distributions were right skewed (towards more problems): one mildly (MSSS-88
feelings), one moderately (MSSS-88 walking) and one notably (MSWS-12v2; Figure 25). Two distributions
were not skewed (MSIS-29phys and MSSS-88 stiffness). These scales have the potential to underestimate
some worsening if they occur.
Scale performance (item analysis)
Response categories: to what extent did the item response categories work
as intended?
Only one of the 11 scales/subscales (the MSWS-12v2) had any reversed thresholds and only one of the
12 items was affected (running). A look at the response category endorsement frequencies indicate a
bimodal distribution with very few people responding to the middle category (sometimes limited). This may
imply that people with MS can either run or they cannot and that further gradations may be empirically
supported. This required further evaluation.
Mapped continuum: to what extent did the items map out a continuum on which
people might be measured?
Item threshold location estimates for all 11 scales/subscales spread over good ranges (minimum 4.6 logits
to maximum 8.1 logits) indicating that each item set (i.e. scale/subscale) mapped out a continuum on
which people might be measured.
Item fit: to what extent do the items of a scale work together?
Item fit statistics indicated misfit for all scales. However, misfit was expected as the CUPID sample was
large (range for item analysis, from 1950 to 3670) and fit statistics are sample size dependent. Therefore,
we examined the implications of smaller samples. At adjusted sample sizes of n= 500 there was very little
item misfit. Also, the ICCs showed adequate coherence between observed scores and predicted values.
These findings implied that each of the 11 scales/subscales was made up of a statistically cohesive item set.
Item scoring bias: did responses to one item bias responses to others?
Across the 11 scales/subscales examined, very few correlations among residuals exceeded the
recommended range of ± 0.30. This implied little item scoring bias.
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Item stability: is item performance stable across important groups?
Item stability was examined across randomisation groups. There was good item performance stability
(10 class intervals) and very little evidence of statistically significant instability despite the large sample
sizes. Visual examination of the DIF plots implied that the statistically significant DIF that was detected was
unlikely to be clinically meaningful.
Person measurement (person analysis)
The results of both the targeting analyses and the scale performance analyses implied that an examination
of person measures was necessary.
Person separation: to what extent were people separated by the scales?
Person separation index for the 11 scales/subscales ranged from 0.85 to 0.93. This indicated that all
11 scales/subscales separated the people well within the sample in terms of the target constructs being
measured. This provides a good basis for measurement in clinical trials.
Person fit statistics: how valid are person measurements?
For each scale, a number of individual person measurements had associated fit residuals outside the rule of
thumb range of –2.5 to +2.5. This number was typically < 10% except for the MSSS-88 feelings subscale
(12.7% of the samples). This indicated that for these scale completions the patterns of responses across
the items was out of keeping with expectation. Fit residuals cannot be computed for people at
the extremes.
For all 11 scales/subscales there were typically many more out of range fit residuals that were < –2.5 than
were >+2.5. Person fit residuals < –2.5 imply response patterns that are more consistent than expected
and tend to occur for people who have given the same response to all, or most, of the items in the set. In
contrast, person fit residuals exceeding +2.5 can indicate response patterns that are clinically inconsistent.
Summary
Rasch measurement theory analyses of CUPID data for MSIS-29v2, MSWS-12v2 and MSSS-88 implied that
performance was generally good. This means that it is legitimate to use the interval estimates for people
and their SEs in subsequent analyses. The targeting plots raise some questions about whether or not some
of the scales might underestimate changes and differences occurring in the study.
Section 3: evaluation of treatment effect per protocol
Methods
In the CUPID study, 493 people with MS were randomised in a ratio of 2 : 1 to receive active treatment
(n= 329) or placebo (n= 164). As has been outlined before, there were multiple visits. The change
between baseline and visit 5 was chosen as an evaluation of symptomatic treatment effect of dronabinol
and the change from baseline to end of study as an indicator of disease-modifying effect. This leads to
two possible hypotheses. First, if dronabinol had a symptomatic benefit there would be an improvement
relative to placebo in visit 5 PROs compared with baseline. Second, if dronabinol had a disease-modifying
effect there would be less deterioration by the end of the study compared with placebo.
There were three main reasons why it was thought reasonable to consider the change between baseline
and visit 5 as an evaluation of the symptomatic treatment effect of dronabinol, despite fully recognising
that the choice of time points was arbitrary. First, visit 5, week 13 after randomisation to treatment group
saw the end of the dose titration period. Second, from a clinic perspective, 3 months represents a
reasonable recall period for an individual to judge a symptomatic benefit, whereas 6 months was more
likely to be associated with recall bias. Third, 13 weeks on treatment was a similar time duration to the
CAMS study,2 which studied the symptomatic effect of cannabinoids on MS-related spasticity.
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The dropout rates have been discussed earlier. Therefore, an accurate and fair comparison would be
of the paired measurements of the subgroups of people within the randomised groups who had paired
measurements at the two relevant time points (baseline and visit 5; baseline and end).
The interval-level person measurement estimates (person locations) derived from the RMT analysis of rating
scale data were analysed, rather than the raw scores generated by summing item scores. Analyses of
change, for both the symptomatic effect and disease-modifying effect, were conducted at the group and
individual person level.
Group-level analyses consisted of assessments of statistical and clinical significance of changes. Statistical
significance of change was assessed using a one-way ANOVA on the change in person locations using
the randomisation treatment as the grouping variable and paired samples t-tests for each treatment.
Clinical significance of change was determined by computing two effect sizes from the person location
estimates: Cohen’s effect size (mean change/SD baseline) and SRMs (mean change/SD change). Effect sizes
were interpreted using Cohen’s widely used and cited criteria: 0.2 as the threshold for a small change;
0.5 the threshold for a moderate change; and 0.8 the threshold for a large change.
Rasch measurement theory also enables a legitimate assessment of change at the individual person level.
This is because RMT provides an estimate of the SE associated with every person location estimate.
This enables the significance of each person’s change in location to be examined as follows:
Significance of change (Sig ChangeÞ= ‘Time 2’ location− ‘Time 1’ location
Standard error of the difference (SEdiff)
(1)
where
SEdiff for a person =√f(SE Time 1 location)2 þ (SE Time 2 location)2g. (2)
Significance of change values were categorised as:
Sig Change ≥+1.96= significant improvement;
0 < Sig Change ≤+1.95= non-significant improvement;
Sig Change= 0= no change;
–1.95 ≤ Sig Change < 0= non-significant worsening; and
Sig Change ≤ –1.96= significant worsening.
The distribution of people across the significance of change categories for active and placebo can be
determined and compared using a chi-squared test for contingency tables.
Results
Symptomatic effect (baseline to visit 5)
Tables 23–33 show the group and individual person change for each of the 11 scales/subscales. Changes
in scores are computed as baseline minus visit 5 so that an improvement is a positive change and a
worsening is a negative change. Results are very consistent across scales.
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TABLE 23 Multiple Sclerosis Impact Scale-29, 20-point physical subscale: symptomatic effect
Analyses
Treatment group
Placebo (n= 149) Active (n= 266)
Descriptive statistics
Pre treatment (baseline), mean (SD) 0.543 (1.155) 0.539 (1.131)
On treatment (visit 5), mean (SD) 0.451 (1.110) 0.427 (1.180)
Change (baseline to visit 5), mean (SD) 0.0916 (0.899) 0.112 (0.881)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 0.052 (0.820)
Paired samples t-test, t-statistic (p-value) 1.243 (0.216) 2.078 (0.039)
Effect sizes
Cohen (mean change/SD pre treatment) 0.079 0.099
SRM (mean change/SD change) 0.102 0.127
Magnitude of change – individual person level
Better – significantly 16.8% (n= 25) 17.7% (n= 47)
Better – not significantly 27.5% (n= 41) 32.3% (n= 86)
No change 10.7% (n= 16) 7.5% (n= 20)
Worse – not significantly 36.2% (n= 54) 33.1% (n= 88)
Worse – significantly 8.7% (n= 13) 9.4% (n= 25)
Percentages may not sum to 100 due to rounding.
TABLE 24 Multiple Sclerosis Impact Scale-29, psychological impact subscale: symptomatic effect
Analyses
Treatment group
Placebo (n= 147) Active (n= 265)
Descriptive statistics
Pre treatment (baseline), mean (SD) –0.442 (1.458) –0.410 (1.400)
On treatment (visit 5), mean (SD) –0.461 (1.477) –0.567 (1.400)
Change (baseline to visit 5), mean (SD) 0.0193 (1.1830) 0.157 (1.155)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 1.319 (0.251)
Paired samples t-test, t-statistic (p-value) 0.198 (0.843) 2.211 (0.028)
Effect sizes
Cohen (mean change/SD pre treatment) 0.013 0.112
SRM (mean change/SD change) 0.016 0.136
Magnitude of change – individual person level
Better – significantly 9.5% (n= 14) 9.8% (n= 26)
Better – not significantly 32.7% (n= 48) 44.5% (n= 118)
No change 10.9% (n= 16) 6.4% (n= 17)
Worse – not significantly 38.8% (n= 57) 31.7% (n= 84)
Worse – significantly 8.2% (n= 12) 7.5% (n= 20)
Percentages may not sum to 100 due to rounding.
RASCH MEASUREMENT THEORY ANALYSIS OF MULTIPLE SCLEROSIS RATING SCALE DATA
NIHR Journals Library www.journalslibrary.nihr.ac.uk
90
TABLE 25 Multiple Sclerosis Walking Scale-12: symptomatic effect
Analyses
Treatment group
Placebo (n= 146) Active (n= 257)
Descriptive statistics
Pre treatment (baseline), mean (SD) 2.573 (1.792) 2.626 (1.786)
On treatment (visit 5), mean (SD) 2.455 (1.901) 2.351 (2.078)
Change (baseline to visit 5), mean (SD) 0.118 (1.459) 0.275 (1.690)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 0.883 (0.348)
Paired samples t-test, t-statistic (p-value) 0.981 (0.328) 2.611 (0.010)
Effect sizes
Cohen (mean change/SD pre treatment) 0.066 0.154
SRM (mean change/SD change) 0.081 0.163
Magnitude of change – individual person level
Better – significantly 13.0% (n= 19) 21.8% (n= 56)
Better – not significantly 39.7% (n= 58) 29.2% (n= 75)
No change 6.8% (n= 10) 13.6% (n= 35)
Worse – not significantly 30.8% (n= 45) 25.7% (n= 66)
Worse – significantly 9.6% (n= 14) 9.7% (n= 25)
Percentages may not sum to 100 due to rounding.
TABLE 26 Multiple Sclerosis Spasticity Scale-88, muscle stiffness subscale, q01–12: symptomatic effect
Analyses
Treatment group
Placebo (n= 148) Active (n= 262)
Descriptive statistics
Pre treatment (baseline), mean (SD) –0.024 (2.115) –0.125 (2.088)
On treatment (visit 5), mean (SD) –0.384 (2.108) –0.447 (2.220)
Change (baseline to visit 5), mean (SD) 0.360 (1.811) 0.321 (1.785)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 0.044 (0.835)
Paired samples t-test, t-statistic (p-value) 2.417 (0.170) 2.913 (0.004)
Effect sizes
Cohen (mean change/SD pre treatment) 0.170 0.154
SRM (mean change/SD change) 0.199 0.180
Magnitude of change – individual person level
Better – significantly 22.3% (n= 33) 20.2% (n= 53)
Better – not significantly 27.0% (n= 40) 34.0% (n= 89)
No change 6.8% (n= 10) 5.3% (n= 14)
Worse – not significantly 31.8% (n= 47) 26.0% (n= 68)
Worse – significantly 12.2% (n= 18) 14.5% (n= 38)
Percentages may not sum to 100 due to rounding.
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TABLE 27 Multiple Sclerosis Spasticity Scale-88, pain/discomfort subscale, q13–21: symptomatic effect
Analyses
Treatment group
Placebo (n= 148) Active (n= 264)
Descriptive statistics
Pre treatment (baseline), mean (SD) –0.745 (1.934) –0.906 (1.983)
On treatment (visit 5), mean (SD) –1.137 (1.768) –1.175 (1.899)
Change (baseline to visit 5), mean (SD) 0.393 (1.528) 0.269 (1.528)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 0.625 (0.430)
Paired samples t-test, t-statistic (p-value) 3.126 (0.002) 2.855 (0.005)
Effect sizes
Cohen (mean change/SD pre treatment) 0.203 0.135
SRM (mean change/SD change) 0.257 0.176
Magnitude of change – individual person level
Better – significantly 18.2% (n= 27) 15.5% (n= 41)
Better – not significantly 29.7% (n= 44) 36.7% (n= 97)
No change 10.1% (n= 15) 11.4% (n= 30)
Worse – not significantly 32.4% (n= 48) 26.9% (n= 71)
Worse – significantly 9.5% (n= 14) 9.5% (n= 25)
Percentages may not sum to 100 due to rounding.
TABLE 28 Multiple Sclerosis Spasticity Scale-88, muscle spasms subscale, q22–35: symptomatic effect
Analyses
Treatment group
Placebo (n= 148) Active (n= 262)
Descriptive statistics
Pre treatment (baseline), mean (SD) –2.053 (2.064) –2.081 (1.905)
On treatment (visit 5), mean (SD) –2.419 (1.803) –2.331 (1.865)
Change (baseline to visit 5), mean (SD) 0.366 (1.713) 0.250 (1.388)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 0.555 (0.457)
Paired samples t-test, t-statistic (p-value) 2.599 (0.010) 2.916 (0.004)
Effect sizes
Cohen (mean change/SD pre treatment) 0.177 0.131
SRM (mean change/SD change) 0.214 0.180
Magnitude of change – individual person level
Better – significantly 15.5% (n= 23) 17.2% (n= 45)
Better – not significantly 30.4% (n= 45) 30.5% (n= 80)
No change 20.3% (n= 30) 16.8% (n= 44)
Worse – not significantly 24.3% (n= 36) 25.6% (n= 67)
Worse – significantly 9.5% (n= 14) 9.9% (n= 26)
Percentages may not sum to 100 due to rounding.
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TABLE 29 Multiple Sclerosis Spasticity Scale-88, ADL subscale, q36–46: symptomatic effect
Analyses
Treatment group
Placebo (n= 148) Active (n= 262)
Descriptive statistics
Pre treatment (baseline), mean (SD) –1.111 (2.142) –1.275 (2.108)
On treatment (visit 5), mean (SD) –1.185 (2.227) –1.474 (2.113)
Change (baseline to visit 5), mean (SD) 0.0739 (1.4350) 0.199 (1.624)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 0.614 (0.434)
Paired samples t-test, t-statistic (p-value) 0.626 (0.532) 1.988 (0.048)
Effect sizes
Cohen (mean change/SD pre treatment) 0.034 0.095
SRM (mean change/SD change) 0.051 0.123
Magnitude of change – individual person level
Better – significantly 14.9% (n= 22) 15.6% (n= 41)
Better – not significantly 33.8% (n= 50) 36.3% (n= 95)
No change 8.1% (n= 12) 10.7% (n= 28)
Worse – not significantly 32.4% (n= 48) 24.0% (n= 63)
Worse – significantly 10.8% (n= 16) 13.4% (n= 35)
Percentages may not sum to 100 due to rounding.
TABLE 30 Multiple Sclerosis Spasticity Scale-88, walking subscale, q47–56: symptomatic effect
Analyses
Treatment group
Placebo (n= 145) Active (n= 255)
Descriptive statistics
Pre treatment (baseline), mean (SD) 1.385 (2.234) 1.196 (2.048)
On treatment (visit 5), mean (SD) 1.011 (2.098) 0.910 (2.304)
Change (baseline to visit 5), mean (SD) 0.374 (1.833) 0.286 (1.905)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 0.200 (0.655)
Paired samples t-test, t-statistic (p-value) 2.454 (0.015) 2.399 (0.017)
Effect sizes
Cohen (mean change/SD pre treatment) 0.167 0.140
SRM (mean change/SD change) 0.204 0.150
Magnitude of change – individual person level
Better – significantly 19.3% (n= 28) 19.2% (n= 49)
Better – not significantly 28.3% (n= 41) 30.2% (n= 77)
No change 20.0% (n= 29) 14.1% (n= 36)
Worse – not significantly 21.4% (n= 31) 27.1% (n= 69)
Worse – significantly 11.0% (n= 16) 9.4% (n= 24)
Percentages may not sum to 100 due to rounding.
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TABLE 31 Multiple Sclerosis Spasticity Scale-88, body movements subscale, q57–67: symptomatic effect
Analyses
Treatment group
Placebo (n= 147) Active (n= 263)
Descriptive statistics
Pre treatment (baseline), mean (SD) –0.143 (2.436) –0.376 (2.262)
On treatment (visit 5), mean (SD) –0.609 (2.260) –0.629 (2.446)
Change (baseline to visit 5), mean (SD) 0.466 (1.885) 0.253 (2.045)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 1.079 (0.299)
Paired samples t-test, t-statistic (p-value) 2.995 (0.003) 2.006 (0.046)
Effect sizes
Cohen (mean change/SD pre treatment) 0.191 0.112
SRM (mean change/SD change) 0.247 0.124
Magnitude of change – individual person level
Better – significantly 25.2% (n= 37) 22.4% (n= 59)
Better – not significantly 25.2% (n= 37) 23.6% (n= 62)
No change 8.8% (n= 13) 9.5% (n= 25)
Worse – not significantly 28.6% (n= 42) 30.4% (n= 80)
Worse – significantly 12.2% (n= 18) 14.1% (n= 37)
TABLE 32 Multiple Sclerosis Spasticity Scale-88, feelings subscale, q68–80: symptomatic effect
Analyses
Treatment group
Placebo (n= 147) Active (n= 261)
Descriptive statistics
Pre treatment (baseline), mean (SD) –0.997 (2.200) –1.023 (2.154)
On treatment (visit 5), mean (SD) –1.270 (2.262) –1.257 (2.343)
Change (baseline to visit 5), mean (SD) 0.273 (1.614) 0.234 (1.856)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 0.045 (0.832)
Paired samples t-test, t-statistic (p-value) 2.050 (0.042) 2.037 (0.043)
Effect sizes
Cohen (mean change/SD pre treatment) 0.124 0.109
SRM (mean change/SD change) 0.169 0.126
Magnitude of change – individual person level
Better – significantly 20.4% (n= 30) 19.9% (n= 52)
Better – not significantly 32.0% (n= 47) 30.3% (n= 79)
No change 14.3% (n= 21) 9.2% (n= 24)
Worse – not significantly 22.4% (n= 33) 23.4% (n= 61)
Worse – significantly 10.9% (n= 16) 17.2% (n= 45)
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Group-level changes
For all 11 scales, both active and placebo groups had positive mean change scores indicating an average
improvement in all 11 target variables. However, the mean change scores were small and none of the
changes for each group was statistically significant. There were no significant differences between
the change scores for active and placebo.
The corresponding effect sizes were small, typically but not always < 0.20 (none exceeding 0.25) and
generally similar for both active and placebo.
There were no clear trends at group level to imply that dronabinol, or placebo, may be superior.
There was no treatment effect on aspects of psychosocial function (MSIS-29v2 psychological impact
subscale; MSSS-88 feelings subscale; and MSSS-88 psychosocial function subscale).
Individual person level change
The tables show that the proportions of people undergoing different degrees of change were relatively
similar between active and placebo. None of the chi-squared values were significant.
Disease-modifying effect
Tables 34–44 show the group and individual person change for each of the 11 scales/subscales between
baseline and the end of the CUPID study. Change scores are computed as baseline minus end so that
an improvement is a positive change and a worsening is a negative change. As CUPID was a study of people
with progressive MS we would expect there to be deterioration over time, on average, particularly in terms
of motor-related functions and symptoms. Psychological functions can be affected by other factors, so it
is hard to anticipate what would happen to these variables over time. However, if dronabinol has a mood
enhancing effect, or simply makes people ‘feel better’, we might expect to see this reflected in the results.
TABLE 33 Multiple Sclerosis Spasticity Scale-88, social function subscale, q81–88: symptomatic effect
Analyses
Treatment group
Placebo (n= 146) Active (n= 260)
Descriptive statistics
Pre treatment (baseline), mean (SD) –0.792 (1.988) –1.004 (1.865)
On treatment (visit 5), mean (SD) –1.112 (1.993) –1.061 (2.012)
Change (baseline to visit 5), mean (SD) 0.320 (1.700) 0.0568 (1.6470)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 2.328 (0.128)
Paired samples t-test, t-statistic (p-value) 2.272 (0.025) 0.556 (0.579)
Effect sizes
Cohen (mean change/SD pre treatment) 0.161 0.030
SRM (mean change/SD change) 0.188 0.034
Magnitude of change – individual person level
Better – significantly 19.9% (n= 29) 11.5% (n= 30)
Better – not significantly 26.7% (n= 39) 36.5% (n= 95)
No change 15.8% (n= 23) 11.9% (n= 31)
Worse – not significantly 28.8% (n= 42) 28.5% (n= 74)
Worse – significantly 8.9% (n= 13) 11.5% (n= 30)
Percentages may not sum to 100 due to rounding.
DOI: 10.3310/hta19120 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 12
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ball et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
95
TABLE 34 Multiple Sclerosis Impact Scale-29, physical impact subscale: disease-modifying effect
Analyses
Treatment group
Placebo (n= 112) Active (n= 173)
Descriptive statistics
Pre treatment (baseline), mean (SD) 0.475 (1.202) 0.472 (1.143)
On treatment (end), mean (SD) 0.861 (1.509) 0.642 (1.189)
Change (baseline to end), mean (SD) –0.3864 (1.3080) –0.170 (1.070)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 2.324 (0.129)
Paired samples t-test, t-statistic (p-value) –3.127 (0.002) –2.091 (0.038)
Effect sizes
Cohen (mean change/SD pre treatment) –0.321 –0.149
SRM (mean change/SD change) –0.295 –0.159
Magnitude of change – individual person level
Better – significantly 10.7% (n= 12) 16.2% (n= 28)
Better – not significantly 23.2% (n= 26) 23.1% (n= 40)
No change 2.7% (n= 3) 3.5% (n= 6)
Worse – not significantly 33.9% (n= 38) 33.5% (n= 58)
Worse – significantly 29.5% (n= 33) 23.7% (n= 41)
TABLE 35 Multiple Sclerosis Impact Scale-29, psychological impact subscale: disease-modifying effect
Analyses
Treatment group
Placebo (n= 109) Active (n= 171)
Descriptive statistics
Pre treatment (baseline), mean (SD) –0.539 (1.481) –0.520 (1.397)
On treatment (end), mean (SD) –0.488 (1.542) –0.574 (1.383)
Change (baseline to end), mean (SD) –0.050 (1.385) 0.055 (1.375)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 0.388 (0.534)
Paired samples t-test, t-statistic (p-value) –0.379 (0.705) 0.522 (0.602)
Effect sizes
Cohen (mean change/SD pre treatment) –0.034 0.039
SRM (mean change/SD change) –0.036 0.040
Magnitude of change – individual person level
Better – significantly 9.2% (n= 10) 12.9% (n= 22)
Better – not significantly 33.9% (n= 37) 34.5% (n= 59)
No change 11.0% (n= 12) 8.8% (n= 15)
Worse – not significantly 35.8% (n= 39) 31.6% (n= 54)
Worse – significantly 10.1% (n= 11) 12.3% (n= 21)
Percentages may not sum to 100 due to rounding.
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TABLE 36 Multiple Sclerosis Walking Scale-12: disease-modifying effect
Analyses
Treatment group
Placebo (n= 92) Active (n= 147)
Descriptive statistics
Pre treatment (baseline), mean (SD) 2.391 (1.768) 2.452 (1.709)
On treatment (end), mean (SD) 2.891 (2.083) 2.831 (1.931)
Change (baseline to end), mean (SD) –0.500 (2.052) –0.378 (1.792)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 0.235 (0.629)
Paired samples t-test, t-statistic (p-value) –2.338 (0.022) –2.559 (0.012)
Effect sizes
Cohen (mean change/SD pre treatment) –0.283 –0.221
SRM (mean change/SD change) –0.244 –0.211
Magnitude of change – individual person level
Better – significantly 12.0% (n= 11) 10.9% (n= 16)
Better – not significantly 25.0% (n= 23) 27.9% (n= 41)
No change 8.7% (n= 8) 8.2% (n= 12)
Worse – not significantly 30.4% (n= 28) 35.4% (n= 52)
Worse – significantly 23.9% (n= 22) 17.7% (n= 26)
Percentages may not sum to 100 due to rounding.
TABLE 37 Multiple Sclerosis Spasticity Scale-88, muscle stiffness subscale, q01–12: disease-modifying effect
Analyses
Treatment group
Placebo (n= 104) Active (n= 158)
Descriptive statistics
Pre treatment (baseline), mean (SD) –0.174 (2.025) –0.276 (2.120)
On treatment (end), mean (SD) 0.213 (2.179) –0.154 (2.244)
Change (baseline to end), mean (SD) –0.387 (2.254) –0.122 (2.070)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 0.956 (0.329)
Paired samples t-test, t-statistic (p-value) –1.751 (0.083) –0.742 (0.459)
Effect sizes
Cohen (mean change/SD pre treatment) –0.191 –0.058
SRM (mean change/SD change) –0.172 –0.059
Magnitude of change – individual person level
Better – significantly 21.2% (n= 22) 20.9% (n= 33)
Better – not significantly 13.5% (n= 14) 22.8% (n= 36)
No change 2.9% (n= 3) 6.3% (n= 10)
Worse – not significantly 30.8% (n= 32) 32.3% (n= 51)
Worse – significantly 31.7% (n= 33) 17.7% (n= 28)
Percentages may not sum to 100 due to rounding.
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TABLE 38 Multiple Sclerosis Spasticity Scale-88, pain/discomfort subscale, q13–21: disease-modifying effect
Analyses
Treatment group
Placebo (n= 104) Active (n= 156)
Descriptive statistics
Pre treatment (baseline), mean (SD) –0.745 (1.791) –1.041 (1.992)
On treatment (end), mean (SD) –0.805 (2.039) –1.082 (1.925)
Change (baseline to end), mean (SD) 0.061 (1.907) 0.0418 (1.730)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 0.007 (0.935)
Paired samples t-test, t-statistic (p-value) 0.324 (0.747) 0.302 (0.763)
Effect sizes
Cohen (mean change/SD pre treatment) 0.034 0.021
SRM (mean change/SD change) 0.032 0.024
Magnitude of change – individual person level
Better – significantly 16.3% (n= 17) 14.7% (n= 23)
Better – not significantly 30.8% (n= 32) 26.3% (n= 41)
No change 6.7% (n= 7) 13.5% (n= 21)
Worse – not significantly 26.9% (n= 28) 31.4% (n= 49)
Worse – significantly 19.2% (n= 20) 14.1% (n= 22)
Percentages may not sum to 100 due to rounding.
TABLE 39 Multiple Sclerosis Spasticity Scale-88, muscle spasms subscale, q22–35: disease-modifying effect
Analyses
Treatment group
Placebo (n= 103) Active (n= 156)
Descriptive statistics
Pre treatment (baseline), mean (SD) –2.129 (2.086) –2.108 (1.916)
On treatment (end), mean (SD) –2.099 (1.894) –2.105 (1.855)
Change (baseline to end), mean (SD) –0.030 (2.071) –0.004 (1.657)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 0.013 (0.911)
Paired samples t-test, t-statistic (p-value) –0.146 (0.884) –0.028 (0.978)
Effect sizes
Cohen (mean change/SD pre treatment) –0.014 –0.002
SRM (mean change/SD change) –0.014 –0.002
Magnitude of change – individual person level
Better – significantly 17.5% (n= 18) 20.5% (n= 32)
Better – not significantly 21.4% (n= 22) 22.4% (n= 35)
No change 11.7% (n= 12) 9.6% (n= 15)
Worse – not significantly 28.2% (n= 29) 33.3% (n= 52)
Worse – significantly 21.4% (n= 22) 14.1% (n= 22)
Percentages may not sum to 100 due to rounding.
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TABLE 40 Multiple Sclerosis Spasticity Scale-88, ADL subscale, q36–46: disease-modifying effect
Analyses
Treatment group
Placebo (n= 103) Active (n= 154)
Descriptive statistics
Pre treatment (baseline), mean (SD) –0.976 (2.091) –1.446 (2.046)
On treatment (end), mean (SD) –0.417 (2.865) –1.213 (2.443)
Change (baseline to end), mean (SD) –0.559 (2.228) –0.233 (2.220)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 1.329 (0.250)
Paired samples t-test, t-statistic (p-value) –2.547 (0.012) –1.302 (0.195)
Effect sizes
Cohen (mean change/SD pre treatment) –0.267 –0.114
SRM (mean change/SD change) –0.251 –0.105
Magnitude of change – individual person level
Better – significantly 15.5% (n= 16) 18.2% (n= 28)
Better – not significantly 15.5% (n= 16) 25.3% (n= 39)
No change 5.8% (n= 6) 3.9% (n= 6)
Worse – not significantly 35.0% (n= 36) 26.6% (n= 41)
Worse – significantly 28.2% (n= 29) 26.0% (n= 40)
TABLE 41 Multiple Sclerosis Spasticity Scale-88, walking subscale, q47–56: disease-modifying effect
Analyses
Treatment group
Placebo (n= 98) Active (n= 145)
Descriptive statistics
Pre treatment (baseline), mean (SD) 1.352 (2.281) 0.790 (1.998)
On treatment (end), mean (SD) 1.335 (2.191) 1.001 (2.064)
Change (baseline to end), mean (SD) 0.017 (1.915) –0.211 (2.220)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 0.685 (0.409)
Paired samples t-test, t-statistic (p-value) 0.085 (0.932) –1.145 (0.254)
Effect sizes
Cohen (mean change/SD pre treatment) 0.007 –0.106
SRM (mean change/SD change) 0.009 –0.095
Magnitude of change – individual person level
Better – significantly 13.3% (n= 13) 19.3% (n= 28)
Better – not significantly 34.7% (n= 34) 21.4% (n= 31)
No change 9.2% (n= 9) 7.6% (n= 11)
Worse – not significantly 23.5% (n= 23) 31.7% (n= 46)
Worse – significantly 19.4% (n= 19) 20.0% (n= 29)
Percentages may not sum to 100 due to rounding.
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TABLE 42 Multiple Sclerosis Spasticity Scale-88, body movements subscale, q57–67: disease-modifying effect
Analyses
Treatment group
Placebo (n= 100) Active (n= 157)
Descriptive statistics
Pre treatment (baseline), mean (SD) –0.058 (2.422) –0.750 (2.190)
On treatment (end), mean (SD) 0.063 (2.299) –0.507 (2.378)
Change (baseline to end), mean (SD) –0.121 (2.181) –0.242 (2.097)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 0.197 (0.657)
Paired samples t-test, t-statistic (p-value) –0.557 (0.579) –1.449 (0.149)
Effect sizes
Cohen (mean change/SD pre treatment) –0.050 –0.111
SRM (mean change/SD change) –0.056 –0.116
Magnitude of change – individual person level
Better – significantly 19.0% (n= 19) 17.8% (n= 28)
Better – not significantly 26.0% (n= 26) 25.5% (n= 40)
No change 5.0% (n= 5) 7.6% (n= 12)
Worse – not significantly 25.0% (n= 25) 28.0% (n= 44)
Worse – significantly 25.0% (n= 25) 21.0% (n= 33)
Percentages may not sum to 100 due to rounding.
TABLE 43 Multiple Sclerosis Spasticity Scale-88, feelings subscale, q68–80: disease-modifying effect
Analyses
Treatment group
Placebo (n= 102) Active (n= 156)
Descriptive statistics
Pre treatment (baseline), mean (SD) –0.858 (2.106) –1.182 (2.141)
On treatment (end), mean (SD) –1.341 (2.215) –1.349 (2.164)
Change (baseline to end), mean (SD) 0.482 (2.002) 0.167 (2.181)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 1.372 (0.243)
Paired samples t-test, t-statistic (p-value) 2.434 (0.017) 0.959 (0.339)
Effect sizes
Cohen (mean change/SD pre treatment) 0.229 0.078
SRM (mean change/SD change) 0.241 0.077
Magnitude of change – individual person level
Better – significantly 25.5% (n= 26) 25.6% (n= 40)
Better – not significantly 37.3% (n= 38) 26.3% (n= 41)
No change 3.9% (n= 4) 7.1% (n= 11)
Worse – not significantly 18.6% (n= 19) 19.2% (n= 30)
Worse – significantly 14.7% (n= 15) 21.8% (n= 34)
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Group-level changes
For eight of the 11 scales/subscales there is no real difference between active- and placebo-treated people.
For three of 11 scales/subscales (MSIS-29phys; MSSS-88 muscle stiffness and ADL subscales), there was a
suggestion that people treated with dronabinol have deteriorated less than people treated with placebo.
These changes within the placebo group and within the active group, and between placebo and active,
were not significant statistically.
Effect size calculations implied that the deterioration in placebo-treated people exceeded the threshold for
small clinical worsening (< –0.20) for two subscales (MSIS-29phys and MSSS-88 ADL subscales) and is
borderline small for the third (MSSS-88 muscle stiffness). The corresponding effect size calculations for
dronabinol-treated people are approximately half the magnitude. This hinted at the possibility of a
disease-modifying treatment effect.
There was no treatment effect on aspects of psychosocial function (MSIS-29v2 psychological impact
subscale; MSSS-88 feelings subscale; or MSSS-88 psychosocial function subscale).
There are two notable findings. First, the mean changes over a considerable period of time are very small.
This implies only clinically small progression during the study in a large cohort of people with a diagnosis of
progressive MS. Second was the high dropout rate. The CUPID study recruited 493 people, randomising
329 to active and 164 to placebo. By the end of the study the maximum number of people completing a
PRO was 173 in the active group, 53% of the original dronabinol-treated cohort and 112 in the placebo
group, 68% of the original placebo-treated cohort.
TABLE 44 Multiple Sclerosis Spasticity Scale-88, social function subscale, q81–88: disease-modifying effect
Analyses
Treatment group
Placebo (n= 104) Active (n= 155)
Descriptive statistics
Pre treatment (baseline), mean (SD) –0.783 (1.963) –1.286 (1.816)
On treatment (end), mean (SD) –1.228 (2.123) –1.271 (1.995)
Change (baseline to end), mean (SD) 0.445 (2.066) –0.014 (1.953)
Magnitude of change – group level
One-way ANOVA, F-statistic (p-value) 3.287 (0.071)
Paired samples t-test, t-statistic (p-value) 2.197 (0.030) –0.091 (0.928)
Effect sizes
Cohen (mean change/SD pre treatment) 0.227 –0.008
SRM (mean change/SD change) 0.215 –0.007
Magnitude of change – individual person level
Better – significantly 24.0% (n= 25) 18.1% (n= 28)
Better – not significantly 26.0% (n= 27) 29.7% (n= 46)
No change 15.4% (n= 16) 6.5% (n= 10)
Worse – not significantly 20.2% (n= 21) 26.5% (n= 41)
Worse – significantly 14.4% (n= 15) 19.4% (n= 30)
Percentages may not sum to 100 due to rounding.
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Individual person-level change
The proportion of people in each of the five change groups is very similar for placebo and active although,
as expected, this changes across scales. The similarity between placebo and active is notable even for the
three scales/subscales where the group analyses hint at a disease-modifying treatment effect.
Perhaps the most striking findings from the individual person-level analysis are the proportions of people
who appear to have improved by the end of the study. In the placebo group, this proportion ranged from
31% (MSSS-88 ADL subscale) to 63% (MSSS-88 feelings subscale). The proportion of people categorised
as having a significant improvement ranged from 9% (MSIS-29v2 psychological impact scale) to 26%
(MSSS-88 feeling subscale), with a mean of 17%. This warrants further examination.
For illustration, Figures 26 and 27 show the SRMs for the two MSIS-29v2 subscales and the individual
person change for the MSIS-29phys.
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FIGURE 26 Standardised response means for the two MSIS-29v2 subscales, by treatment group. (a) MSIS-29v2
physical impact subscale; and (b) MSIS-29v2 psychological subscale.
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Summary
The results imply that dronabinol was not associated with either a symptomatic or a disease-modifying
benefit. There was also no evidence that dronabinol improved people’s psychosocial functioning in either
the short or the long term.
There were, however, some particularly notable findings. First, the degree of progression at a group and
individual person level in the placebo group was smaller than might be expected for a cohort of people
with a diagnosis of progressive MS. The largest deterioration in any one scale only just exceeded clinically a
small change according to Cohen’s criteria for interpreting effect sizes. This makes it difficult to show a
disease-modifying effect even if it were present. Second, and related to this, notable numbers of people
appeared to have improved (up to 63% on one subscale), some significantly (up to 26% on one subscale),
by the end of the study. Third, the dropout rate from both treatment groups, particularly the active group,
was very high (nearly 50%).
Section 4: exploratory evaluation of treatment effect by
baseline disability level
Analyses presented earlier in this report hinted towards a treatment effect in people with lower EDSS
scores at baseline and limited progression in participants with high EDSS scores. For this reason we
explored the changes in the MS-specific PROs of people who were less disabled (baseline EDSS score of
4.0–5.5) and those who were more disabled (baseline EDSS score of 6.0–6.5). These analyses were
undertaken in the full knowledge of being exploratory post-hoc analyses in non-randomised groups. As
such, any results should be interpreted with caution.
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FIGURE 27 Individual-person change for the MSIS-29phys, by treatment group.
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Methods
Patient-reported outcomes were compared in active and placebo for the two disability-defined subgroups.
Specifically, these were examined for evidence of a symptomatic effect (change from visit 1 to visit 5) and a
disease-modifying effect (change from visit 1 to end of study). The statistical significance of change scores in
people with paired data using paired samples t-tests and clinical significance was determined using two effect
size calculations: Cohen’s effect size (mean change/SD baseline) and the SRM (mean change/SD change).
Effect sizes were interpreted using Cohen’s criteria (0.2 is the threshold for a clinically small change; 0.5 is the
threshold for a clinically moderate change; and 0.8 is the threshold for a clinically large change).
Results
Symptomatic effect
Table 45 shows the results of analyses to determine evidence of a symptomatic effect. Sample sizes of the
comparison groups varied notably, with the more disabled subgroup being far larger that the less
disabled subgroup.
Results for all 11 scales/subscales implied an improvement at visit 5 relative to visit 1. No t-statistics were
significant at the p< 0.001 level (no Bonferroni correction). Effect sizes did not suggest any patterns in the
data in terms of the comparison between active treatment in the less and more disabled subgroups. Some
scales had larger effect sizes in the less disabled subgroup, some had larger effect sizes in the more
disabled subgroup, and some were equal.
The comparisons of active with placebo were similar for most scales. Five MSSS-88 subscales (stiffness,
pain, walking, body movements and social function) recorded notably larger benefits in the placebo group
than in the active group among the less disabled cohort.
The two effect sizes (Cohen’s effect size and SRM) produced different results, as we have noted in our
previous work.
Disease-modifying effect
Table 46 shows the results of analyses to determine evidence of a disease-modifying effect. Again, sample
sizes of the comparison groups varied notably, with the more disabled subgroup being far larger that the
less disabled subgroup. The sample size for the less disabled people on placebo was particularly small
(between 23 and 29).
In the less disabled subsample, change scores were mostly negative, implying a worsening in these
outcomes between the beginning and end of the study. Effect sizes for placebo and active were similar
for eight scales. For two scales/subscales (MSWS-12v2; MSIS-29phys) there was notably less worsening in
the active than the placebo group. In contrast, there was greater worsening in the active group for the
MSSS-88 walking subscale.
In the more disabled group, effect sizes for both active and placebo were generally similar across the
scales. It is notable that the group-based deterioration in physical function in the placebo group of
the more disabled group was surprisingly small over the 3 years of the study, with the largest change
being considered small by Cohen’s criteria.
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Figures 28 and 29 show the SRM plots for the MSIS-29phys and MSWS-12v2, in the two subgroups
defined by baseline EDSS score.
Finally, individual person changes were examined (computed as described previously), for the MSIS-29v2
and MSWS-12v2. These results are shown in Figures 30 and 31. For the MSIS-29phys, the plot shows
less difference between the two disability groups than is implied by the effect sizes. For the MSWS-12v2,
the differences between the two disability groups are notable.
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FIGURE 28 Standardised response means for the MSIS-29phys, by treatment group and baseline EDSS score
subgroup. (a) Baseline EDSS score of 4.0–5.5; and (b) baseline EDSS score of 6.0–6.5. Effect size difference
(SRM)= 0.28; effect size difference (Cohen’s)= 0.29.
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FIGURE 29 Standardised response means for the MSWS-12v2, by treatment group and baseline EDSS score
subgroup. (a) Baseline EDSS score of 4.0–5.5; and (b) baseline EDSS score of 6.0–6.5. Effect size difference
(SRM)= 0.40; effect size difference (Cohen’s)= 0.67.
DOI: 10.3310/hta19120 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 12
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ball et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
107
Placebo
(n = 29)
Active
(n = 61)
Better –
significantly
Worse – not
significantly
Worse –
significantly
Better – not
significantly
No change
Level of change
0
5
10
15
20
25
30
35
40
45
50
(a)
W
it
h
in
-t
re
at
m
en
t 
g
ro
u
p
 p
er
ce
n
ta
g
e 
(%
)
Placebo
(n = 111)
Active
(n = 191)
Better –
significantly
Worse – not
significantly
Worse –
significantly
Better – not
significantly
No change
0
5
10
15
20
25
30
35
40
(b)
W
it
h
in
-t
re
at
m
en
t 
g
ro
u
p
 p
er
ce
n
ta
g
e 
(%
)
Level of change
FIGURE 30 Individual-person change for the MSIS-29v2phys, in each treatment group, by disability subgroup.
(a) Baseline EDSS score of 4.0–5.5; and (b) baseline EDSS score of 6.0–6.5.
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FIGURE 31 Individual-person change for the MSWS-12v2, in each treatment group, by disability subgroup.
(a) Baseline EDSS score of 4.0–5.5; and (b) baseline EDSS score of 6.0–6.5.
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Summary
Exploratory post-hoc analyses in generally small, non-randomised samples of disability subgroups did not
suggest a clear symptomatic or a disease-modifying treatment effect on the MS-specific PROs used in the
CUPID study. There were some hints of a potential disease-modifying effect, with reduced progression
measured by the MSIS-29phys and MSWS-12v2. Indeed, the effect size differences between active and
placebo for these two scales/subscales was striking, regardless of calculation method. However, these
effects were not supported by a benefit on MSSS-88 physical function subscales (ADL, walking, body
movements). Indeed, the MSSS-88 walking subscale came to the opposite conclusion, favouring placebo.
Perhaps the most notable finding from these analyses was the size of the worsening over time in the
placebo group. In the more disabled subgroup, which was reasonably large (n= 88–111), the effect
size-based worsening on the five self-report physical function scales/subscales ranged from –0.01 to –0.34,
implying very little deterioration. Deterioration in the (very small) placebo-treated lower disability subgroup
(n= 23–29) was larger, with effects sizes for four of the five scale/subscales ranging from clinically small
to clinically large.
Section 5: reflections and lessons learned from Rasch
measurement theory analysis of Cannabinoid Use in
Progressive Inflammatory brain Disease data
This chapter has concerned the application of the modern, sophisticated psychometric method RMT to
data generated by MS-specific PRO measures used in a large multicentre Phase III pivotal clinical trial.
Historically, despite its availability since the 1960s, RMT has been used frugally before. There may be two
main reasons for this: the inaccessibility of RMT to clinicians, and the lack of emphasis on COAs as primary
and secondary end points. The first reason is changing as RMT is becoming more widely known,
understood and used. The second reason is changing, as there is increasing recognition of the importance
of measuring patient-focused outcomes. In particular, the US Food and Drug Administration (FDA) has
emphasised the importance of patient-focused COA and the use of PROs. Indeed, recently, two important
figures related to COAs in general – the road map to patient-focused outcome assessment (Figure 32) and
the wheel and spokes diagram for the qualification of COAs (Figure 33) – have appeared on their website.
The evaluation of scale performance was informative. Analyses show the scales performed adequately,
although the suboptimal targeting for some scales/subscales means there is room for improvement. It is
difficult to quantify the implication of limitations in scale performance. However, our findings mean that
we can be relatively confident in the interpretation of subsequent analyses.
The main finding of the study was that Δ9-THC does not appear to have either a symptomatic or a
disease-modifying effect as measured using these MS-specific PROs. There were some suggestions of
improvement but no consistent findings. It seems that the chance of detecting a disease-modifying effect,
if present, was slim as the progression in the sample, on average, was statistically and clinically small. Also,
a reasonably large proportion of people appeared to improve their function over time, which is surprising
for people diagnosed as having a chronic progressive disabling incurable neurological disease.
These findings raised questions of the completeness of our understanding of progressive MS and the need
for more basic research to understand exactly what is progressing in progressive MS.
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Chapter 6 Economic evaluation
Introduction
The aim of the economic evaluation was to compare the costs and consequences of cannabinoids
(Δ9-THC) with those of usual care in progressive MS in the UK outpatient setting. The primary analytical
perspective was the NHS and Personal and Social Services (PSS), with the patient perspective considered
in secondary analyses. The primary health economic outcome was the quality-adjusted life-year (QALY)
estimated using the EQ-5D18 and the primary economic end point was the 36-month follow-up. Costs
and QALYs were discounted after the first year at the UK treasury rate of 3.5%.
Methods
Resource use
Resource use data were collected at participant level using a combination of patient self-report
questionnaires and clinical records. Table 47 details the resource use data collected in the trial and the
time points at which it was collected.
TABLE 47 Details of resource use data collected as part of the trial
Resource use item Sources
Time period (figures in brackets
indicate follow-up intervals)
Medication (see Appendix 8) CRF 36-month trial period
Other intervention costs (additional neurology consultations,
management of AEs)
Expert
opinion
36-month trial period
CRF
SAEs
Hospital admissions CRF 36-month trial period
SAEs
Primary and acute care services (GP, community nurse, MS specialist
nurse, physiotherapist, rehabilitation clinic visit, occupational
therapist, speech therapist, neurologist, psychologist, chiropodist,
optician, continence advisor, social worker)
Patient
questionnaire
Baseline, 4.5 months (1, 2)
and 6 months (3, 4, 5, 6)
Alternative practitioners (reflexologist, osteopath, homeopath,
herbalist, masseuse, chiropractor, acupuncturist, hypnotist)
Patient
questionnaire
Baseline, 4.5 months (1, 2)
and 6 months (3, 4, 5, 6)
Informal care from friends/family Patient
questionnaire
Baseline, 4.5 months (1, 2)
and 6 months (3, 4, 5, 6)
Formal personal care services Patient
questionnaire
Baseline, 4.5 months (1, 2)
and 6 months (3, 4, 5, 6)
Home adaptations and equipment Patient
questionnaire
Baseline, 4.5 months (1, 2)
and 6 months (3, 4, 5, 6)
Day care Patient
questionnaire
Baseline, 4.5 months (1, 2)
and 6 months (3, 4, 5, 6)
Respite care Patient
questionnaire
Baseline, 4.5 months (1, 2)
and 6 months (3, 4, 5, 6)
Treatment-related travel Patient
questionnaire
Baseline, 4.5 months (1, 2)
and 6 months (3, 4, 5, 6)
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Intervention resource use, for delivery of Δ9-THC (other than medication which was based on patient-level
data) was estimated based on the clinical protocol for delivery of the intervention.
Unit costs for resource use
Resource use data (i.e. number of visits, hours of care, respite episodes, hospital admissions) were
combined with unit costs to estimate resource costs. Unit costs attached to health service resource use
were based as far as possible on those faced by the NHS. Unit costs used were for 2010/11. Resource
use was valued using available national unit costs for the NHS, usually the Personal and Social Services
Research Unit (PSSRU)19 or NHS reference costs (www.gov.uk/government/publications/2010–11-reference-
costs-publication) (Table 48). Future costs were discounted at the UK treasury rate of 3.5% per year,
in line with National Institute for Health and Care Excellence (NICE) methods guidance.20 The value of
adaptations and equipment were annualised over a 10-year time period. This is a pragmatic and
simplifying assumption, used to reflect the costs over the longer term use of these items of expenditure
(e.g. bathroom adaptations, stair lifts), but this assumption does not impact on the results presented here.
Hospitalisation data were limited to episodes reported as MS- or medication-related AEs or SAEs in trial
CRFs, consistent with the trial protocol. Inpatient episodes were valued using relevant Healthcare Resource
Group codes for MS patients (see Table 48). Informal (unpaid) care provided by friends and family was
valued using the equivalent NHS/PSS hourly home care rate (as a shadow price) based on the replacement
valuation method. Travel mileage was valued using national Automobile Association rates including
standing and running costs. Sources and assumptions for all unit costs are reported.
TABLE 48 Unit costs and sources (£, 2010–11)
Resource use item Unit Unit cost (£) Source Notes
Cost to NHS/PSS
GP (at practice) Per visit 36 PSSRU19 11.7-minute consultation
Nurse (at practice) Per visit 15 PSSRU19 15.5-minute surgery visit
Nurse home visit Per visit 30 PSSRU19 25-minute home visit
MS nurse clinic visit Per visit 25 PSSRU19 Clinical nurse specialist
MS nurse home visit Per visit 38 PSSRU19 25-minute home visit
Physiotherapist clinic visit Per visit 34 PSSRU19 1-hour visit
Physiotherapist home visit Per visit 47 PSSRU19 Per visit
Occupational therapist clinic visit Per visit 34 PSSRU19 1-hour visit
Rehabilitation clinic visit Per visit 34 Assumed equivalent
to occupational
therapy clinic visit
Speech therapist clinic visit Per visit 34 PSSRU19 1-hour visit
Speech therapist home visit Per visit 47 PSSRU19 Per visit
Neurologist consultation Per visit 145 NHS reference costs Per consultation
Psychologist consultation Per visit 135 PSSRU19 1-hour visit
Chiropodist clinic visit Per visit 31 PSSRU19 1-hour visit
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TABLE 48 Unit costs and sources (£, 2010–11) (continued )
Resource use item Unit Unit cost (£) Source Notes
Chiropodist home visit Per visit 47 Assumed equivalent
to physiotherapist
home visit
Optician visit Per visit 20 Assumed equivalent
to private visit
Continence advisor clinic visit Per visit 25 PSSRU19 Clinical nurse specialist
Continence advisor home visit Per visit 38 PSSRU19 25-minute visit
Social worker home visit Per visit 212 PSSRU19 1-hour visit
Acupuncturist clinic visit Per visit 34 Assumed equivalent
to physiotherapist
clinic visit
Personal care Per hour 18 PSSRU19 1-hour visit
Day care Per session 36 PSSRU19 3-hour session
Respite care Per session 1005 PSSRU19 1-week stay
Elective inpatient HRG for MS Per admission 1511 NHS reference costs Average length of stay
2.66 days
Non-elective inpatient HRG
for MS
Per admission 2263 NHS reference costs Average length of stay
4.97 days
Non-elective inpatient HRG for
MS short stay
Per admission 501 NHS reference costs Overnight admission for
drug complications
MS-related outpatient
procedures (urinary tract
infections, catheters, Botox
to bladder)
Per procedure 128–206 NHS reference costs
Private patient costs
Physiotherapist clinic visit Per visit 34 Assumed equivalent
to NHS cost
Chiropodist clinic visit Per visit 31 Assumed equivalent
to NHS cost
Alternative practitioners
clinic visits
Per visit 34 Assumed equivalent
to a physiotherapist
clinic visit
Home care Per hour 18 Assumed equivalent
to NHS hourly rate for
home care workers
Travel costs Per mile 0.6862 Automobile
Association
Automobile running and
standing costs
HRG, health-related group.
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Outcomes
The primary health economic outcome is the QALY calculated using the EuroQol EQ-5D. QALYs are a
generic measure of health outcome which simultaneously capture changes in health-related quality of life
(HRQoL) and survival combined into a single measure of treatment effect. Patient HRQoL was assessed by
responses to the EQ-5D, a generic measure of health status with five domains (mobility, self-care, usual
activity, pain/discomfort and anxiety/depression). Health states described by the EQ-5D have been valued
on a scale of 0 (dead) to 1 (full health), with some states at worse than dead, based on the preferences of
a community sample of people in the UK for time spent in each health state.18 The EQ-5D is the measure
preferred by NICE in health technology assessments.20 Patient-level QALYs are calculated by applying an
area under the curve method,21 which assumes linear change between discrete follow-up points in time.
As with future costs, future QALYs after the first year are discounted using the UK treasury rate of 3.5%
per annum.
Statistical methods
Descriptive analyses are undertaken and the means and distributions of resource use and costs, by type,
and QALYs at each time point are presented, using complete case data, with no discounting applied.
Discounted aggregated (category subgroup) costs are then presented with means, measures of variability
and 95% CIs at each time point. Between-group comparisons are presented using multivariable regression
based on a generalised linear model (GLM) used to estimate the treatment effect on costs and outcomes
controlling for baseline costs and six other baseline covariates specified a priori in the trial SAP (study site,
sex, age, weight, MS type and EDSS score). Because cost data are skewed, a GLM with an identity link and
gamma distribution was used to estimate the regression coefficients.22 The goodness of fit of the selected
link and family function was confirmed using the modified Park test. Statistical analyses were performed
on Stata version 12.0 (StataCorp LP, College Station, TX, USA). Primary analyses of between-group
differences are based on data with missing values replaced using multiple imputation (see Methods, below)
and where future costs and QALYs are discounted.
Post-hoc subgroup analysis
Consistent with the analyses of effectiveness data (Chapter 3), post-hoc economic analyses were
undertaken among those patients with a baseline EDSS score of 4.0–5.5. Accordingly, the relationship
between costs and outcomes with treatment allocation and covariates pre-specified in the trial SAP were
examined in a regression analysis on the subgroup of patients with a baseline EDSS score of 4.0–5.5.
Missing data
As a consequence of participants not returning or submitting postal and internet questionnaires or
dropping out of the study, there was a large number of missing data. Additionally, levels of missing cost
and QALY data were different because of differences in the timing of questionnaires. The number of
missing questionnaires in each treatment group for resource use and the EQ-5D are shown in Tables 49
and 50. Half of the cost data are missing, although most of this (74% or 179/241 missing questionnaires)
was intermittent missing data (i.e. these patients missed one or more questionnaires, but provided
subsequent data and did not drop out of the study entirely). This suggests that these data were missing at
random. There were no between-group differences in missing cost (χ2= 0.122; p= 0.73) or EQ-5D data
(χ2= 1.805; p= 0.18).
Missing cost and QALY data were associated with study site (p= 0.004 and p< 0.001, respectively),
age (p= 0.05 and p= 0.003, respectively) (younger patients more likely to have missing data); and, for
QALY outcomes, hospitalisation costs (p= 0.02) (patients with missing data had significantly higher
hospitalisation costs). No other baseline or cost variables had a significant effect on missing cost
or QALY data.
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
116
Imputation of missing data
Data analysis confined to complete cases would ignore data from most patients departing from an
ITT analysis. Missing data are handled using the method of multiple imputation using chained equations
(ICE)23 on costs and EQ-5D scores. This method imputes values based on the available data. Missing data
were not imputed for patients who died or did not have baseline cost or utility data. The sets of predictor
variables were based on the dependent variable at all other time points and on the six baseline covariates
selected a priori in the multivariable regression. The incomplete response variables were aggregated
health-care costs and social care costs. The data set was imputed 50 times and the ICE program uses
the 50 data sets simultaneously for statistical analysis, thereby accounting for both within- and
between-data set variability.
TABLE 49 Summary of missing cost data
Time point Active n (%) Placebo n (%)
N 329 164
Baseline 5 (2) 1 (1)
4.5-month follow-up 71 (22) 28 (17)
9-month follow-up 73 (22) 33 (20)
15-month follow-up 84 (26) 38 (23)
21-month follow-up 95 (29) 48 (29)
27-month follow-up 109 (33) 44 (27)
33-month follow-up 107 (33) 46 (28)
Completed all questionnaires 159 (48) 82 (50)
TABLE 50 Summary of missing EQ-5D data
Time point Active n (%) Placebo n (%)
N 329 164
Baseline 2 (1) 0 (0)
3-month follow-up 38 (12) 9 (5)
6-month follow-up 40 (12) 16 (10)
12-month follow-up 44 (13) 17 (10)
18-month follow-up 58 (18) 23 (14)
24-month follow-up 62 (19) 24 (15)
30-month follow-up 68 (21) 30 (18)
36-month follow-up 79 (24) 25 (15)
Completed all questionnaires 217 (66) 118 (72)
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Results
Intervention costs (delivery of Δ9-tetrahydrocannabinol)
Intervention costs reflect the costs of resources required to deliver a new intervention (Δ9-THC) over and
above usual care. This required an understanding of the resources typically involved in the usual care of
progressive MS patients and the additional resources expected to be required to deliver the CUPID
intervention in current UK outpatient settings. This information was obtained from the clinical protocol
and advice provided from the clinical teams delivering the intervention. Frequency of appointments with
consultant neurologists in this patient group is usually one per year, more if patients are experiencing
problems, for example with walking or bladder control. The additional resources that would be needed to
add the CUPID intervention (Δ9-THC) to current UK practice comprise drug acquisition, an additional
hospital consultation to monitor induction and management of AEs, as well as additional patient costs to
collect monthly prescriptions.
Table 51 presents the mean cost of the 3-year CUPID Δ9-THC intervention, estimated at £27,433 per
patient enrolled in the active treatment group. Medication use was based on observed patient-level data.
Dose was estimated using the median dose achieved by patients in the active treatment group who were
compliant for the duration of the trial (n= 178). This was two capsules twice per day. The cost of the
medication was based on a quote of £561.50 from a pharmaceutical importer (Pharmarama) provided on
6 March 2012 for a pack of 60 2.5-mg capsules of Marinol® dispensed against a private prescription
(excluding any VAT charge). This unit cost was established with agreement from the trial team for use as
the base case cost for intervention medication, in the absence of any other published informative unit
cost (at that time). On this basis the price per capsule was £9.36. Noting that 3.5-mg capsules were used
in the CUPID study, the daily cost associated with the median dose in the CUPID study was £37.43 or,
alternatively, £13,663.17 per year for fully compliant patients. As a long-term treatment, it is important to
factor in compliance otherwise the cost of the treatment will be overestimated. Thus, the median dose was
multiplied by the number of days patients were medication compliant (i.e. days between induction date
and date of medication discontinuation). On this basis the average cost per treated patient per year was
£10,780. Pharmacy and drug wastage costs are assumed to be included in these estimates.
TABLE 51 Intervention resource use and costs (Δ9-THC)
Cost
category Cost Source
Level cost
incurred
Total per compliant
patient first year
Mean cost, all
treated patients
first year
Mean discounted
cost, all treated
patients 3 years
Marinol®
(3.5-mg
capsule)
£9.36 Quote for 2.5-mg
capsule (Pharmarama/
distributor price)
Median
daily dose
(four
capsules)
£13,663 £10,780 £27,303
Additional
Induction
consultation
£140 PSSRU hospital
consultant
One visit £140 £140 £140
Managing
AEs
£501 NHS reference costs
(per admission)
Five
overnight
inpatient
admissions
N/A £8 Included in hospital
cost data
Total £13,803 £10,928 £27,443
N/A, not applicable.
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Health and social care resource use and costs, NHS/personal and social
services perspective
Table 52 summarises the key NHS-/PSS-funded health and social care cost data collected in the trial.
Detailed resource use and cost data measured for the 6-month period preceding baseline and 4.5, 9, 15,
21, 27 and 33 months thereafter are presented in Appendix 8, Tables 67 and 68. These summary results
are based on the non-imputed and undiscounted data set. It can be seen that the resource use cost data
for all categories in both groups are positively skewed (i.e. the mean is greater than the median). Mean
costs for the treatment group (Δ9-THC) were almost £5900 over 36 months, compared with a mean
estimate in placebo participants of £8849; however, median costs were similar, highlighting the
non-normal distribution of data. To highlight the reason for differences in mean total cost estimates,
the mean total costs were higher in the placebo group due to an outlying value in NHS/PSS homecare
(where we see a mean cost of £5641 compared with £1871; see Figure 35), otherwise, costs were
generally higher in the active group in most resource categories. CIs indicate wide variation in the data
and that there were no statistically significant differences between the treatment groups.
NHS-/personal and social services-funded other health-care costs
The proportion of costs attributable to each type of NHS-/PSS-funded primary or acute care service
provider in each treatment group is illustrated in Figure 34. Resource use was higher in the active
treatment group for almost all categories, based on the complete-case data set. Patients attended an
average of three or more consultations with neurologists during the trial accounting for 25–29% of total
NHS health-care costs. GP visits accounted for approximately 20% of NHS primary/acute sector health-care
costs in both groups. Physiotherapy was the third largest cost category, accounting for almost 20% of
NHS primary/acute sector health-care costs.
NHS-/personal and social services-funded social care costs
Social care costs are included in Figure 35. Most variations between treatment groups were due to outliers
(i.e. individual patients reporting very high use of home care, day care or respite care). This can particularly
skew results where unit costs are high, such as in respite care, or where the use of resources is high, such
as in home care use in some instances. One participant in the placebo group reported over 12,000 hours
of home care, at an estimated cost in excess of £200,000 compared with a mean cost of home care in
other placebo participants of £5641 (see Table 52).
NHS-/personal and social services-funded multiple sclerosis-related
hospital episodes
Unplanned admissions accounted for approximately 70% of hospital costs in both treatment groups
(Figure 36). These mainly involved urinary tract infections (30%), relapses (18%) and MS-related
fractures and falls (14%). The average length of stay for an unplanned admission was 10.7 days.
Each hospital-based rehabilitation episode averaged 7 days. Planned MS-related admission involved mostly
treatment with medications such as Botox (63%), MS reviews (21%) or insertion/removal of catheters
(16%). Planned admission lasted, on average, 3.4 days. Most day cases involved insertion/removal of
catheters (52%) or administration of medications such as Botox or intravenous steroids (26%). Admissions
for suspected side effects were mainly for overnight observation for mood disturbances (average length of
stay, 1.33 days). Most were in the active group (five out of six cases).
Total costs by treatment group and follow-up (complete cases and
imputed data)
Estimated total discounted NHS/PSS other health and social care cost data are presented in Appendix 8,
Tables 69 and 70, to illustrate the evolution of costs within each treatment group over each study follow-up.
Overlapping 95% CIs at every time point suggest no statistically significant between-treatment-group
differences in costs.
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Placebo
Active
Other < £50
Psychologist
Rehab/OT
CN/MSN
Social worker
Physio
GP
Neurologist
0 100 200 300 400 500
Undiscounted costs (£)
477.86 (25%)
324 (19.6%)
386.04 (20.2%)
300 (18.1%)
368.16 (19.3%)
155.12 (9.4%)
210.67 (11%)
118.09 (7.1%)
151.55 (7.9%)
99.92 (6%)
116.75 (6.1%)
52.68 (3.2%)
60.28 (3.2%)
125.7 (7.6%)
138.86 (7.3%)
479.21 (29%)
–
FIGURE 34 Proportion (%) of costs attributable to each type of NHS-/PSS-funded primary or acute care service
provider in each treatment group. The estimated cost (percentage of total within-treatment group cost) is given
for each type of service provider. CN, practice or clinic nurse (at GP practice); MSN, MS nurse; OT, occupational
therapist; physio, physiotherapist; rehab, rehabilitation clinic visit.
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Placebo
Active
1870.71 (78.2%)
5641.11 (93.1%)
Home care
69.06 (2.9%)
Day care
73.76 (1.2%)
149.73 (6.3%)
Adaptations
194.87 (3.2%)
Respite
303.4 (12.7%)
147.07 (2.4%)
0 2000 4000 6000
Undiscounted costs (£)
FIGURE 35 Proportion (%) of costs attributable to each type of NHS-/PSS-funded social care provider in each
treatment group. The estimated cost (percentage of total within-treatment group cost) is given for each type of
care provider. Note: percentages may not sum to 100 due to rounding.
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Placebo
Active
5.1 (0.9%)
7.18 (1.7%)
Day cases
Side effects
Planned
Rehabilitation
Unplanned
5004003002001000
Undiscounted costs (£)
289.77 (68.6%)
419.58 (70.8%)
85.79 (20.3%)
100.8 (17%)
36.85 (8.7%)
59.7 (10.1%)
3.05 (0.7%)
7.61 (1.3%)
FIGURE 36 Proportion (%) of costs attributable to each type of MS-related hospital episode in each treatment
group. The estimated cost (percentage of total within-treatment group cost) is given for each type of episode.
Note: percentages may not sum to 100 due to rounding.
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Comparison of NHS/personal and social services resource use costs by
treatment group
To assess differences in NHS/PSS resource use costs between treatment groups, regression analyses were
applied to consider the relationship between total NHS costs and treatment allocation, adjusting for
covariates pre-specified in the trial SAP (Table 53). As the cost data were skewed, a GLM with an identity
link and gamma distribution was used to estimate the regression coefficients.22 Total costs for health and
social care were £165.22 higher in the placebo group, although this was not significant after adjusting
for other factors (p= 0.75). Only baseline EDSS score and baseline costs had a statistically significant effect
on total other costs in the study.
Confidence intervals, SEs and associated p-values for each of the main components of total aggregated
discounted costs were also estimated using a GLM including covariates for treatment group, study site,
sex, age, weight, MS type, baseline EDSS score and baseline costs (Table 54). Once the costs of the CUPID
intervention are included (mainly medication costs), the additional (adjusted) cost per treated patient over
3 years was £27,794.31.
Post-hoc subgroup analysis of total NHS costs by treatment group
From the main analysis of time to EDSS score progression, there was a suggestion of a differential effect of
treatment between those patients with a baseline EDSS score of 4.0–5.5 and those with a baseline EDSS
score of 6.0–6.5 (see Chapter 3). Accordingly, the relationship between total NHS costs with treatment
TABLE 53 Total other health and social care costs over trial period (excluding the cost of the CUPID intervention):
regression results (discounted, imputed data)
Variable Coefficient SE p-value Direction
Treatment group –165.22 524.09 0.753 Placebo> active
Study site –0.293 2.462 0.905
Sex –266.49 579.36 0.646 Men>women
Age –41.93 35.88 0.243 Younger> older
Weight –1.96 19.91 0.921
MS type –174.70 532.19 0.743 PPMS> SPMS
Baseline EDSS score 847.81 293.98 0.004 Higher> lower
Baseline cost 4.21 0.81 < 0.001 Higher> lower
Constant 803.21 3232.16 0.804
TABLE 54 Comparison of aggregated NHS/PSS mean costs (£) by treatment group over trial period (discounted
imputed data)
Resource
use item
Active,
mean (SE); n
Placebo,
mean (SE); n
Adjusted mean
difference, mean (SE) 95% CI p-value
Total other
costs
6111.58 (896.77);
n= 325
7217.84 (1520.78);
n= 163
–165.22 (524.09) –1193.50 to 863.07 0.753
Intervention
costs
27,442.30 (857.37);
n= 329
0 27,442.30 25,755.66 to 29,128.95 –
Total costs 33,553.88 (1837.75);
n= 325
7217.84 (1520.78);
n= 163
27,529.14 (3363.06) 20,957.66 to 34,120.61 < 0.001
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allocation and covariates pre-specified in the trial SAP were examined in a regression based on the
subgroup of patients with a baseline EDSS score of 4.0–5.5 (Tables 55 and 56). Intervention costs were
higher for treated patients in this subgroup, suggesting enhanced medication compliance. Including
intervention costs (mainly the cost of medication), the additional adjusted cost per treated patient over
3 years was £30,130.37. Study site also emerged as significantly related to overall NHS costs, possibly as a
result of poorer treatment retention in some sites.
Private-/patient-funded other health and social care resource use
Table 57 summarises the key private-/patient-funded costs for other health and social care, based on
data collected in the trial. Detailed private/patient resource use and cost data measured for the 6-month
period preceding baseline and 4.5, 9, 15, 21, 27 and 33 months thereafter are presented in Appendix 8,
Tables 71 and 72. These summary results are based on complete case data and are not discounted.
It can be seen that the resource cost data for all categories in both groups are positively skewed
(i.e. the mean is greater than the median). The table also shows that for all observed resource data
there were no statistically significant differences between the treatment groups although, unlike the
NHS-/PSS-funded resource use, mean total costs were higher in the active group. In the informal/home
care costs there was an outlier, in the active treatment group, reporting in excess of £1.3M of estimated
informal home care use, over the follow-up time frame (see Table 57). This highlights the wide variation
in the burden on informal care. Although these extreme estimates are rare, such impacts are likely to fall
on some providers. The estimated costs for home care (informal care), estimated using a shadow price
for unpaid care, represents almost 95% of the total estimated private and patient costs (see further
detail below).
TABLE 56 Comparison of total mean NHS/PSS aggregated costs (£) by treatment group over trial period for the
baseline EDSS score of 4.0–5.5 subgroup (discounted imputed data)
Resource
use item
Active,
mean (SE); n
Placebo,
mean (SE); n
Adjusted mean
difference, mean (SE) 95% CI p-value
Total other
costs
3304.69 (678.21);
n= 75
2391.40 (369.29);
n= 34
436.67 (428.55) –404.28 to 1275.62 0.309
Intervention
costs
29,948.03 (1697.11);
n= 75
0 29,948.03 26,567.20 to 33,328.86 –
Total costs 33,252.72 (1792.98);
n= 75
2391.40 (369.29);
n= 34
30,130.37 (2767.07) 35,554.43 to 24,706.31 < 0.001
TABLE 55 Total costs (including the cost of the CUPID intervention) over trial period, among the baseline EDSS
score of 4.0–5.5 subgroup: regression results (imputed data, discounted costs)
Variable Coefficient SE p-value Direction
Treatment group 30,130.37 2767.07 < 0.001 Active> placebo
Study site –39.57 12.52 0.002 Later < earlier
Sex –3082.87 2877.98 0.284 Women> men
Age –152.78 177.88 0.390 Older < younger
Weight 123.50 93.07 0.185 Heavier> lighter
MS type –1180.88 2464.73 0.632 SPMS> PPMS
Baseline EDSS score 1820.88 2187.51 0.405 Higher> lower
Baseline cost –1.49 3.77 0.693 Lower> higher
Constant 54,009.09 15,629.37 0.001
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Private-/patient-funded other health-care costs
The proportion of costs attributable to each type of private-/patient-funded primary or acute care service
provider in each treatment group is illustrated in Figure 37. The relative importance of each cost
component was the same in both treatment groups. Resource use was higher in the placebo group
for all major categories, based on the complete case data set.
Placebo
Active
Optician
Acupuncture
Chiropodist
Travel costs
Physio
Alternative
practitioners
0 100 200 300 400 500
Undiscounted costs (£)
461.07 (42.1%)
288.17 (26.3%)
309.85 (35.6%)
227.74 (26.2%)
161.01 (14.7%)
159.06 (18.3%)
98.37 (9%)
82.8 (9.5%)
64.27 (5.9%)
69.28 (8%)
21.46 (2%)
20.75 (2.4%)
FIGURE 37 Proportion (%) of costs attributable to each type of private-/patient-funded primary or acute care
service provider in each treatment group. The estimated cost (percentage of total within-treatment group cost for
primary or acute care services) is given for each type of service provider. Physio, physiotherapist.
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Private-/patient-funded social care costs
Privately provided social care costs are included in Figure 38. Note that access to unpaid informal care and
adaptations/equipment supplied by the NHS/PSS may be influenced by other factors including living
arrangements and income.
Aggregated resource use costs by treatment group and follow-up (complete
cases and imputed data)
Aggregated and discounted private/patient other health and social care cost data are presented in
Appendix 8, Table 73 and illustrate the evolution of costs within each treatment group over each study
follow-up. There were no statistically significant differences between groups at any time point.
0 20,000 40,000 60,000
Undiscounted costs (£)
52795 (94.1%)
56697 (95.9%)
611 (1.1%)
1642 (2.8%)
2637 (4.7%)
708 (1.2%)
0 (0%)
27 (0.05%)
49 (0.1%)
62 (0.1%)
Home care
(unpaid)
Home care
(paid)
Adaptations
Day care
Respite
Placebo
Active
FIGURE 38 Proportion (%) of costs attributable to each type of private-/patient-funded social care provider in each
treatment group. The estimated cost (percentage of total within-treatment group cost) is given for each type of
care provider. Note: percentages may not sum to 100 due to rounding.
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Comparison of private/patient resource use costs by treatment group
Regression analyses were used to assess the relationship between total other private costs and treatment
allocation, adjusting for covariates pre-specified in the trial SAP (Table 58). As the cost data were skewed,
a GLM regression model with an identity link and gamma distribution was used to estimate the regression
coefficients.22 Once other factors were included, total other private patient costs were higher in the
treatment group by an estimated £5637.19, although this difference was not statistically
significant (p= 0.65).
Post-hoc subgroup analysis of total private costs by treatment group
A subgroup analysis previously described was performed regressing costs and treatment allocation to
patients in earlier EDSS stages (baseline EDSS score of 4.0–5.5). There were no significant differences
between treatment groups on total private/patient costs based on the subgroup analysis (Table 59).
Once other factors were included, total other private patient costs were higher in the placebo group
by an estimated £8784.21, although this difference was not statistically significant (p= 0.33).
TABLE 58 Total costs at month 33: regression results (imputed data, discounted costs)
Variable Coefficient SE p-value Direction
Treatment group 5637.19 12,561.61 0.654 Active> placebo
Study site 132.05 60.79 0.032 Later> earlier
Sex 24,773.05 14,276.24 0.085 Women> men
Age –411.49 827.17 0.621 Younger> older
Weight 975.74 458.85 0.036 Heavier> lighter
MS type 1279.35 11,090.55 0.908 SPMS> PPMS
Baseline EDSS score 12,372.36 8184.30 0.132 Higher> lower
Baseline cost 0.79 0.37 0.038 Higher> lower
Constant –129,423.40 71,718.17 0.072
TABLE 59 Total costs over trial period, among baseline EDSS score of 4.0–5.5 subgroup: regression results (imputed
data, discounted costs)
Variable Coefficient SE p-value Direction
Treatment group –8784.21 9062.82 0.333 Placebo> active
Study site 28.14 47.71 0.557 Later> earlier
Sex 6748.30 11,394.18 0.555 Men> women
Age 700.13 644.04 0.279 Older> younger
Weight 45.91 347.14 0.895 Heavier> lighter
MS type 16,016.74 8486.58 0.061 Secondary> primary
Baseline EDSS score 13,433.89 8440.93 0.114 Higher> lower
Baseline cost 1.38 0.50 0.007 Higher> lower
Constant –101,605.00 59,700.67 0.091
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Health outcomes: quality-adjusted life-years
The primary health economic outcome was the QALY, over 36 months, estimated using the EQ-5D.
The EQ-5D questionnaire is based on five dimensions (mobility, self-care, usual activity, pain/discomfort
and anxiety/depression), with each dimension having three levels (no problem, some problem or extreme
problems, i.e. unable to perform the task in question). The percentages of the different responses to
each of the five dimensions, at each follow-up, are presented in Figure 39. There appeared to be very little
change in the domains of mobility, usual activities and pain/discomfort regardless of treatment group
or time. Most patients reported some problem with mobility (over 90%), usual activities (over 70%) and
pain/discomfort (over 60%) at every time point. Self-care appeared to be the only domain where changes
were seen over time. At baseline the majority of patients reported no problems with self-care and almost
none reported severe problems. By the final follow-up the majority reported some problems with self-care
and a small proportion in both treatment groups reported severe problems. Placebo patients consistently
reported fewer problems with anxiety/depression over the study period, although this might have been
due to baseline differences.
European Quality of Life-5 Dimensions scores by treatment group and
follow-up
Mean EQ-5D scores in each treatment group at each follow-up are presented in Figure 40. There were no
statistically significant differences at any time point.
Comparison of quality-adjusted life-year outcomes between
treatment groups
For the final regression analyses, the relationship between total QALYs with treatment allocation and
covariates pre-specified in the trial SAP were examined (Tables 60 and 61). Over the 36-month follow-up
there was no difference between the treatment groups. Baseline EDSS and EQ-5D scores were significant
predictors of QALY outcomes at the 0.001 level.
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FIGURE 40 Mean EQ-5D scores, with 95% CIs, by treatment group and follow-up. The number of patients with an
EQ-5D score reported at each follow-up is given directly above the CI for placebo and directly below the CI
for active.
TABLE 60 Total QALYs at month 36: regression results (discounted, imputed data)
Variable Coefficient SE p-value Direction
Treatment group –0.0001 0.04 0.998 No direction
Study site 0.0001 <0.001 0.675 No direction
Sex –0.0758 0.05 0.121 Women> men
Age –0.0019 0.002 0.507 No direction
Weight –0.0010 0.002 0.494 No direction
MS type 0.0087 0.04 0.844 No direction
Baseline EDSS score –0.1094 0.03 < 0.001 Higher < lower
Baseline EQ-5D score 1.5102 0.09 < 0.001 Higher
Constant 1.4666 0.31
ECONOMIC EVALUATION
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Post-hoc subgroup analysis of quality-adjusted life-year outcomes by
treatment group
A subgroup analysis was performed regressing QALYs and treatment allocation limited to patients in earlier
EDSS stages (baseline EDSS score of 4.0–5.5). There were no statistically significant between-group
differences in the subgroup analysis although this was based on a diminished sample size (Tables 62 and 63).
In contrast to the full sample, QALYs among active patients were higher in this subgroup compared with
placebo where QALYs were little changed from those in the full sample. The overall QALY-adjusted
difference in favour of treatment in the subgroup (0.0658), while sufficient to support a cost-effectiveness
analysis, remains a relatively small benefit compared with the additional treatment costs outlined earlier.
Differences may also have been due to random chance because of the small number of placebo patients
(n= 34) in this subgroup.
TABLE 61 Quality-adjusted life-years by treatment group and year (imputed, discounted QALYs)
Time point
Treatment group
Adjusted mean
difference, mean (SE) 95% CI p-valueActive, mean (SE); n Placebo, mean (SE); n
Year 1 0.5633 (0.01); n= 321 0.5553 (0.02); n= 163 –0.0098 (0.01) –0.0380 to 0.0183 0.491
Year 2 0.5310 (0.01); n= 321 0.5193 (0.02); n= 163 –0.0040 (0.02) –0.0399 to 0.0319 0.826
Year 3 0.5214 (0.02); n= 321 0.4933 (0.02); n= 163 0.0135 (0.02) –0.0239 to 0.0510 0.478
Total QALYs 1.6152 (0.03); n= 321 1.5669 (0.05); n= 163 –0.0001 (0.04) –0.0846 to 0.0848 0.998
Values do not sum to total as each year and total were imputed separately.
TABLE 62 Total QALYs at month 36: regression results (discounted, imputed subgroup analysis)
Variable Coefficient SE p-value Direction
Treatment group 0.0658 0.08 0.436 Active> placebo
Study site 0.0001 < 0.001 0.778 No direction
Sex –0.1004 0.09 0.278 Women> men
Age –0.0043 0.006 0.447 Older < younger
Weight –0.0047 0.003 0.153 Heavier < lighter
MS type –0.0035 0.08 0.965 No direction
Baseline EDSS score –0.0419 0.07 0.547 Higher < lower
Baseline EQ-5D score 1.4565 0.18 < 0.001 Higher
Constant 1.4666 0.31
TABLE 63 Quality-adjusted life-years by treatment group and year (discounted, imputed subgroup analysis)
Time point
Treatment group
Adjusted mean
difference, mean (SE) 95% CI p-value
Active,
mean (SE); n
Placebo,
mean (SE); n
Year 1 0.6208 (0.02); n= 75 0.5448 (0.03); n= 34 0.0109 (0.03) –0.0552 to 0.0669 0.704
Year 2 0.5959 (0.02); n= 75 0.5173 (0.04); n= 34 0.0131 (0.04) –0.0610 to 0.0873 0.728
Year 3 0.5877 (0.02); n= 75 0.4978 (0.04); n= 34 0.0419 (0.04) –0.0337 to 0.1175 0.277
Total QALYs 1.8041 (0.06); n= 75 1.5599 (0.10); n= 34 0.0658 (0.08) –0.1000 to 0.2316 0.436
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Subgroup EQ-5D scores over the study period are illustrated in Figure 41. These appear to show a
consistent trend for higher EQ-5D scores in patients in the active group who had a baseline EDSS score of
4.0–5.5, compared with placebo. Adjusting for baseline, the difference at the final follow-up was 0.047
based on a complete case analysis. In patients with higher baseline EDSS score (6.0–6.5), the mean EQ-5D
score appears to have the same trajectory in both active and placebo groups (adjusted difference at final
follow-up 0.012). Neither finding was statistically significant.
Low-baseline EDSS (4.0–5.5)
High-baseline EDSS (6.0–6.5)
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FIGURE 41 European Quality of Life-5 Dimensions weighted index score by follow-up and EDSS subgroup.
Top panel=baseline EDSS score of 4.0–5.5; bottom panel=baseline EDSS score of 6.0–6.5.
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
134
Conclusions
The CUPID trial did not show any consistent or marked between-group differences either in mean costs
(other than the treatment cost) or mean QALYs. As no evidence was found for the clinical effectiveness of
the CUPID intervention, a cost-effectiveness analysis combining group differences in costs and effects was
not undertaken.
In terms of point estimates, after controlling for baseline covariates and imputation of missing data, costs
from the NHS/PSS perspective were significantly lower in the placebo group with no between-group
difference in QALYs. The mean additional cost of the 3-year CUPID intervention was estimated to be
£27,529.14 per patient (see Table 54) with a negligible difference in QALYs (–0.0001) (see Table 60).
This indicates that placebo dominates the CUPID intervention in this treatment population achieving
comparable health outcomes at lower cost.
The clinical effectiveness analysis of the CUPID study suggested that patients in earlier EDSS stages (score
of 4.0–5.5) at baseline may have represented a subgroup of positive-treatment responders. A post-hoc
subgroup analysis, restricted to this subgroup, estimated the mean additional cost of Δ9-THC in patients
with less severe disease at baseline to be £30,130.37 (see Table 55), with an additional 0.0658 QALYs
over 3 years (see Table 62). This indicates that the CUPID intervention may provide modest health benefits
for progressive MS patients in earlier disease stages but at a high cost. These data indicate a cost per
QALY gained for Δ9-THC in this subgroup in excess of £400,000, which is well above the cost-per-QALY
threshold values used by NICE in their guidance on value for money and use of interventions in NHS in
England. Owing to the small sample size, particularly in the placebo group, findings from the subgroup
analysis should be treated with caution.
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Chapter 7 Discussion
Primary outcome measures
No treatments have as yet shown clinical efficacy in the modification of progressive MS in the absence of
relapses. Results of this study did not show an overall treatment effect of oral dronabinol on the clinical
disease course in progressive MS, as assessed by either sustained EDSS progression or using the
MSIS-29phys. Several factors might have reduced the ability to detect any potential treatment effect,
in particular treatment discontinuation, loss to follow-up and less overall disease progression than
expected. Long-term studies in progressive neurological diseases are notoriously difficult to undertake:
loss to follow-up might hinder interpretation of results and low event rates and discontinuation of study
medication also decrease the power to detect a treatment effect. Overall, loss to follow-up in the CUPID
study was around the level expected, but more attrition occurred in the dronabinol group. This coincided
with a higher number of AEs than in the placebo group, which also largely accounted for premature
treatment discontinuation, although no major safety concerns were reported. As in previous studies
of cannabinoids, most AEs occurred during the dose titration period, but the high lipid solubility of
cannabinoids means that long-term build-up can occur some months after treatment initiation. Any future
long-term studies to investigate disease-modifying effects of cannabinoids should use lower doses to
reduce the risk of AEs, which in turn should increase compliance and reduce potential error in any
ITT analysis.
Low progression rates make the identification of a treatment effect less likely and further work is necessary
to establish optimum inclusion criteria for trials of progressive MS. Although recent studies have tried to
be more specific about monitoring pre-trial progression to fulfil inclusion criteria, the CUPID study was
designed to be a pragmatic study for people with progressive MS, testing some of the findings from
the CAMS extension phase, which suggested that dronabinol might have an effect on MS progression.
Future studies should ensure that the population recruited has a high chance of progression. Our study
population was skewed towards the higher end of the EDSS score range (52% had a baseline score of 6.0;
26% had a baseline score of 6.5). Mean EDSS score at baseline was 5.9 (SD 0.69), higher than most other
recent studies of treatments in progressive disease. Some studies have taken account of the slower
progression rates in patients with higher EDSS scores by adjusting recruitment to ensure a lower overall
mean EDSS score. The PROMiSe study24 was adjusted to 40% recruitment of patients with an EDSS score
of 3.0–5.0, producing a mean EDSS score of 4.9 and yearly progression rate of 16% in patients with
primary progressive MS, compared with 24% estimated in the CUPID study.
Secondary outcome measures
When the overall population was considered, none of the secondary outcome measures demonstrated a
treatment effect. Once again, mean change over time was generally less than expected, reducing the
opportunity to identify any potential treatment effect. The same arguments can be applied to secondary
measures as for primary outcomes: premature discontinuation, selective drop-out and lack of progression
may have affected our ability to detect treatment effects.
Although brain atrophy, as assessed using longitudinal comparison of MRI, is being used as a surrogate for
clinical disability progression (particularly in Phase II studies), there remains controversy over its validity in
this regard. Although a recent meta-analysis demonstrated reasonable correlation between treatment
effects on brain atrophy and disability progression over 2 years in RRMS (R2= 0.48),25 fewer studies exist in
progressive MS and treatment effects on both MRI and clinical end points have not been demonstrated.
Our current results showed that overall rate of brain atrophy was as expected, whereas clinical change was
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less than expected. Even in the less disabled subgroup (baseline EDSS score of 4.0–5.5), where disability
did alter significantly over time and there was an apparent treatment effect, this was not mirrored in a
treatment effect on brain atrophy from MRI.
Further analyses
Pre-specified subgroup analyses suggested that dronabinol might have a slight potentially beneficial effect
in terms of EDSS score progression and other outcome measures in less disabled patients (baseline EDSS
score of < 6.0). Conversely, dronabinol might have a slight potentially negative effect in patients with
higher EDSS scores. One possible explanation for these findings is that cannabinoids have been shown to
reduce muscle stiffness2,26,27 and, although an antispasticity effect might improve function at lower levels of
disability, if walking is compromised by weakness, dronabinol might reduce muscle tone to the point
where muscle power becomes affected and walking is more difficult. This side effect is well known with
agents such as baclofen. Distinguishing a symptomatic effect from a disease-modifying effect can be a
difficult task. In Parkinson’s disease, for example, it is generally accepted that L-dopa has a symptomatic
effect that can have a profound long-term impact on disability, although it is generally regarded as not
having a neuroprotective role.
Treatment effects shown in pre-specified analyses at each EDSS level below 6.0 led us to combine EDSS
score levels of 4.0 to 5.5 in a post-hoc fashion, which confirmed treatment effects in both primary
outcomes. The suggestion of a potential effect in lower disability groups might have relevance for inclusion
criteria in future clinical trials in progressive MS. It is well known that the EDSS is not a linear scale and
people affected by MS tend to spend considerably more time at EDSS scores of 6.0 and 6.5 (needing one
or two sticks for mobility), yet progress relatively rapidly through scores of 4.0 to 5.5. It is, therefore, not
surprising that this subpopulation progressed faster than more disabled individuals and that a treatment
effect was detected in this subgroup.
Economic evaluation
Dronabinol is associated with high additional costs and has no evidence of incremental health gains and is,
therefore, not cost-effective compared with standard care, which dominates dronabinol in this patient
group. Exploratory analyses in the subgroup of patients with lower EDSS scores, suggests potential health
gains, but at a high incremental cost relative to potential incremental QALY gains, with estimates of cost
per QALY likely to be in excess of £400,000 per QALY gained.
Rasch analysis
All MS-specific scales performed well as measurement instruments. Some scales were less optimally
targeted to the study sample. This may have influenced the interpretation of changes and differences.
Typically suboptimal targeting reduces the ability to detect changes and differences. There was no clear
and consistent evidence for a symptomatic or disease-modifying treatment effect. There was some
suggestion, from exploratory post-hoc analyses, that less disabled people might derive a disease-modifying
benefit. However, this was not a consistent effect across scales measuring related constructs and at best
provides a potential hypothesis for formal testing.
DISCUSSION
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Symptomatic evaluation
This study was not designed to demonstrate symptomatic benefits and the high level of treatment
discontinuation is likely to have had an effect on our ability to show this at the end of the 3-year study.
Safety
Serious adverse events (including death or hospitalisation because of MS-related problems) were expected
to occur relatively frequently in this patient population and about one-third of all participants experienced
at least one SAE. The number and nature of SAEs were broadly similar in the two treatment groups.
Two SUSARs were reported in the active treatment group. Of these, one participant with a previous history
of seizure was hospitalised following a grand mal seizure and trial treatment was discontinued. Seizures
are known to be more prevalent in people with MS than in the general population and may also occur
following overdose of dronabinol in patients with existing seizure disorders. The second SUSAR was
reported following the non-urgent hospitalisation of a participant for colonoscopic investigation of altered
bowel habit. In this case, the SUSAR classification was largely as a result of the interpretation of reporting
guidelines and trial treatment was continued.
The number and nature of minor AEs was also similar across the two groups with the exception of known
cannabinoid-related effects (dizziness and light-headedness; dissociative and thinking or perception
disorders) which occurred more frequently in the active group. These treatment-related AEs contributed to
the higher incidence of premature discontinuation of trial medication in participants in the active group
than in the placebo group.
Further work
This independent study provides the largest data set on cannabinoid exposure over time currently available.
Most outcomes, both primary and secondary, did not provide any evidence for a treatment effect with
dronabinol. However, the results do suggest that further study of less disabled people with progressive
MS may be warranted. In addition, results suggest that studies of antiprogressive treatments in progressive
MS should pay careful attention to the pre-study progression of potential participants. A reasonable
degree of ongoing progression is a prerequisite for antiprogressive treatments to have a substrate to
effect. Our results therefore elude to an incomplete understanding of progressive MS and further
advancing our understanding of progression in people with progressive MS would be very valuable.
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Chapter 8 Conclusions
Implications for health care
The CUPID study has a few important implications for health care. First, it will come as a disappointment to
people with progressive MS who have witnessed, over some 40 years, multiple negative clinical trials for
progressive MS.
Another implication for health care concerns the potential medicinal use of cannabinoids in MS. This will
strengthen the case against their use. While this is a reasonable interpretation if one takes the negative
clinical trials at face value, it is known that many people with MS find benefit from cannabinoids. This
anomaly warrants further investigation. One option is that the measures used to determine effectiveness
are missing important benefits.
Recommendations for research
The results from the CUPID study point to three major themes for research.
First, research is required to better understand exactly what is progressing in progressive MS so that clinical
trials are better informed. A concerted effort is required to carefully and systematically document and
monitor over time cohorts of people with a diagnosis of progressive disease. This will lead to disease
profiles and trajectories. In addition, the CUPID study implied that a substantial proportion of people
improved in terms of aspects of their physical function. This would seem surprising for a disease whose
hallmark is purported to be progressive physical disability. One explanation for this is that people adapt
to their worsening function – the so-called response shift. If this were the explanation, we would expect to
see RMT analyses to show DIF by time point; this was not a finding in the CUPID study.
A second major theme for research builds on the hypothesis that cannabinoids may have an effect in less
disabled people. This may be because people with higher levels of disability did not progress in the
outcomes measured or that there is a treatment effect in only the less disabled.
A third area for research is further development of COAs. Although the measures were shown to be
robust, limitations were identified. The role of the measurement instruments in clinical trials should not
be underestimated and their quality must not be compromised.
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Appendix 1 Participating sites and principal
investigators
TABLE 64 The CUPID study sites and PIs
Site PI
Plymouth, Derriford Hospital Professor J Zajicek
Aberdeen Royal Infirmary Dr R Coleman
Birmingham, West Midlands Rehabilitation Centre Dr C Ko-Ko
Bristol, Frenchay Hospital Professor N Scolding
Cambridge, Addenbrookes Hospital Rev Dr A Coles
Cardiff, University Hospital of Wales Professor N Robertson
Coventry, University Hospitals Coventry & Warwickshire Dr A Shehu
Edinburgh, Western General Hospital Dr B Weller
Gloucestershire Royal Hospital Dr R Martin
Hertford County Hospital Dr D Kidd
Irvine, Ayrshire Central Hospital Dr P Mattison
Leicester General Hospital Dr B Kendall
London, Charing Cross Hospital Dr R Nicholas
Manchester, Hope Hospital Dr P Talbot
Newcastle, Royal Victoria Infirmary Dr M Duddy
Norfolk and Norwich University Hospital Dr M Lee
Nottingham University Hospital Professor C Constantinescu
Oxford, John Radcliffe Hospital Dr J Palace
Poole General Hospital Dr C Hillier
Preston, Royal Preston Hospital Dr P Tidswell
Sheffield, Royal Hallamshire Hospital Dr S Howell
Stoke on Trent, University Hospital of North Staffordshire Professor C Hawkins
Taunton & Somerset Hospital Dr E Fathers
Truro, Royal Cornwall Hospital Dr B McLean
London, Barts and London NHS Trust Professor G Giovannoni
University Hospital of Birmingham Dr G Mazibrada
Reading, Royal Berkshire Hospital Dr A Weir
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Appendix 2 NHS research and development
approval dates
TABLE 65 The CUPID study sites and dates of R&D approval
Site Date approval received
Plymouth, Derriford Hospital 19 May 2006
Birmingham, West Midlands Rehabilitation Centre 13 June 2006
Nottingham University Hospital 13 June 2006
Truro, Royal Cornwall Hospital 20 June 2006
Aberdeen Royal Infirmary 23 June 2006
Manchester, Hope Hospital 28 June 2006
Bristol, Frenchay Hospital 28 June 2006
Irvine, Ayrshire Central Hospital 29 June 2006
Preston, Royal Preston Hospital 29 June 2006
Norfolk and Norwich University Hospital 4 July 2006
Edinburgh, Western General Hospital 7 July 2006
Stoke on Trent, University Hospital of North Staff 14 July 2006
Taunton & Somerset Hospital 24 July 2006
Newcastle, Royal Victoria Infirmary 30 August 2006
Sheffield, Royal Hallamshire Hospital 31 August 2006
Cardiff, University Hospital of Wales 31 August 2006
London, Charing Cross Hospital 14 September 2006
Oxford, John Radcliffe Hospital 26 September 2006
Poole General Hospital 11 October 2006
Cambridge, Addenbrookes Hospital 27 October 2006
Coventry, University Hospitals Coventry & Warwickshire 23 January 2007
Leicester General Hospital 23 March 2007
The Barts and London NHS Trust 4 April 2007
Gloucestershire Royal Hospital 20 April 2007
Reading, Royal Berkshire Hospital 14 August 2007
University Hospital of Birmingham 24 September 2007
Hertford County Hospital 6 November 2007
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Appendix 3 Study recruitment May 2006–
July 2008 by site
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Appendix 4 Participant information sheet
Cannabinoid Use in Progressive Inflammatory brain Disease
(CUPID study)
PARTICIPANT INFORMATION SHEET
Invitation to participate
We would like to invite you to take part in a research study. Before you decide whether or not to
participate, it is important for you to understand why the research is being done and what it will involve.
Please take time to read this information carefully and discuss it with family and friends or your own
doctor if you wish.
l Part 1 explains the purpose of this study and what will happen to you if you take part.
l Part 2 gives more detailed information about the conduct of the study.
If anything is not clear or you would like more information, please ask us. Remember, your participation is
entirely voluntary – it’s up to you.
PART 1
What is the purpose of this study?
Current treatments for primary or secondary progressive multiple sclerosis (MS) are aimed at relieving
specific symptoms. Few treatments actually help the disease itself, so the next step is to find treatments
that can slow down the disease in the long term.
Results from a previous study have shown that tetrahydrocannabinol (THC) – found in the cannabis
plant – appears to have an effect on slowing disability in progressive MS, when taken for a year. To find
out if THC really does slow progression of disability, we need to conduct a new study over a longer period
of time. In this study, we will assess the effects of THC on progressive MS by comparing it with an
inactive substance, called a placebo (or dummy).
Why might I be suitable for the study?
People who have primary or secondary progressive MS and are between 18–65 years old are being invited
to take part in this study. To be included in the study, your MS must have become worse over the last
year and you must be able to walk at least 20 metres (with or without a walking aid). You must not have
taken any cannabis in any form in the month prior to joining the study.
If there is a possibility that you may be pregnant or you are breastfeeding or planning a pregnancy, you
may not take part in this study. More details are included in Part 2. If you have had a significant relapse
in the last six months or have taken steroids in the last three months, you will not be able to join the study
immediately but may be considered for entry at a later date. Your study doctor will confirm all these details
with you if you would like to take part and will also check other aspects of your health to ensure your
suitability to participate.
If you decide to take part in the study, please note:
l Cannabis may cause side effects that may affect your ability to drive or operate dangerous machinery,
so you should take extra care and consult your GP or study doctor if you do get any side effects. If your
work or daily life involves driving or operating machinery, it may be better not to take part in this
study. You should avoid driving or operating machinery if your concentration is affected by medication.
DOI: 10.3310/hta19120 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 12
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ball et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
155
l If you drive, you should inform your insurance company that you are participating in the study and may
have been prescribed cannabis medication. Some insurers will require a letter from your doctor stating
that you are fit to drive whilst taking medication.
l Although we are authorised to use cannabis for this trial, it is an illegal drug. You must not under any
circumstances give your study medication to anyone else.
l You must not take your medication out of the United Kingdom before checking with your study doctor
or nurse. Some countries will not allow cannabis-based medicines and others will need to see official
documentation, which we will be able to provide.
l It is important that you do not take any extra cannabis preparations during the study period, since this
would interfere with the results of the study. Such preparations include nabilone, smoked cannabis and
cannabis taken in food or drink. We will check your urine for cannabis at intervals throughout
the study.
l This is a long-term study so you should be prepared to take part for up to three and a half years.
Do I have to take part?
No. Participation in this study is entirely voluntary and it is up to you to decide whether or not to take part.
If you do decide to take part you will be asked to sign a consent form, but you are still free to withdraw
at any time in the future and without giving a reason. You will be given a copy of this information sheet
and a copy of your signed consent form to keep. If you decide not to take part, or you withdraw from the
study at any point, your usual medical care will not be affected in any way.
Who decides which study medication I will receive?
This type of study is known as a ‘randomised trial’ which means that your treatment will be chosen
randomly (by chance) by a computer at the beginning of the trial. If you decide to take part, you will be
allocated to receive either the active cannabis treatment or the placebo (dummy) treatment. Two thirds of
the people in the study will be allocated to active treatment and one third to placebo. Both treatments are
in the form of capsules which are taken by mouth and all capsules look identical. You will not be given
anything to smoke. This is a ‘double-blind’ study which means that neither you nor the study team will
know which treatment you are taking until the end of the study, in order that study assessments are not
biased. However, your study doctor would be able to find out what you are taking very quickly, should it
be necessary. It is important to note that once you are allocated to your treatment, you will remain on the
same treatment throughout the study.
How many capsules do I have to take and for how long?
You will be asked to take the capsules twice a day for 3 years (possibly three and a half years). During
the first four weeks of the study, your study doctor will adjust the number of capsules you are taking in
order to find the amount that suits you best. If you have any side effects from the study medication
which you find unacceptable, then you may be advised to reduce your dose. When the correct dosage
has been found for you, you will continue to take the same amount each day, usually between two and
four capsules twice a day.
What about my usual medications?
You should continue as normal with all your usual medicines and any other therapy prescribed by your
family doctor or specialist. We will ask you about any medicines that you are currently taking (include
supplements, vitamins and alternative remedies) at your first visit and will check whether these have
changed at each subsequent visit.
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What else is involved if I take part?
Clinic visits
All participants will need to attend the study clinic 11 times (six times during the first six months and
then once every six months for the remainder of the trial). Most people will end the study at this point
(after 3 years). Some participants (depending on their final clinic assessment) will be asked to continue in
the study for an extra six months and to attend one extra clinic.
At each visit your study doctor will ask about your general health and whether you have had any side
effects from your medication. You will then be given a new prescription for your study medication. A
different doctor will make an assessment of disability (the EDSS score) at every visit. This may take up to
20 minutes. About half of the study visits also include a series of assessments to measure your progress.
These include a timed 25 feet walk, a peg test (placing small pegs in holes and removing them by hand)
and a number counting exercise. These assessments take about 15–20 minutes to complete and will be
carried out by a nurse, a doctor or a therapist.
Questionnaires
If you take part in the study, the co-ordinating centre will send you a questionnaire booklet to complete
approximately every three months throughout the trial. This booklet will take about half an hour to
complete. If you have any difficulties in completing the questionnaires, you can telephone the trial
co-ordinating centre on [telephone number supplied] (Freephone) during normal office hours and a
member of the research team will be able to help you. Freepost envelopes will be provided for you to
return the questionnaires.
Some of the questionnaires ask about your general health and well-being and about how MS is affecting your
day to day life. Other questionnaires will ask specifically about services you have used (e.g. visiting your GP)
or equipment and adaptations that you have needed for your home because of your MS. During the first
and last six months of the study we will also send you a very short questionnaire (six times in total), asking
specifically about services that you have used in the previous 2 days. One questionnaire specifically asks about
symptoms relating to depression. The co-ordinating centre will send the results of this questionnaire to your
study doctor. Only your trial number will appear on these results and no-one at the co-ordinating centre
will be able to identify you from them. Your study doctor will be able to identify you from your trial number
and if your study doctor thinks that you may be depressed, he/she may contact your MS Specialist Nurse or
GP so that you can receive support and treatment as appropriate.
If you have access to a computer and the internet there will be an option to complete the questionnaire
booklets online. All questionnaires will be anonymous and identified only by a study number and initials.
Blood samples
There are two reasons for taking blood samples during the study. Unfortunately, if you are unwilling to
provide blood samples then you will not be able to participate in the study.
i) To assess the safety of taking study medication: At each visit you will be asked to provide a small
blood sample (equivalent to two teaspoons). This sample will be tested for factors that indicate your
general health, including liver function and blood count. By regularly checking your blood, your study
doctor can see the effect of medication on your general well-being. Should the results of these blood tests
change significantly during the study, your study doctor will inform both you and your GP.
ii) To try to identify genes and markers that may be linked to MS and cannabinoids: This sample
(approximately four teaspoons) will be collected from you at the start of the study and at the end of
each year (four samples in all). We hope that identifying genes and markers linked to MS may lead to a
better understanding of why the condition develops and possibly lead to improved treatments. There are
more details about this research in Part 2.
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MRI scans
At your study centre, all participants will undergo regular MRI (Magnetic Resonance Imaging) brain
scans at the start of the trial, and then at the end of each study year (four scans in total). The scans will
usually be performed at the hospital where your study clinics are held and each scan takes approximately
20 minutes. If you are claustrophobic (have a fear of enclosed spaces), or have had any metallic implants
(such as a cardiac pacemaker) you will not be able to have a scan and will unfortunately not be able to
join the study. Orthopaedic metal is usually safe to scan but it is important to tell your study doctor if you
have ever had any metal implanted. You may have had an MRI scan in the past, but please ask your study
doctor or nurse for further information about the procedure if necessary.
Study diary and identity card
Each participant will be given a study diary. This contains useful information about storing and taking
study medication and also serves as an appointment card. The blank pages can be used to write down any
changes in your MS or other symptoms, or to record visits to your GP, specialist nurse etc. This will help
when filling in your study questionnaires or talking to your study doctor.
You will also be given an identity card (the size of a credit card) which should be carried at all times.
The card states that the holder is taking part in a clinical trial and provides a contact telephone number at
the trial co-ordinating centre in case of query or emergency.
What are the possible risks or disadvantages of taking part?
The study involves attending a study clinic every six months, usually in addition to any other hospital
appointments you may have. If you live a long way from your study centre, or if you can foresee any other
difficulties in taking part in the study, please consider these carefully before agreeing to take part.
Cannabis can cause an increase in heart rate and a reduction in blood pressure. For this reason, people
with a history of heart disease will not be permitted to take part in the study. There may be other illnesses
that might exclude you from participation in the study, which your study doctor will check before you are
accepted into the study.
The House of Lords Select Committee assessed the safety of cannabis in 1998 and found that no-one
has ever died as a direct result of recreational or medicinal use of cannabis. It is generally thought that
cannabis may possibly be mildly addictive but in our previous study we found no evidence of withdrawal
syndrome in participants after twelve months of treatment. There is no convincing evidence for any long
term toxic effects of cannabis.
During the collection of blood samples, you may experience pain and/or bruising where the blood has
been taken. Infection or blood clots are a very rare complication. Some people feel faint or light headed
when they have blood taken. If this happens to you, you should lie down prior to having the blood taken
to avoid falling and causing injury to yourself.
What side effects may I experience?
Possible side effects of cannabis may include a “high” feeling, although in previous studies some patients
taking the placebo drug have also experienced this. Other possible symptoms include increased appetite,
weakness, dry mouth, dizziness and poor concentration.
Any new symptoms should be discussed with the study doctor at your clinic visits. If you have any queries
between visits you should also contact your study doctor, or you can telephone the Freephone study
helpline [telephone number supplied] for advice. If necessary, the dose of your treatment can be adjusted
to reduce unwanted side effects. Please note, though, that you may not notice any side effects at all.
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What are the benefits of taking part?
You have two chances in three of receiving an active cannabis treatment that may help to slow down
progression of your disability, although improvement cannot be guaranteed. By taking part, you will be
helping in an important study to decide the usefulness of THC as a treatment for multiple sclerosis in
the future.
Will I have to pay for travel?
No. We will pay any travel or parking expenses incurred as a result of attending study visits at a fixed rate
per mile for use of your own vehicle or the full amount if using public transport (bus, taxi or train),
provided that receipts or tickets are produced.
Will the information collected during the study be kept confidential?
Yes. All the information collected about you during the study will remain strictly confidential. The details
are included in Part 2.
Contact for further information
If you have any questions, please do not hesitate to contact your local study team (Local Contact Details).
Alternatively, you may contact the co-ordinating centre in Plymouth on [telephone number supplied]
(Freephone) or visit the study website at [web address supplied].
This completes Part 1 of the Information Sheet. If you are considering taking part in the study,
please read the information in Part 2 before making any decision.
PART 2
What if new information about cannabis-based medicines
becomes available?
If new and relevant information becomes available during the course of the study, we will tell you and give
you the opportunity to discuss whether you want to continue in the study.
What happens if I don’t want to carry on with the study?
If you decide to withdraw from the study at any time we will still need to use the information collected up
to this time.
What if something goes wrong?
The study organisers do not believe that you will suffer any injury by participating in this study so there
are no special compensation arrangements. If you have any concerns about the way that you have been
approached or treated during this study, you are free to follow the usual NHS complaints procedure. If you
are harmed due to someone’s negligence then you may have grounds for legal action but you may have
to pay for this yourself. Your right to claim for compensation for injury where you can prove negligence is
not affected.
Will the information collected during the study be kept confidential?
The study will be conducted in accordance with the Data Protection Act (1998). All information collected
about you during the study will remain strictly confidential.
Your name and address will be held by the co-ordinating office in Plymouth so that study questionnaires
can be mailed directly to you. Your personal details will be stored securely on a computer, accessible only
by members of the co-ordinating team. Your name and address will not appear on any study forms or
questionnaires so that you cannot be recognised from them. All other information collected about you
during this study will be entered onto a separate, secure database at the co-ordinating centre and will only
be identifiable by a study number and initials. Only members of the co-ordinating team will have direct
access to these data.
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If you consent to take part in the study, your medical records may be inspected by the doctors looking
after you and by members of the co-ordinating team responsible for monitoring the safe conduct of the
study. During the study an audit may be carried out by responsible members of either the Medical
Research Council, the study sponsor (Plymouth Hospitals NHS Trust) or the Medicines and Healthcare
Products Regulatory Agency (MHRA) who would also have access to your medical records for this purpose.
Anonymised data collected during the study may be transferred to the supplier of study medication
outside the European Economic Area. This information may be used in applications to gain a marketing
authorisation for study medication. Some countries outside Europe may not have laws which protect your
privacy to the same extent as the Data Protection Act in the UK or European Law, however no-one will be
able to identify you from the data transferred.
If you agree to take part we will inform your general practitioner, unless you specifically ask us not to.
What about pregnancy?
Cannabis may disrupt reproductive hormones. If you or your partner usually rely on a hormonal form of
contraception (the contraceptive pill or an injectable or implanted contraceptive), you must also use a
barrier method of contraception (condom or diaphragm with spermicidal jelly) to prevent pregnancy
occurring to you or your partner during the study period. No extra precautions are required if you are
post-menopausal (women) or have been surgically sterilised (men or women), if you have an intra-uterine
contraceptive device (coil) in place or you abstain from intercourse for the study period. If you or your
partner becomes pregnant during the study, please inform your study doctor as soon as possible so that
appropriate advice can be given.
What will happen to my blood samples?
l Your samples will be stored by Professor John Zajicek at the Peninsula Medical School in Exeter.
l Your name will not appear anywhere on the samples. Only your initials and a study number will
be used.
l Your blood will not be tested for any inherited diseases.
l Your samples will only be used for research about MS and cannabinoids. No other research can be
performed on your samples without your permission.
l Samples will be stored indefinitely. This is because new scientific techniques related to MS and the
relationship of cannabinoids to MS may emerge in the future, allowing further research that was not
possible at the time of collection.
l Future work may involve collaborations with other academic groups outside the Peninsula Medical
School. If this occurs, no personal details or information that could identify you would be shared with
these groups.
l You will not derive any direct benefit from this part of our research nor will you be informed of
any results.
l If at any time you decide to withdraw your consent for participation in the CUPID study, you may also
request that any samples already collected are destroyed.
Will I be able to find out how other participants are getting on?
About 500 people will be recruited to the study from all over UK. At your study visits, you may meet
other people who are taking part in the study. We encourage you not to discuss your progress
with each other because there is a chance that this could affect the outcome of the study. For the same
reason, we cannot give you any specific details about how people are getting on in other parts of UK.
However, we can give you some general information about the study, in the form of a newsletter,
including updates about recruitment.
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What happens at the end of the study?
At the end of the study, you will have to stop taking your study medication and return any unused
medication to your study centre. We will plan a programme to reduce your study medication gradually
after your last visit. We hope that it may be possible to offer active trial medication for a fixed period to
all participants who have completed the study, whilst we are preparing the results, but this cannot be
guaranteed. Whether or not the study medication then becomes available on prescription after the study
will depend upon the study results and the decision of the relevant authorities.
What will happen to the results of the study?
We intend to publish the study results in a medical journal approximately 9 months after the last
participant completes the trial. Each participant will receive a summary of the results at the time of
publication and this summary will also be posted on the website (www.pms.ac.uk/cnrg/cupid). If you want
to find out what treatment you were taking during the study, you will be able to do so, but only after the
last participant completes the trial. It may take up to five years for all participants to complete the study,
so you may have to wait a while.
Who is organising and funding the study?
The study is being conducted by the Clinical Neurology Research Group at the Peninsula Medical School
(Universities of Exeter and Plymouth) in conjunction with the Department of Mathematics and Statistics,
University of Plymouth. The study is funded by the Medical Research Council with support from the
MS Society and the MS Trust. The study has been approved by the South and West Devon Research
Ethics Committee.
Thank you for considering taking part in this study. You may also find it helpful to read the
enclosed leaflet “Medical Research and You”, published by Consumers for Ethics in Research
(CERES). The leaflet gives more information about medical research and considers some
questions you may want to ask.
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Appendix 5 Cannabinoid Use in Progressive
Inflammatory brain Disease trial organisation
Trial Steering Committee
The TSC members were Professor Nigel Leigh, Professor of Neurology, Brighton and Sussex Medical
School, University of Sussex (chairperson); Dr Carl Counsell, Reader in Neurology, University of Aberdeen;
Professor David Jones, Professor of Medical Statistics, University of Leicester; Professor Andrew Nunn,
Associate Director & Chair of Infections Research Theme, MRC Clinical Trials Unit, London;
Ms Nicola Russell, Director of Special Projects, Multiple Sclerosis Trust; and Professor Alan Thompson,
Professor of Clinical Neurology and Neurorehabilitation, University College London.
Independent Data Monitoring Committee
The IDMC members were Professor Richard Grey, Professor of Medical Statistics, Clinical Trial Service Unit,
University of Oxford (chairperson); Professor Ian Bone, Formerly Consultant Neurologist, Institute of
Neurological Sciences, University of Glasgow; and Professor Michael Hutchinson, Consultant Neurologist,
University College Dublin.
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Appendix 6 Patient and public involvement in the
Cannabinoid Use in Progressive Inflammatory brain
Disease study
The CUPID study was developed as a consequence of findings from our previous CAMS study2,3 whichsupported the theory that cannabis-based medicines might have a neuroprotective effect in progressive
MS. On completion of the CAMS study, feedback about the experience of clinical trial participation was
obtained from semistructured interviews with 10 study participants and an end-of-trial postal survey with
more than 500 respondents. As the target population (people with MS) of the two studies were similar,
findings from the post-CAMS survey were used to inform certain aspects of the design and conduct of the
CUPID study.
Specifically, previous study participants reported that physical limitations led to practical difficulties in
completing study questionnaires, with a significant proportion signifying a willingness or preference to
have completed web-based questionnaires instead. As one of the joint primary outcomes in the CUPID
study was a patient-reported measure, both postal and web-based options for self-report instruments
were included in this study, with additional telephone support for questionnaire completion from the
co-ordinating centre.
The treatment and follow-up period for the CAMS study was only 1 year and from participant feedback it
was clear that one of the challenges of the CUPID study would be to keep participants with accumulating
disability engaged and involved for 3 years. Various strategies were therefore introduced from the start
of the CUPID study to optimise participant retention and data completeness. These included regular
participant newsletters, practical and financial support for travel and parking for study visits and a 24-hour
access Freephone helpline. In participants for whom the study became burdensome or who developed
‘trial fatigue’, a policy of reducing the number or frequency of questionnaires and/or visits was adopted,
with an emphasis on maximising completeness of primary outcome data.
During the set-up and development of the CUPID study, members of the MRC consumer group reviewed
and commented upon the draft participant information sheet. Local people with MS and lay volunteers also
commented on the readability and acceptability of the study information and self-completion questionnaires.
Members of a local MS support group undertook the specific task of reviewing the resource use
questionnaire for the health economic component of the study. Lay membership of the TSC comprised
representatives from the two major UK MS charities (the MS Trust and the MS Society), one as a full member
and one as an observer. Apart from supporting and publicising the study, these representatives made an
important contribution to TSC meetings on behalf of the MS community and provided advice on the
interpretation and dissemination of the study results.
Patient and public involvement in the CUPID study contributed to various aspects of study conduct
including the development of accessible study information and high-quality documentation, the
introduction of a number of strategies to promote participant retention and data completeness and
representation of the interests of people with MS by inclusion of relevant TSC members.
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Appendix 7 End Point Committee terms of
reference
Cannabinoid Use in Progressive Inflammatory brain Disease
study End Point Committee
Terms of reference
Background
Primary outcomes
As described in the study protocol, the CUPID study has two joint primary outcome measures:
l Physician-based EDSS: time to EDSS progression of at least 1 point from a baseline EDSS score of 4.0,
4.5 or 5.0 or at least 0.5 points from a baseline EDSS score ≥ 5.5. Once identified, deterioration must
be confirmed at the next scheduled 6-monthly visit.
l Patient-based MSIS-29 physical impact scale version 2: overall mean change from baseline to end
of study.
For the purpose of any licensing application for treatment effects on progression, the EDSS score will be
considered as the single primary outcome measure. The MSIS-29v2 will be treated as secondary.
Missing outcome data
In a proportion of study participants, some of the eight or nine scheduled EDSS scores are missing as a
result of non-attendance at individual visits (e.g. through illness), study site organisational problems
(e.g. lack of assessor) or complete loss to follow-up. As a result, in these participants it may not be possible
to judge whether or not their MS has progressed according to the protocol definition.
Collection of additional clinical details
For some participants in whom EDSS scores are missing, supplementary clinical details have been collected
from hospital records in order to help estimate EDSS score for secondary analysis purposes. All such
supplementary information has been obtained within the limits of REC approval and the informed consent
process. Hospital notes of participants with missing EDSS scores were examined during routine site
monitoring visits. Where these records contained either direct entries relating to inpatient or outpatient
episodes or documentary evidence in the form of clinical correspondence relating to the period(s) for
which EDSS data were missing, relevant information was transcribed (verbatim where possible) on to
purpose-designed forms. Information acquired in this way was largely, but not exclusively, related to the
participant’s mobility in order to facilitate estimation of EDSS. Dates of original entries or correspondence
were recorded and all data collection forms were signed and dated by the person responsible for recording
the data.
End Point Committee
Composition
The EPC will comprise Professor John Zajicek (chief investigator), Professor Jeremy Hobart (Professor of
Clinical Neurology and Health Measurement, Peninsula College of Medicine & Dentistry) and Dr Timothy
Harrower (independent chairperson, Consultant Neurologist, Royal Devon & Exeter NHS Foundation Trust).
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Aim
The EPC has been set up with the aim of adjudicating on MS progression in participants for whom
confirmation of this end point is not clear due to missing EDSS scores. In accordance with the wishes of
the TSC, decisions made by the EPC will be included in a secondary analysis, rather than the primary
analysis of study data.
Scope
It is not necessary or expected that the EPC will review EDSS end points for every trial participant. The
committee will only be responsible for judging EDSS progression (and/or the estimated timing of any such
progression) in participants for whom missing data renders this unclear.
At the study end, 95 participants have missing EDSS scores such that either (i) disease progression cannot
be confirmed or (ii) the onset date of confirmed progression is unclear. The committee will not be
required to adjudicate in the case of 57 of these participants who have been irretrievably lost to follow-up
(e.g. moved house or died) and/or for whom no additional clinical information is available (these cases
have been scrutinised by the Trial Co-ordinator and decisions verified by the Assistant Trial Co-ordinator).
In X of the remaining 38 cases, the committee will use the available additional clinical information to
consider whether or not progression can be confirmed. In Y cases where progression is confirmed but the
onset date is uncertain, the committee will review the available information in an effort to make a realistic
estimate of the date of onset of progression.
Process
It is anticipated that the committee will meet once only. Members will be provided with a summary sheet
for each participant being reviewed and, blinded to the treatment allocation, will consider all available
study EDSS scores and any supplementary clinical information available from the notes review process.
Any information which might unblind (e.g. trial/centre number or details of adverse events) will be
removed before data are presented to the committee. Where possible, dates of recorded clinical
information will be provided for comparison with scheduled study time points and existing EDSS score
dates. An audit trail providing a record of the additional information source, date sourced and person
responsible for acquiring/providing the information is available separately.
On the basis of information provided, the committee may decide that a participant should be:
1. Treated as having progressed at a particular time within the 3-year follow-up period.
2. Treated as if there was no MS progression during the 3 years of follow-up.
3. Treated as progression unknown/lost to follow-up.
In view of the complexity of the disease area and the features of the EDSS scale it is not possible to
stipulate what level of evidence would be sufficient to be convincing of disease progression or to give
specific guidance regarding the criteria for decision-making. Members of the EPC will use their clinical
judgement and, in each case, the final decision of the EPC will be based on agreement of all three
members. Decisions will be documented on the individual summary sheet provided, signed and dated by
the committee Chair. These data will then be incorporated into the final study database.
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Appendix 8 Economic evaluation
Detailed NHS/personal and social services resource use by
treatment group and follow-up
TABLE 67 NHS/PSS resource use in natural units by treatment group and follow-up (complete case analysis)
Resource use item
Active Placebo
Range Mean SD Range Mean SD
GP visits
Baseline 0–15 2.18 1.98 0–20 2.39 2.82
4.5 months 0–15 1.52 2.00 0–8 1.38 1.61
9 months 0–12 1.34 1.74 0–9 1.31 1.64
15 months 0–25 1.73 2.39 0–6 1.54 1.50
21 months 0–36 1.89 3.07 0–18 1.68 2.41
27 months 0–35 1.94 3.06 0–16 2.05 2.42
33 months 0–28 1.81 2.71 0–15 1.64 2.15
Total 0–145 10.72 13.64 0–55 9.00 8.42
Community nurse
Baseline 0–10 0.35 1.13 0–24 0.66 2.35
4.5 months 0–6 0.23 0.77 0–7 0.31 0.87
9 months 0–8 0.18 0.79 0–4 0.16 0.56
15 months 0–78 0.84 5.42 0–15 0.35 1.48
21 months 0–12 0.43 1.46 0–20 0.54 2.02
27 months 0–10 0.47 1.30 0–24 0.60 2.53
33 months 0–160 1.70 11.33 0–21 0.51 2.07
Total 0–37 2.87 6.05 0–49 0.51 6.87
MS nurse
Baseline 0–8 0.81 1.09 0–6 0.81 1.11
4.5 months 0–8 0.68 1.49 0–5 0.57 1.09
9 months 0–4 0.34 0.67 0–11 0.39 1.17
15 months 0–4 0.42 0.66 0–3 0.41 0.71
21 months 0–6 0.48 0.83 0–3 0.32 0.57
27 months 0–7 0.51 0.89 0–7 0.51 0.93
33 months 0–8 0.51 0.95 0–6 0.54 1.03
Total 0–12 3.13 3.20 0–13 2.72 2.66
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TABLE 67 NHS/PSS resource use in natural units by treatment group and follow-up (complete
case analysis) (continued )
Resource use item
Active Placebo
Range Mean SD Range Mean SD
Physiotherapist
Baseline 0–40 2.19 4.34 0–24 2.34 3.99
4.5 months 0–24 1.50 3.21 0–12 1.35 2.54
9 months 0–26 1.32 2.94 0–45 1.44 4.77
15 months 0–52 2.14 5.19 0–26 1.62 3.57
21 months 0–30 1.98 4.17 0–15 1.30 2.64
27 months 0–50 1.62 4.75 0–12 1.18 2.34
33 months 0–40 2.19 5.23 0–19 1.39 3.15
Total 0–69 9.99 13.86 0–58 8.33 11.31
Rehabilitation
Baseline 0–5 0.15 0.62 0–2 0.11 0.37
4.5 months 0–14 0.18 1.15 0–6 0.13 0.61
9 months 0–2 0.09 0.32 0–8 0.13 0.75
15 months 0–4 0.15 0.51 0–8 0.15 0.77
21 months 0–3 0.15 0.49 0–4 0.18 0.64
27 months 0–3 0.12 0.42 0–3 0.08 0.38
33 months 0–12 0.23 1.08 0–6 0.19 0.79
Total 0–18 0.92 2.48 0–11 0.67 1.62
Occupational therapist
Baseline 0–8 0.43 0.94 0–6 0.58 1.19
4.5 months 0–12 0.41 1.19 0–4 0.24 0.61
9 months 0–6 0.37 0.90 0–21 0.45 1.99
15 months 0–6 0.46 0.99 0–6 0.51 1.17
21 months 0–7 0.43 0.98 0–6 0.53 1.00
27 months 0–20 0.47 1.63 0–12 0.43 1.42
33 months 0–10 0.53 1.51 0–16 0.45 1.64
Total 0–31 2.51 4.18 0–29 2.27 3.95
Speech therapy
Baseline 0–4 0.09 0.48 0–4 0.08 0.46
4.5 months 0–4 0.06 0.35 0–3 0.04 0.28
9 months 0–2 0.03 0.20 0–2 0.05 0.29
15 months 0–4 0.06 0.35 0–3 0.07 0.36
21 months 0–4 0.09 0.44 0–2 0.04 0.24
27 months 0–7 0.06 0.50 0–3 0.07 0.36
33 months 0–8 0.51 1.94 0–2 0.34 1.21
Total 0–16 0.51 1.94 0–6 0.34 1.21
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TABLE 67 NHS/PSS resource use in natural units by treatment group and follow-up (complete
case analysis) (continued )
Resource use item
Active Placebo
Range Mean SD Range Mean SD
Neurologist
Baseline 0–6 0.83 0.93 0–5 0.94 1.01
4.5 months 0–8 0.96 1.73 0–7 0.98 1.52
9 months 0–3 0.34 0.55 0–4 0.43 0.70
15 months 0–6 0.50 0.77 0–2 0.44 0.56
21 months 0–11 0.47 0.93 0–3 0.47 0.60
27 months 0–9 0.43 0.81 0–3 0.49 0.64
33 months 0–6 0.47 0.77 0–2 0.43 0.56
Total 0–24 3.29 4.02 0–15 3.30 3.23
Psychologist
Baseline 0–3 0.04 0.28 0–10 0.08 0.82
4.5 months 0–3 0.02 0.21 0–3 0.05 0.33
9 months 0–3 0.06 0.34 0–3 0.07 0.40
15 months 0–7 0.07 0.52 0–4 0.05 0.38
21 months 0–14 0.19 1.22 0–3 0.09 0.41
27 months 0–6 0.06 0.45 0–1 0.03 0.18
33 months 0–4 0.06 0.42 0–8 0.09 0.78
Total 0–15 0.45 1.71 0–8 0.39 1.20
Chiropodist
Baseline 0–7 0.17 0.69 0–4 0.17 0.60
4.5 months 0–5 0.16 0.60 0–2 0.08 0.32
9 months 0–6 0.14 0.57 0–5 0.21 0.71
15 months 0–5 0.17 0.67 0–5 0.21 0.71
21 months 0–6 0.17 0.69 0–6 0.28 0.84
27 months 0–7 0.22 0.87 0–4 0.23 0.63
33 months 0–5 0.21 0.72 0–7 0.36 1.05
Total 0–32 1.26 4.10 0–12 1.07 2.48
Optician
Baseline 0–3 0.18 0.45 0–4 0.24 0.56
4.5 months 0–3 0.18 0.44 0–4 0.18 0.54
9 months 0–6 0.16 0.54 0–3 0.12 0.39
15 months 0–4 0.14 0.46 0–1 0.11 0.32
21 months 0–4 0.17 0.52 0–2 0.19 0.44
27 months 0–2 0.20 0.44 0–2 0.17 0.42
33 months 0–2 0.14 0.38 0–2 0.16 0.43
Total 0–7 1.01 1.37 0–5 0.91 1.32
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TABLE 67 NHS/PSS resource use in natural units by treatment group and follow-up (complete
case analysis) (continued )
Resource use item
Active Placebo
Range Mean SD Range Mean SD
Continence advice
Baseline 0–6 0.32 0.84 0–6 0.47 1.08
4.5 months 0–4 0.29 0.70 0–3 0.27 0.66
9 months 0–17 0.24 1.16 0–5 0.27 0.79
15 months 0–8 0.26 0.79 0–3 0.29 0.67
21 months 0–4 0.23 0.66 0–3 0.25 0.63
27 months 0–5 0.35 0.88 0–4 0.30 0.74
33 months 0–3 0.24 0.62 0–3 0.29 0.66
Total 0–20 1.77 3.08 0–9 1.35 2.13
Social worker
Baseline 0–4 0.15 0.59 0–4 0.08 0.40
4.5 months 0–4 0.11 0.54 0–4 0.17 0.62
9 months 0–4 0.09 0.45 0–1 0.04 0.19
15 months 0–3 0.12 0.46 0–5 0.17 0.73
21 months 0–26 0.25 1.79 0–2 0.07 0.29
27 months 0–26 0.24 1.80 0–4 0.13 0.56
33 months 0–2 0.14 0.47 0–3 0.14 0.53
Total 0–56 0.99 4.65 0–10 0.73 1.76
Acupuncturist
Baseline 0–7 0.06 0.52 0–8 0.13 0.91
4.5 months 0–2 0.02 0.15 0–6 0.08 0.58
9 months 0–1 0.01 0.09 0–5 0.10 0.59
15 months 0–3 0.01 0.19 0–6 0.11 0.72
21 months 0–6 0.06 0.51 0–1 0.01 0.09
27 months 0–8 0.05 0.56 0–15 0.13 1.37
33 months 0–6 0.04 0.42 0–9 0.08 0.83
Total 0–13 0.26 1.30 0–34 0.63 3.89
Home care hours
Baseline 0–546 8.06 58.76 0–1014 19.82 119.73
4.5 months 0–377 6.22 42.60 0–2028 34.40 228.75
9 months 0–1456 29.78 176.00 0–2496 40.90 278.66
15 months 0–676 12.34 77.28 0–2340 45.02 266.21
21 months 0–611 13.30 70.56 0–2288 53.84 274.30
27 months 0–897 16.70 98.24 0–2119 61.99 295.61
33 months 0–1378 26.30 146.20 0–1664 77.24 287.32
Total 0–4635.80 103.98 540.06 0–11,765 313.40 1419.23
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TABLE 67 NHS/PSS resource use in natural units by treatment group and follow-up (complete
case analysis) (continued )
Resource use item
Active Placebo
Range Mean SD Range Mean SD
Day-care episodes
Baseline 0–40 0.16 2.33 0–26 0.25 2.34
4.5 months 0–14 0.10 1.15 0–18 0.13 1.54
9 months 0–32 0.14 2.01 0–135 1.03 11.80
15 months 0–40 0.30 2.86 0–48 0.38 4.28
21 months 0–52 0.31 3.47 0–26 0.48 3.10
27 months 0–78 0.48 5.54 0–10 0.12 0.95
33 months 0–26 0.12 1.75 0–52 0.59 5.05
Total 0–202 1.92 16.56 0–61 2.05 9.48
Respite episodes
Baseline 0–20 0.07 1.11 0–2 0.02 0.17
4.5 months 0–1 0.02 0.15 0–1 0.01 0.09
9 months 0–8 0.04 0.51 0–1 0.02 0.12
15 months 0–8 0.05 0.55 0–2 0.03 0.22
21 months 0–5 0.03 0.36 0–2 0.03 0.21
27 months 0–1 0.02 0.13 0–2 0.02 0.18
33 months 0–2 0.05 0.25 0–2 0.03 0.22
Total 0–16 0.30 1.58 0–3 0.15 0.52
Hospital episodes
Baseline Not collected
4.5 months 0–2 0.05 0.22 0–1 0.02 0.15
9 months 0–2 0.07 0.28 0–1 0.02 0.13
15 months 0–2 0.05 0.22 0–2 0.05 0.24
21 months 0–3 0.07 0.29 0–3 0.05 0.30
27 months 0–2 0.07 0.27 0–2 0.08 0.29
33 months 0–2 0.07 0.26 0–2 0.05 0.24
Total 0–5 0.37 0.84 0–10 0.27 0.93
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TABLE 68 NHS/PSS resource use costs by treatment group and follow-up (complete case analysis, costs
not discounted)
Resource use item
Active Placebo
Range Mean SD Range Mean SD
GP
Baseline 0–540 78.44 71.32 0–720 86.13 101.46
4.5 months 0–540 54.56 71.88 0–288 49.76 57.98
9 months 0–432 48.09 62.52 0–324 46.99 58.88
15 months 0–900 62.45 85.92 0–216 55.43 54.00
21 months 0–1296 68.00 110.35 0–648 60.52 86.84
27 months 0–1260 69.87 110.10 0–576 73.80 87.17
33 months 0–1008 65.19 97.71 0–540 58.88 77.58
Total 0–5220 386.04 490.91 0–1980 324.00 303.10
Clinic nurse
Baseline 0–210 7.22 25.33 0–360 13.90 49.68
4.5 months 0–120 4.53 16.43 0–120 5.51 16.51
9 months 0–180 3.93 16.89 0–60 3.32 10.57
15 months 0–2340 22.35 161.46 0–450 7.74 41.47
21 months 0–360 9.68 37.28 0–300 9.83 32.21
27 months 0–180 10.16 29.76 0–360 10.75 40.00
33 months 0–4800 48.11 339.81 0–315 9.28 34.53
Total 0–1095 68.58 165.76 0–735 45.37 112.22
MS nurse
Baseline 0–228 21.82 30.96 0–228 21.76 31.34
4.5 months 0–200 17.31 37.48 0–152 15.01 29.02
9 months 0–114 8.80 18.07 0–275 10.43 30.48
15 months 0–100 11.04 17.76 0–114 11.66 21.75
21 months 0–150 12.96 22.78 0–76 8.76 15.91
27 months 0–266 14.67 28.52 0–175 14.66 27.21
33 months 0–200 14.24 27.35 0–150 14.55 27.32
Total 0–354 82.97 85.75 0–325 72.74 69.50
Physiotherapist
Baseline 0–1360 79.46 157.63 0–816 82.95 141.31
4.5 months 0–940 55.25 120.82 0–564 49.19 96.82
9 months 0–884 47.55 102.63 0–1530 51.53 164.28
15 months 0–1768 78.53 184.07 0–940 59.28 134.72
21 months 0–1410 74.75 162.13 0–564 47.97 99.21
27 months 0–1700 60.51 176.92 0–470 41.68 84.59
33 months 0–1360 81.05 194.45 0–893 51.00 121.80
Total 0–2346 368.16 492.90 0–1972 300.00 397.08
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TABLE 68 NHS/PSS resource use costs by treatment group and follow-up (complete case analysis, costs
not discounted) (continued )
Resource use item
Active Placebo
Range Mean SD Range Mean SD
Rehabilitation
Baseline 0–170 5.25 20.92 0–68 3.75 12.53
4.5 months 0–476 6.19 39.13 0–204 4.53 20.69
9 months 0–68 2.92 10.88 0–272 4.41 25.44
15 months 0–136 5.13 17.33 0–272 5.17 26.29
21 months 0–102 4.94 16.53 0–136 6.16 21.78
27 months 0–102 4.02 14.33 0–102 2.83 12.91
33 months 0–408 7.66 36.79 0–204 6.63 26.77
Total 0–612 31.22 84.24 0–374 22.80 55.02
Occupational therapist
Baseline 0–272 14.59 31.85 0–204 19.61 40.32
4.5 months 0–408 14.10 40.61 0–136 8.00 20.79
9 months 0–204 12.75 30.56 0–714 15.31 67.50
15 months 0–204 15.54 33.49 0–204 17.27 39.82
21 months 0–238 14.68 33.44 0–204 17.88 33.99
27 months 0–680 16.07 55.37 0–408 14.45 48.42
33 months 0–340 18.07 51.21 0–544 15.27 55.81
Total 0–1054 85.53 142.10 0–986 77.12 134.21
Speech therapy
Baseline 0–141 3.67 18.26 0–136 2.95 16.54
4.5 months 0–136 2.46 13.53 0–102 1.35 10.01
9 months 0–68 1.11 6.94 0–68 2.02 10.48
15 months 0–136 2.24 12.78 0–141 3.15 16.54
21 months 0–136 3.20 15.83 0–94 1.91 11.03
27 months 0–238 2.22 17.19 0–102 2.48 13.59
33 months 0–272 3.60 23.21 0–68 2.35 11.41
Total 0–544 18.71 67.50 0–269 13.51 48.22
Neurologist
Baseline 0–870 119.94 135.08 0–725 136.99 146.12
4.5 months 0–1160 139.38 250.27 0–1015 141.80 220.76
9 months 0–435 49.84 80.07 0–580 61.98 101.79
15 months 0–870 72.80 111.87 0–290 63.29 80.98
21 months 0–1595 67.54 135.09 0–435 68.75 86.50
27 months 0–1305 62.61 117.57 0–435 71.29 92.08
33 months 0–870 67.93 111.76 0–290 62.67 81.49
Total 0–3480 477.86 582.64 0–2175 479.21 468.99
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TABLE 68 NHS/PSS resource use costs by treatment group and follow-up (complete case analysis, costs
not discounted) (continued )
Resource use item
Active Placebo
Range Mean SD Range Mean SD
Psychologist
Baseline 0–405 5.83 37.85 0–1350 10.77 110.21
4.5 months 0–405 2.62 27.81 0–405 6.95 44.46
9 months 0–405 7.91 46.40 0–405 9.27 53.45
15 months 0–945 9.37 70.12 0–540 6.43 50.82
21 months 0–1890 25.38 164.92 0–405 11.64 55.07
27 months 0–810 8.59 61.27 0–135 4.50 24.33
33 months 0–540 8.51 56.80 0–1080 12.58 105.88
Total 0–2025 60.28 230.67 0–1080 52.68 162.60
Chiropodist
Baseline 0–217 5.46 22.63 0–141 5.62 20.43
4.5 months 0–188 5.67 21.86 0–62 2.51 10.02
9 months 0–186 4.48 18.19 0–155 6.63 22.09
15 months 0–155 5.25 20.93 0–155 6.64 22.05
21 months 0–186 5.64 22.90 0–186 8.55 26.04
27 months 0–217 7.27 27.96 0–124 6.97 19.47
33 months 0–155 6.85 22.84 0–217 11.43 32.71
Total 0–992 41.10 130.68 0–372 33.27 76.83
Optician
Baseline 0–60 3.64 8.92 0–80 4.79 11.30
4.5 months 0–60 3.50 8.76 0–80 3.53 10.85
9 months 0–120 3.28 10.85 0–60 2.44 7.85
15 months 0–80 2.78 9.17 0–20 2.22 6.31
21 months 0–80 3.42 10.41 0–40 3.79 8.71
27 months 0–40 4.00 8.88 0–40 3.33 8.33
33 months 0–40 2.79 7.69 0–40 3.22 8.66
Total 0–140 20.13 27.33 0–100 18.29 26.33
Continence advisor
Baseline 0–228 9.51 26.66 0–228 14.20 34.66
4.5 months 0–152 8.48 21.50 0–114 8.04 20.74
9 months 0–646 7.28 42.50 0–190 7.87 25.04
15 months 0–304 7.59 25.81 0–114 8.17 20.17
21 months 0–100 6.38 18.21 0–76 6.87 17.54
27 months 0–152 9.75 24.99 0–100 7.93 19.42
33 months 0–114 6.61 17.43 0–114 8.53 20.03
Total 0–760 50.15 93.94 0–342 39.07 64.26
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TABLE 68 NHS/PSS resource use costs by treatment group and follow-up (complete case analysis, costs
not discounted) (continued )
Resource use item
Active Placebo
Range Mean SD Range Mean SD
Social worker
Baseline 0–848 32.72 125.00 0–848 16.91 84.87
4.5 months 0–848 23.83 115.09 0–848 35.85 130.44
9 months 0–848 18.22 95.83 0–212 8.09 40.78
15 months 0–636 25.09 97.46 0–1060 37.02 154.23
21 months 0–5512 52.55 379.75 0–424 14.62 60.77
27 months 0–5512 50.11 381.10 0–848 28.27 119.59
33 months 0–424 28.65 98.75 0–636 30.54 111.82
Total 0–11,872 210.67 986.47 0–2120 155.12 372.52
Acupuncturist
Baseline 0–238 2.20 17.71 0–272 4.59 31.04
4.5 months 0–68 0.53 5.17 0–204 2.75 19.87
9 months 0–34 0.27 3.00 0–170 3.37 20.16
15 months 0–102 0.42 6.52 0–204 3.78 24.41
21 months 0–204 1.89 17.29 0–34 .29 3.16
27 months 0–272 1.70 19.01 0–510 4.25 46.56
33 months 0–204 1.38 14.22 0–306 2.88 28.32
Total 0–442 8.77 44.15 0–1156 21.56 132.44
Home care
Baseline 0–9828 145.14 1057.62 0–18,252 356.71 2155.09
4.5 months 0–6786 111.96 766.82 0–36,504 619.24 4117.43
9 months 0–26,208 536.13 3185.79 0–44,928 736.24 5015.79
15 months 0–12,168 222.15 1390.97 0–42,120 810.44 4791.79
21 months 0–10,998 239.33 1269.98 0–41,184 969.10 4937.43
27 months 0–16,146 300.65 1768.36 0–38,142 1115.78 5320.96
33 months 0–24,804 473.33 2523.55 0–29,952 1390.30 5171.76
Total 0–83,444 1871.71 9721.10 0–211,770 5641.11 25,545.98
Day care
Baseline 0–1440 5.89 84.04 0–936 9.06 84.41
4.5 months 0–504 3.63 41.25 0–648 4.76 55.57
9 months 0–1152 4.92 72.29 0–4860 37.10 424.62
15 months 0–1440 10.87 102.80 0–1728 13.71 153.94
21 months 0–1872 11.23 125.07 0–936 17.38 111.69
27 months 0–2808 17.18 199.28 0–360 4.20 34.35
33 months 0–936 4.22 62.82 0–1872 21.36 181.88
Total 0–7272 69.06 596.22 0–2196 73.76 341.43
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TABLE 68 NHS/PSS resource use costs by treatment group and follow-up (complete case analysis, costs
not discounted) (continued )
Resource use item
Active Placebo
Range Mean SD Range Mean SD
Respite care
Baseline 0–20,100 68.24 1119.10 0–2010 18.50 175.58
4.5 months 0–1005 23.37 151.76 0–1005 7.39 86.18
9 months 0–8040 39.26 509.78 0–1005 15.34 123.70
15 months 0–8040 53.33 554.62 0–2010 31.90 217.84
21 months 0–5025 34.36 358.97 0–2010 25.99 207.92
27 months 0–1005 18.27 134.58 0–2010 16.75 183.49
33 months 0–2010 45.27 248.85 0–2010 34.07 225.00
Total 0–16080 303.40 1590.07 0–3015 147.07 526.66
Hospital
Baseline Not collected
4.5 months 0–4526 57.19 361.84 0–2263 34.62 260.69
9 months 0–3268 128.19 522.81 0–2263 26.05 207.67
15 months 0–4526 81.78 434.70 0–2263 74.84 376.07
21 months 0–6789 116.79 553.21 0–2263 76.38 380.67
27 months 0–3268 103.75 451.35 0–2263 134.67 504.22
33 months 0–3268 105.11 442.53 0–2263 76.09 380.21
Total 0–10057 592.81 1427.75 0–7060 422.65 1140.30
Adaptations and equipment
Baseline 0–921.50 17.26 83.11 0–991.00 36.53 136.68
4.5 months 0–1292.50 27.41 132.71 0–4870.25 61.77 426.59
9 months 0–4671.63 34.95 302.77 0–4206.13 55.15 383.37
15 months 0–988.00 33.29 135.14 0–1202.00 37.49 138.04
21 months 0–2656.50 30.49 205.41 0–772.50 41.70 129.02
27 months 0–1817.00 42.24 242.68 0–861.00 20.55 98.62
33 months 0–1274.00 17.24 107.33 0–198.00 7.75 31.04
Total 0–2765.75 149.73 397.22 0–4206.13 194.87 541.35
Concomitant medications
Baseline Not collected
4.5 months 0–830.34 133.05 163.10 0–658.66 112.26 129.61
9 months 0–816.52 131.80 159.38 0–659.66 115.66 130.49
15 months 0–1090.68 177.56 214.31 0–891.22 155.17 178.64
21 months 0–1090.68 180.65 216.93 0–881.15 154.02 174.15
27 months 0–1090.68 178.74 213.63 0–881.15 155.51 176.14
33 months 0–1090.68 181.70 215.93 0–881.15 156.36 175.61
Total 0–5995.76 983.50 1176.54 0–4843.92 848.98 958.94
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TABLE 69 Aggregated other NHS/PSS resource use costs by treatment group and follow-up (discounted costs,
complete cases)
Resource use type
Active Placebo
Mean SD 95% CI Mean SD 95% CI
Total other costs
Baseline 750.11 2819.92 306.99 to 1193.22 957.92 2642.96 377.20 to 1538.64
4.5 months 672.58 1085.26 502.85 to 843.12 1105.80 4216.66 179.30 to 2032.30
9 months 1038.15 3615.01 470.10 to 1606.21 1122.36 5028.73 17.42 to 2227.29
15 months 839.90 1964.29 532.22 to 1147.58 1364.94 4994.17 267.60 to 2462.28
21 months 987.31 2094.31 659.27 to 1315.35 1372.94 5018.67 270.22 to 2475.66
27 months 913.21 2185.58 570.88 to 1255.55 1658.66 5279.56 498.61 to 2818.71
33 months 1032.92 2563.26 631.42 to 1434.41 1801.33 5114.86 677.47 to 2925.19
Total 5473.78 11,980.30 3597.25 to 7350.32 8426.03 25,922.73 2730.18 to 14,121.88
TABLE 70 Aggregated other NHS/PSS resource use costs by treatment group and follow-up (discounted costs,
imputed data)
Resource use type
Active Placebo
Mean SD 95% CI Mean SD 95% CI
Total other costs
Baseline 750.11 2819.92 306.99 to 1193.22 957.92 2642.96 377.20 to 1538.64
4.5 months 885.12 232.97 426.74 to 1343.50 905.28 242.88 425.58 to 1384.99
9 months 1106.70 238.89 636.26 to 1577.13 1079.20 336.36 414.08 to 1744.33
15 months 968.53 167.81 638.21 to 1298.84 1078.76 287.13 511.62 to 1645.91
21 months 1017.91 128.26 765.25 to 1270.56 1276.82 307.79 668.38 to 1885.26
27 months 919.30 138.64 645.80 to 1192.80 1365.83 328.06 717.23 to 2014.42
33 months 1126.78 169.21 793.04 to 1460.52 1526.62 347.05 839.82 to 2213.41
Total 6111.58 896.77 4346.67 to 7876.49 7217.84 1520.78 4213.67 to 10,222.01
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Detailed private/patient resource use by treatment group and
follow-up
TABLE 71 Private resource use in natural units by treatment group and follow-up (complete case analysis)
Resource use item
Active Placebo
Range Mean SD Range Mean SD
Physiotherapist
Baseline 0–52 0.77 4.10 0–26 1.21 5.05
4.5 months 0–75 0.86 5.31 0–28 0.96 4.07
9 months 0–26 0.64 2.97 0–32 1.21 4.33
15 months 0–52 1.01 4.93 0–26 1.68 5.17
21 months 0–26 1.09 4.41 0–25 1.37 4.60
27 months 0–29 1.12 4.39 0–26 1.98 5.90
33 months 0–52 1.30 5.32 0–40 1.92 6.07
Total 0–129 6.70 21.10 0–89 8.48 20.30
Chiropodist
Baseline 0–6 0.26 0.89 0–5 0.21 0.80
4.5 months 0–6 0.27 0.96 0–5 0.18 0.66
9 months 0–4 0.27 0.80 0–3 0.15 0.48
15 months 0–6 0.33 1.02 0–6 0.39 1.14
21 months 0–8 0.36 1.12 0–5 0.40 1.15
27 months 0–6 0.39 1.18 0–8 0.46 1.30
33 months 0–12 0.42 1.33 0–6 0.45 1.26
Total 0–27 2.03 5.50 0–21 2.51 5.41
Optician
Baseline 0–2 0.23 0.51 0–4 0.25 0.59
4.5 months 0–2 0.14 0.39 0–2 0.10 0.32
9 months 0–3 0.16 0.46 0–2 0.15 0.42
15 months 0–4 0.17 0.47 0–4 0.29 0.63
21 months 0–4 0.17 0.47 0–2 0.16 0.44
27 months 0–2 0.19 0.45 0–2 0.20 0.51
33 months 0–2 0.17 0.45 0–2 0.15 0.38
Total 0–7 1.04 1.35 0–5 1.07 1.25
Acupuncturist
Baseline 0–14 0.29 1.60 0–24 0.22 1.99
4.5 months 0–12 0.28 1.49 0–12 0.26 1.47
9 months 0–14 0.19 1.21 0–10 0.33 1.61
15 months 0–24 0.39 2.14 0–25 0.63 3.36
21 months 0–24 0.30 1.97 0–12 0.16 1.20
27 months 0–24 0.27 1.96 0–12 0.30 1.67
33 months 0–24 0.23 1.85 0–7 0.06 0.64
Total 0–110 2.04 10.83 0–45 1.89 7.70
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TABLE 71 Private resource use in natural units by treatment group and follow-up (complete
case analysis) (continued )
Resource use item
Active Placebo
Range Mean SD Range Mean SD
Alternative practice
Baseline 0–58 1.78 5.42 0–32 2.01 5.63
4.5 months 0–136 1.77 9.13 0–24 1.32 3.93
9 months 0–60 1.39 5.69 0–25 1.52 4.18
15 months 0–51 1.51 4.93 0–41 2.01 5.78
21 months 0–52 1.56 5.47 0–32 1.76 4.87
27 months 0–52 1.58 5.47 0–32 2.08 5.07
33 months 0–64 1.58 6.23 0–25 2.16 4.95
Total 0–275 9.11 30.28 0–154 13.52 28.75
Home care hours
Baseline 0–130 8.89 24.69 0–780 32.37 123.29
4.5 months 0–156 12.84 31.88 0–338 12.05 46.08
9 months 0–143 10.04 27.17 0–273 16.96 51.71
15 months 0–260 15.22 40.69 0–676 35.61 121.95
21 months 0–468 18.84 51.60 0–840 36.24 140.93
27 months 0–429 15.96 47.07 0–468 17.50 63.57
33 months 0–728 18.92 67.69 0–819 28.16 118.12
Total 0–1092 91.25 188.38 0–2769 146.52 402.99
Unpaid care hours
Baseline 0–16,640 542.76 1410.61 0–2951 471.24 569.92
4.5 months 0–2834 407.37 533.29 0–5954 555.85 905.82
9 months 0–2730 370.38 487.03 0–3302 546.00 720.25
15 months 0–26,208 571.86 2135.95 0–2678 437.68 522.19
21 months 0–39,312 746.68 3170.85 0–2158 457.64 485.93
27 months 0–34,632 636.34 2767.60 0–1846 472.87 484.96
33 months 0–3562 437.15 606.98 0–2106 463.01 515.38
Total 0–75,504 3149.85 6630.51 0–11,206 2933.05 2821.25
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TABLE 72 Private resource use costs by treatment group and follow-up (complete case analysis,
undiscounted)
Resource use item
Active Placebo
Range Mean SD Range Mean SD
Physiotherapist
Baseline 0–1768 26.23 139.55 0–884 41.30 171.54
4.5 months 0–2550 29.24 180.65 0–952 32.75 138.27
9 months 0–884 21.91 100.87 0–1088 41.01 147.28
15 months 0–1768 34.28 167.50 0–884 57.21 175.94
21 months 0–884 36.91 149.92 0–850 46.60 156.45
27 months 0–986 38.02 149.12 0–884 67.43 200.69
33 months 0–1768 44.11 180.76 0–1360 65.41 206.32
Total 0–4386 227.74 717.45 0–3026 288.17 690.34
Chiropodist
Baseline 0–235 8.14 32.26 0–235 10.16 36.35
4.5 months 0–155 7.11 24.89 0–188 10.09 35.37
9 months 0–94 5.23 17.12 0–188 10.67 43.26
15 months 0–282 15.23 47.60 0–282 13.51 43.65
21 months 0–235 15.60 47.08 0–248 14.34 45.28
27 months 0–248 18.61 52.31 0–282 15.97 50.34
33 months 0–282 19.08 55.24 0–564 18.10 60.43
Total 0–893 98.37 219.45 0–1269 82.81 233.78
Optician
Baseline 0–40 4.57 10.14 0–80 4.91 11.78
4.5 months 0–40 2.71 7.72 0–40 1.91 6.38
9 months 0–60 3.28 9.13 0–40 3.05 8.40
15 months 0–80 3.35 9.42 0–80 5.71 12.61
21 months 0–80 3.33 9.49 0–40 3.28 8.73
27 months 0–40 3.82 8.96 0–40 4.00 10.24
33 months 0–40 3.33 9.01 0–40 3.05 7.68
Total 0–140 20.75 26.99 0–100 21.46 25.10
Acupuncturist
Baseline 0–476 9.76 54.25 0–816 7.51 67.69
4.5 months 0–408 9.62 50.83 0–408 8.75 50.00
9 months 0–476 6.37 41.01 0–340 11.16 54.73
15 months 0–816 13.18 72.78 0–850 21.59 114.40
21 months 0–816 10.32 67.02 0–408 5.57 40.84
27 months 0–816 9.12 66.63 0–408 10.20 56.89
33 months 0–3740 7.66 62.75 0–238 2.02 21.91
Total 0–3740 69.28 368.18 0–1530 64.27 261.79
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TABLE 72 Private resource use costs by treatment group and follow-up (complete case analysis,
undiscounted) (continued )
Resource use item
Active Placebo
Range Mean SD Range Mean SD
Alternative practitioners
Baseline 0–1972 60.65 184.24 0–1088 68.42 191.51
4.5 months 0–4624 60.09 310.43 0–816 44.75 133.76
9 months 0–2040 47.41 193.54 0–850 51.65 142.22
15 months 0–1734 51.35 167.72 0–1394 68.27 196.40
21 months 0–1768 53.03 185.82 0–1088 59.79 165.70
27 months 0–1768 53.78 185.82 0–1088 70.83 172.39
33 months 0–2176 53.76 211.97 0–850 73.47 168.22
Total 0–9350 309.85 1029.58 0–5236 461.07 977.42
Home care
Baseline 0–2340 159.95 444.37 0–14,040 582.72 2219.18
4.5 months 0–2808 231.04 573.78 0–6084 216.88 829.38
9 months 0–2574 180.68 489.06 0–4914 305.34 930.70
15 months 0–4680 273.99 732.48 0–12,168 640.93 2195.17
21 months 0–8424 339.15 928.72 0–15,116 652.35 2536.82
27 months 0–7722 287.32 847.16 0–8424 315.04 1144.33
33 months 0–13,104 340.63 1218.51 0–14,742 506.81 2126.14
Total 0–19,656 1642.42 3390.93 0–49,842 2637.35 7253.95
Informal care
Baseline 0–299,520 9769.74 25,390.93 0–53,118 8482.39 10,258.59
4.5 months 0–51,012 7332.73 9599.26 0–107,172 10,005.38 16,304.73
9 months 0–49,140 6666.81 8766.52 0–59,436 9828.00 12,964.54
15 months 0–471,744 10,293.51 38,447.11 0–48,204 7878.21 9399.37
21 months 0–707,616 13,440.26 57,074.99 0–38,844 8237.54 8746.79
27 months 0–623,376 11,454.15 49,816.83 0–33,228 8511.61 8729.32
33 months 0–64,116 7868.62 10,925.71 0–37,908 8334.11 9276.78
Total 0–1,359,072 56,697.24 119,349.22 0–201,708 52,794.85 50,782.44
Adaptations and equipment
Baseline 0–1036 62.32 145.15 0–894 74.05 143.36
4.5 months 0–5714 203.33 670.79 0–4903 196.48 594.72
9 months 0–9158 151.10 735.89 0–969 84.59 218.65
15 months 0–3542 139.35 360.34 0–1972 170.16 346.81
21 months 0–3099 100.81 320.03 0–1180 77.48 188.99
27 months 0–2463 67.83 210.03 0–2126 80.41 279.33
33 months 0–1224 32.34 105.36 0–885 27.39 93.36
Total 0–7123 707.97 1261.98 0–5397 610.57 1007.70
continued
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TABLE 72 Private resource use costs by treatment group and follow-up (complete case analysis,
undiscounted) (continued )
Resource use item
Active Placebo
Range Mean SD Range Mean SD
Travel
Baseline 0–643 32.85 55.74 0–238 33.51 42.89
4.5 months 0–388 24.32 44.52 0–186 25.52 33.80
9 months 0–736 23.80 62.11 0–125 20.62 29.51
15 months 0–507 22.58 45.40 0–304 29.80 44.99
21 months 0–400 23.31 43.86 0–191 24.12 36.69
27 months 0–219 24.37 38.51 0–219 24.63 38.09
33 months 0–249 22.05 33.38 0–175 23.28 31.36
Total 0–1169 159.06 193.20 0–891 161.01 178.51
Respite care
Baseline 0–6030 18.61 335.00 0–936 5.74 73.31
4.5 months 0–2010 8.91 126.35 0–2736 20.12 234.61
9 months 0–10230 42.91 640.16 0 0.00 0.00
15 months 0 0 0.00 0 0.00 0.00
21 months 0–720 3.08 47.07 0–1872 33.47 216.58
27 months 0–936 4.25 63.11 0–1005 8.38 91.74
33 months 0–1005 12.31 98.05 0–1872 24.38 194.89
Total 0–1005 34.17 157.99 0–2010 49.02 269.04
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TABLE 73 Aggregated private resource use costs by treatment group and follow-up (discounted, complete cases)
Resource
use item
Active Placebo
Mean SD 95% CI Mean SD 95% CI
Health care
Baseline 108.40 240.51 70.61 to 146.19 124.23 284.46 61.73 to 186.73
4.5 months 123.19 226.77 87.56 to 158.83 123.64 210.36 77.42 to 169.86
9 months 119.61 277.35 76.17 to 163.05 164.22 332.97 91.06 to 237.38
15 months 147.63 312.20 98.73 to 196.53 216.42 432.10 121.48 to 311.36
21 months 144.11 304.13 96.47 to 191.74 161.57 310.46 93.36 to 229.79
27 months 152.82 312.08 103.94 to 201.70 206.88 328.68 134.66 to 279.10
33 months 156.13 358.64 99.95 to 212.31 187.94 298.05 122.45 to 253.43
Total 842.72 1542.18 601.16 to 1084.28 1060.67 1605.21 707.96 to 1413.37
Social care
Baseline 10,038.87 25,358.73 6054.07 to 14,023.69 9169.28 10,261.99 6914.47 to 11,424.08
4.5 months 7760.10 9499.35 6272.16 to 6599.69 10,452.99 16,039.83 6869.33 to 14,036.66
9 months 6949.40 8819.82 5567.90 to 8330.89 10,204.19 13,184.49 7307.24 to 13,101.14
15 months 10,444.95 37,631.73 4550.51 to 16,339.40 8501.89 9485.25 6417.75 to 10,586.03
21 months 13,343.61 54,982.61 4731.41 to 21,955.81 8681.22 8521.63 6808.81 to 10,553.63
27 months 11,140.18 47,135.25 3757.15 to 18,523.21 8471.07 8393.07 6626.91 to 10,315.23
33 months 766.89 10,310.85 6047.85 to 9277.93 8292.46 8640.36 6393.96 to 10,190.95
Total 57,301.13 114,682.41 39,337.85 to 75,264.41 54,603.82 50,018.62 43613.52 to 65,594.11
Total private costs
Baseline 10,147.28 25,352.84 6163.39 to 14,131.16 9293.51 10,232.74 7045.13 to 11,541.89
4.5 months 7932.40 9497.69 6439.96 to 9424.85 10,576.63 16,324.61 6989.72 to 14,163.54
9 months 7113.42 8813.43 5782.50 to 8498.34 10,368.41 13,176.49 7473.21 to 13,263.60
15 months 10,592.58 37,684.42 4689.89 to 16,495.28 8718.31 9499.53 6631.04 to 10,805.59
21 months 13,487.72 54,988.66 4874.57 to 22,100.87 8842.79 8523.04 6970.08 to 10,715.51
27 months 11,293.01 47,142.36 3908.86 to 18,677.15 8677.94 8427.20 6826.28 to 10,529.60
33 months 7819.02 10,334.86 6200.22 to 9437.82 8480.40 8682.45 6572.65 to 10,388.14
Total 58,143.84 114,838.26 40,156.16 to 76,131.53 55,664.49 50,115.70 44,652.86 to 66,676.12
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Method for estimating concomitant medication costs
Costs were calculated for MS-related medications as per clinical guidance. This list was further refined
to exclude low-cost or short-course treatments (e.g. antibiotics). On this basis, costs were estimated
for 35 drugs prescribed during the trial (Table 74). The British National Formulary online was consulted on
20 August 2012 for unit costs. Dosages were estimated on typical doses observed in the trial assuming
100% adherence. Short courses of normally longer-term medication were excluded.
TABLE 74 Concomitant medication costs by drug and drug class
Drug class Medication Cost (£) % of total
Antidepressants Citalopram 15,336.51 3.7
Nortriptyline 2123.02 0.5
Escitalopram 1550.85 0.3
Mirtazapine 858.32 0.2
Imipramine 566.91 0.1
Lofepramine 555.96 0.1
Subtotal 20,991.57 5.0
Antiepileptic Pregabalin 37,054.35 8.9
Gabapentin 32,297.42 7.8
Clonazepam 8202.94 2.0
Carbamazepine 5025.58 1.2
Levetiracetam 2692.02 0.6
Oxcarbazepine 1716.66 0.4
Primidone 1853.20 0.4
Sodium valproate 741.28 0.2
Subtotal 89,583.45 21.5
Antispasticity Baclofen 20,496.24 4.9
Botulinum toxin 4490.79 1.1
Dantrolene 3979.56 0.9
Subtotal 28,966.59 6.9
Disease-modifying drugs Mitoxantrone 1392.98 0.3
Alemtuzumab 756.91 0.2
Azathioprine 419.40 0.1
Methotrexate 453.38 0.1
Subtotal 3022.67 0.7
Fatigue Modafinil 80,955.70 19.5
Amantadine 15,473.02 3.7
Subtotal 96,428.72 23.2
Laxatives Macrogol 13,562.9 3.3
Sodium picosulphate 214.58 0.1
Subtotal 13,777.48 3.4
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TABLE 74 Concomitant medication costs by drug and drug class (continued )
Drug class Medication Cost (£) % of total
Steroids Methylprednisolone 6758.90 1.6
Urine/bladder Tolterodine 57,429.76 13.8
Solifenacin 33,266.58 8.0
Oxybutynin 31,953.48 7.7
Trospium 15,342.60 3.7
Desmopressin 11,333.84 2.7
Duloxetine 2574.98 0.6
Propiverine 2442.29 0.6
Tamsulosin 1316.79 0.3
Alfuzosin 1014.38 0.2
Subtotal 156,674.70 37.6
Total 416,204.10 100.00
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